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Abstract 
Stents are expandable tubes made of different materials that are used to open a conduct that has 
been obstructed. Specifically, in the field of tracheal stents, there has been a need for improvement due 
to post-implantation problems, such as bacterial colonization, granulation tissue formation, migration 
and acute pain. Bacterial colonization by potentially pathogenic microorganisms (PPMs) reduces the 
quality of life of patients inducing infection or even sepsis, which can lead to patient death, if appropriate 
measures are not taken. Moreover, re-stenosis of post-inflammatory scars, as well as the growth of 
inflammatory granulation tissue, can be a life-threatening complication. However, both complications 
could be resolved by pharmacologically activating the stents with antiproliferative drugs. To avoid these 
problems, it is reasonable to propose the local use of antiproliferative drugs, such as paclitaxel (PCTXL), 
with a controlled release to reduce the recurrence of the stenosis, resulting in tissue healing and 
reduced stent implantation time. Finally, tracheal stents suffer from poor adaptability to the implantation 
area. This lack of fitting leads to migration of the stent along the trachea, causing pain and threatening 
critical parts like the vocal cords. In addition, this migration or displacement of the stent causes the 
formation of granuloma tissue at the edges of the stents due to mechanical stress and rubbing. 
However, both problems, stent migration and granuloma tissue formation, can be avoided by re-
designing the stent using 3D printing technology to increase the adaptability creating a suitable stent 
for the desired implantation zone. 
The above-mentioned complications are urging physicians and patients to demand a new generation 
of stents with different properties that can allow the treatment of several pathologies, such as re-
stenosis, and avoid associated problems, such as infection, migration and bleeding. 
This work develops an innovative coating technology using plasma treatments to create an 
antibacterial coating. The resulting materials were capable to reduce bacterial colonization and avoid 
biofilm formation. Surface treatments have been adapted to create micro- and nanostructured surfaces 
using silver as antibacterial agent. The developed metallic silver coating showed hydrophobic behaviour 
and antibacterial activity against Gram-positive and Gram-negative strains. In addition, an adaptation 
of this coating was used in combination with an adaptation of a previously developed drug delivery 
platform, such as nanoparticles, to encapsulate paclitaxel and allow sustained release from the surface 
of the material. Pegylated polyester nanoparticles were fabricated using a synthesized amine-terminal 
polymer and showed paclitaxel encapsulation properties with a controlled release. The developed drug 
release system was effective against different types of cells, such as patient-extracted stenotic cells. 
Finally, in order to provide a solution to the low adaptability that causes stent migration and 
granulation tissue, this work explores the use of the additive manufacturing technologies to fabricate a 
customized anatomical device with the aim of revolutionizing the current stent technology and offering 
an innovative solution to uncovered clinical needs. The developed work represents a proof of concept 
of a protocol to fabricate anatomical objects using patient information and additive manufacturing 
technology. As a result of the manufacturing protocol, an anatomical silicone-based stent was 
 x 
successfully fabricated using patients scan, 3D software and different additive manufacturing 
technologies. 
 xi 
Resum 
Els stents són tubs expansibles fets de diferents materials que s'utilitzen per obrir conductes que han 
estat obstruïts. Específicament, en el camp dels stents traqueals, existeix una necessitat de millora per 
evitar els problemes post-implantació, tals com la colonització bacteriana, la formació de teixit de 
granulació, la migració del dispositiu i el dolor agut. La colonització bacteriana per microorganismes 
potencialment patògens (PPM, sigles en anglès) redueix la qualitat de vida dels pacients, indueix 
infecció o fins i tot sèpsia, i pot conduir a la mort del pacient si no es prenen les mesures adequades. 
A més, la re-estenosis de les cicatrius postinflamatòries, així com el creixement del teixit inflamatori de 
granulació, poden ser complicacions potencialment mortals. No obstant això, ambdues complicacions 
podrien resoldre's activant farmacològicament els stents mitjançant fàrmacs antiproliferatius. Per evitar 
aquesta problemàtica, és raonable proposar l'ús local de fàrmacs antiproliferatius, com per exemple el 
paclitaxel (PCTXL), que redueix la recurrència de la estenosis mitjançant un alliberament controlat, 
donant com resultat la cicatrització del teixit i la reducció del temps d'implantació del stent. Així mateix, 
els stents traqueals sofreixen d'una mala adaptabilitat a l'àrea d'implantació. Aquesta falta d'ajust 
condueix a la migració del stent al llarg de la tràquea, causant dolor crític i greus problemes en zones 
delicades com les cordes vocals. A més, aquesta migració o desplaçament del stent provoca la 
formació de teixit de granulació en els extrems, a causa de l'estrès mecànic i el fregament. No obstant 
això, tots dos problemes, la migració i la formació de teixit de granulació, es poden evitar redissenyant 
el stent, mitjançant tecnologia d'impressió 3D per augmentar l'adaptabilitat creant un dispositiu 
completament anatòmic. 
Aquestes complicacions fan que els metges i els pacients sol·licitin una nova generació de stents 
amb diferents propietats que permetin el tractament de diverses patologies, com la re-estenosis, i que 
evitin problemes associats, com la infecció, la migració i el sagnat. 
Aquest treball desenvolupa una tecnologia innovadora de recobriments, utilitzant tractaments per 
plasma per crear un recobriment antibacterià. Els materials resultants han estat capaços de reduir la 
colonització bacteriana i evitar la formació de biofilm. Els tractaments de superfície s'han adaptat per 
crear superfícies micro- i nanoestructurades, utilitzant plata com a agent antibacterià. El recobriment 
de plata metàl·lica desenvolupat, va mostrar un comportament hidrofòbic i una activitat antibacteriana 
contra soques Gram-positives i Gram-negatives. A més, es va utilitzar una modificació d'aquest 
recobriment en combinació amb una plataforma d'alliberament controlat de fàrmacs mitjançant 
nanopartícules, per encapsular paclitaxel i permetre l'alliberament controlat des de la superfície del 
material. Les nanopartícules de polièster-PEG es van fabricar utilitzant un polímer sintètic amb amines 
terminals i va presentar propietats d'encapsulació de paclitaxel i un alliberament controlat del mateix. 
Així, el sistema d'alliberament de fàrmac desenvolupat va ser eficaç contra diferents tipus de cèl·lules 
com les cèl·lules estenòtiques extretes del pacient. 
Per tant, i amb la finalitat de proporcionar una solució a la baixa adaptabilitat que provoca la migració 
del stent i el teixit de granulació, aquest treball presenta com a solució l'ús de les tecnologies de 
 xii 
fabricació additives per obtenir un dispositiu anatòmic personalitzat i millorar així l'adaptabilitat. Aquesta 
tesi ha desenvolupat un protocol com a prova de concepte, per crear objectes anatòmics, utilitzant la 
informació dels pacients i la tecnologia de fabricació d'additiva. Com a resultat, el stent de silicona 
anatòmic es va fabricar amb èxit mitjançant diferents tecnologies de fabricació additives, i es van 
proporcionar propietats antibacterianes mitjançant els recobriments desenvolupats prèviament. 
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Resumen 
Los stents son tubos expandibles hechos de diferentes materiales que se utilizan para abrir 
conductos que han sido obstruidos. Específicamente, en el campo de los stents traqueales, existe una 
necesidad de mejora para evitar los problemas post-implantación, tales como la colonización 
bacteriana, la formación de tejido de granulación, la migración del dispositivo y el dolor agudo. La 
colonización bacteriana por microorganismos potencialmente patógenos (PPM, siglas en inglés) 
reduce la calidad de vida de los pacientes, induce infección o incluso sepsis y puede conducir a la 
muerte del paciente, si no se toman las medidas adecuadas. Además, la re-estenosis de las cicatrices 
post-inflamatorias, así como el crecimiento del tejido inflamatorio de granulación, pueden ser 
complicaciones potencialmente mortales. Sin embargo, ambas complicaciones podrían resolverse 
activando farmacológicamente los stents mediante fármacos antiproliferativos. Para evitar esta 
problemática, es razonable proponer el uso local de fármacos antiproliferativos, como por ejemplo el 
paclitaxel (PCTXL), que reduce la recurrencia de la estenosis mediante una liberación controlada, 
dando como resultado la cicatrización del tejido y la reducción del tiempo de implantación del stent. Así 
mismo, los stents traqueales sufren de una mala adaptabilidad en el área de implantación. Esta falta 
de ajuste conduce a la migración del stent a lo largo de la tráquea, causando dolor crítico y graves 
problemas en zonas delicadas como las cuerdas vocales. Además, esta migración o desplazamiento 
del stent provoca la formación de tejido de granulación en los bordes de los stents, debido al estrés 
mecánico y al frotamiento. Sin embargo, ambos problemas, la migración del stent y la formación de 
tejido de granulación, se pueden evitar rediseñando el stent, usando tecnología de impresión 3D para 
aumentar la adaptabilidad creando un dispositivo completamente anatómico. 
Estas complicaciones hacen que los médicos y los pacientes soliciten una nueva generación de 
stents con diferentes propiedades que permitan el tratamiento de varias patologías, como la re-
estenosis, y que eviten problemas asociados, como la infección, la migración y el sangrado. 
Este trabajo desarrolla una tecnología innovadora de recubrimientos, utilizando tratamientos por 
plasma para crear un recubrimiento antibacteriano. Los materiales resultantes han sido capaces de 
reducir la colonización bacteriana y evitar la formación de biofilm. Los tratamientos de superficie se han 
adaptado para crear superficies micro- y nano-estructuradas, utilizando plata como agente 
antibacteriano. El recubrimiento de plata metálica desarrollado, mostró un comportamiento hidrófobico 
y una actividad antibacteriana contra cepas Gram-positivas y Gram-negativas. Además, se utilizó una 
modificación de este recubrimiento en combinación con una plataforma de liberación controlada de 
fármacos mediante nanopartículas, para encapsular paclitaxel y permitir la liberación controlada desde 
la superficie del material. Las nanopartículas de poliéster-PEG se fabricaron utilizando un polímero 
sintético con aminas terminales y presentó propiedades de encapsulación de paclitaxel y una liberación 
controlada del mismo. Así, el sistema de liberación de fármaco desarrollado fue eficaz contra diferentes 
tipos de células como las células estenóticas extraídas del paciente. 
 xiv 
Por consiguiente, y con el fin de proporcionar una solución a la baja adaptabilidad que provoca la 
migración del stent y el tejido de granulación, este trabajo presenta como solución el uso de las 
tecnologías de fabricación aditivas para obtener un dispositivo anatómico personalizado y mejorar así 
la adaptabilidad. Esta tesis ha desarrollado un protocolo como prueba de concepto, para crear objetos 
anatómicos, utilizando la información de los pacientes y la tecnología de fabricación de aditiva. Como 
resultado, el stent de silicona anatómico se fabricó con éxito mediante diferentes tecnologías de 
fabricación aditivas, y se proporcionaron propiedades antibacterianas mediante los recubrimientos 
desarrollados previamente. 
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1.1 Introduction 
In 1900, human life expectancy never exceeded the progressive decrease in quality of tissues, 
therefore there was no need for tissue replacement. For centuries, when a tissue became diseased or 
damaged, people could treat or remove that specific part with limited resources. However, during the 
last century, the situation changed thanks to medical advances, such as the development of antibiotics 
like penicillin, chemical treatments and more important, hygiene, which increased the human survival.1 
In the last few years, there has been an explosive growth of transplantations and implantations of 
medical devices to replace damaged tissues and increase the life expectancy.2,3 
During the last few decades, many efforts of biomedical engineers have been centered on the 
replacement of body tissues, structures or organs with living tissues, known as transplants. However, 
the limitations involving transplants include ethical or immunological concerns, availability of tissues, 
second-site morbidity, tendency to resorption, compromise in biomechanical properties and the use of 
immunosuppressant drugs. These limitations urge the need to develop alternatives with ameliorated 
fully synthetic materials or modified natural materials, such as implants or prosthesis.4 
Implants are being used for different reasons, such as the replacement of tissues that have either 
been damaged or destroyed through pathological processes, to treat congenital defects and corrective 
trauma or cosmetic surgery. For example, metallic prostheses are used in orthopedic surgery to replace 
bone tissue that has been fractured or damage due to aging. In the treatment of wounds the application 
of biomaterials may be in the form of suture materials, artificial ligaments and bone fixators.5 However, 
biomaterials were not only used as prosthesis, coatings for sensors6,7, pacemakers and drug delivery 
systems within the body, among others8,9, are other examples of applications that requires biomaterials. 
Biomaterials have generated much interest to develop devices, organs or tissues to be in contact 
with body fluids and body parts acting as a native part of the body without the previous limitations and, 
ideally, without causing major unwanted responses.10 Biomaterials have evolved during the years and 
nowadays three different generations are clearly differentiated: bioinert materials (first generation), 
bioactive and biodegradable materials (second generation) and materials designed to stimulate 
specific cellular responses at the molecular level (third generation).11 
The main limitation of the inert biomaterials is that these materials are adopted from other areas of 
science and technology without substantial redesign for medical use. However, the human body 
consists of a highly corrosive environment and a broad variety of textures and mechanical properties 
and such requirements are imposed to select the best materials for each device. Second generation of 
biomaterials present the ability to interact with the biological environment to enhance the biological 
response. Additionally, this kind of biomaterials has the ability to undergo a progressive degradation 
while new tissue regenerates and heals. Despite all the progress that has been made, the structure of 
the tailor-made biomaterials is relatively simple in comparison to that of the complex cellular structure 
of the tissues being replaced.5 Finally, the third generation of biomaterials are able to stimulate specific 
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cellular responses at the molecular level through their 3D environment. These materials combine the 
bioactivity and biodegradability together with 3D porous structures that stimulate cellular homing, 
attachment and proliferation and functionalized surfaces with proteins to mimic the extracellular matrix 
(ECM).11 
Although first generation materials helped in the development of new medical treatments, there are 
still some complications that bioengineers have to take into account when designing a new implant or 
prosthesis regarding to Biocompatibility and Biofunctionality, such as chemical signaling (receptor-
ligand recognition, intracellular signals cascade, cellular response), interfacial stability with host tissues, 
biomechanical mismatch of elastic moduli, matrix deformation, cell deformation, micro or nanostructure, 
matrix stiffness, controlled degradation, generation of wear debris, maintenance of a stable blood 
supply, lack of ability to self-repair, the ability to modify their structure and properties in response to 
environmental factors, such as mechanical load or blood flow and their limited lifetimes.4,12 Regarding 
the non-specific response from biological systems upon implantation, this phenomenon can be caused 
because the biomaterial does not mimic the environment. In order to obtain a suitable biomaterial, it is 
important that the material fulfils the requirements of biocompatibility and biofunctionality for each 
specific application. Because of that, a common approach is to fabricate medical devices with the 
biomaterial having the adequate bulk properties and additionally adding a surface treatment to enhance 
its surface properties.13 
In the present days, implants such as jaw bone14, heart valves15, pacemaker8,16 and vascular8,17 and 
non-vascular18–21 stents have to be in close contact with tissues of different nature.22 In this context, it 
is important to use smart engineered biomaterials23,24 in order to keep the biocompatibility and the 
biofunctionality between the surfaces of the devices and the surrounding tissues. These smart materials 
shall present the bulk material properties to match the mechanical and structural behavior and, 
additionally, present specific features to elicit the desired response on each tissue depending on its 
surface. However, the performance of this devices that are designed to be implanted at the interface of 
surfaces with drastically different properties is challenging and consequently, this new generation of 
materials needs multifunctional surfaces that should be designed to specifically interact with the 
different tissues and applications. This is especially relevant for devices whose surfaces are directly in 
contact with tissues and fluids, such as the case of a stent. 
In the present days, tracheal implants are a clear example of medical devices that require the 
engineering of biomaterials with multifunctional surfaces. Tracheal stents are hollow tubes used to treat 
laryngotracheal stenosis, which causes the reduction of the trachea wall, by restoring the airway 
passage to the lungs. This reduction in the trachea wall caused by tracheal stenosis or cancer25 leads 
to a considerable reduction in the quality of life of the patients with problems of breathing, speaking and 
swallowing.26 In order to restore airway passage, different debulking methods can be endoscopically 
used to recover lumen patency, and once reopened, stents are implanted to avoid restenosis.27–29 The 
only property of current stents consists on mechanical expansion to maintain the passage open. 
However, different complications related to stent implantation30,31, such as stent migration, obstruction 
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by secretions and granulomas32,33, persistent bacteria colonization34 and recurrence35, are threatening 
the life of patients and often the initial pathology remains unhealed. 
Considering the previous listed problems that affects tracheal stents, this work pretends to develop 
a customizable solution for each of them by grouping all the post-implantation problems into three 
different blocks, such as avoid bacteria colonization, design a drug delivery platform to treat stenotic 
tissue and recurrence, and re-design the stent with an anatomical geometry to increase the adaptability 
and avoid migration and the formation granulation tissue. 
As mentioned before, one of the most common complications related to stent implantation is bacterial 
colonization.36–38 Bacterial colonization can reduce quality of life, induce infection or even sepsis that 
can cause death of the patient, if appropriate care is not taken.33,39 Bacterial colonization and biofilm 
formation onto the implanted medical devices are a serious problem accounting for over 80% of 
intrahospital microbial infections. 40 Although antibiotics can treat the great majority of them, they are 
not completely effective in the case of a contaminated device, can generate resistance, increase the 
cost41 and produce adverse effects on patients.40,42 Silver presents high toxicity against 
microorganisms, wide spectrum of action, non-bacterial resistance and is not toxic to human tissues.43 
Because of that, prevention by avoiding biofilm formation by means of covering catheters and tubs with 
different antimicrobial agents like silver can be more convenient.44,45 
The second main problem consists in a recurrence of tracheobronchial stenosis after stent removal 
and granulation tissue formation, Figure I-1. Tracheal resection surgery is the gold standard treatment 
with excellent results in the 90% of the cases, but it is not always a definitive treatment.30,46–48 The 
recurrence rate can reach, up to 10%35, present a rate of major complications of 8-12%30,31 and a 
mortality rate of 5%46,49. In addition, there are other treatments like the endoscopic treatment, combined 
with different techniques, such as laser thermal ablation or electrocautery, the resection and mechanical 
dilatation with rigid bronchoscopy, the mechanical balloon dilatations and the silicone stent 
implantation.28,29 However, the effectivity of long term multimodal endoscopic treatment is not exempt 
from recurrence and presents a great variability accounting nearly half of the patients (55-90%).50,51 
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Figure I-1. Granulation tissue at the edges of the tracheal stent. This type of tissue is caused by the rubbing and movement of 
the stent over the tracheal airway.33 
In the recent years, some clinical experiences using topical drugs to treat subglottic stenosis have 
been published. Pharmacological treatment in combination with the endoscopy, is based in the 
intralesional injection of corticoids or, more recently, topical use of mitomycin-C.52,53 Both have shown 
mixed results in small series of patients. Now, none of these treatments are definitive, but some animal 
models with dogs have shown that after weekly repeated topical treatments of mitomycin in metallic 
prosthesis, the stents did not induce the formation of granulation tissue.54 
In other applications, e.g. cardiology, antiproliferative drug eluting stents have become a great 
advance to avoid re-stenosis.55,56 Similarly, in tracheal stenosis, researchers observed in animal studies 
that auto-expandable metallic silicone prostheses previously soaked with paclitaxel (PCTXL) avoided 
granulation tissue formation in 100%, 96%, 76% and 65% of cases at 1, 4, 8 and 12 weeks respectively, 
in contrast of the non-drug eluting stents, which were occluded at first week.57 Recently, other 
antiproliferative drugs, such as Pirfenidone and Rapamycin, used as treatment for other pulmonary 
pathologies, such as idiopathic pulmonary fibrosis, are being used as possible future treatments for 
benign and malignant tracheal stenosis applied from a prosthesis.58 
Finally, the last main problem related with post-implantation disadvantages consisted on the low 
adaptability of the current stents to the trachea airway. As human trachea is not a perfect circular 
transversal profile (Figure I-2), but an elliptical, D-Shaped, U-Shaped or triangular contour depending 
on sex and age, the current stents present poor adaptability in the implantation area.59,60 This lack of 
fitting leads to migration of the stent along the trachea causing severe pain and threatening critical parts 
of the airway, such as the vocal cords.61 Besides, this migration or movement of the stent causes 
granuloma tissue at the edges of the stents as a consequence of mechanical stress and rubbing.32,62 In 
addition, this inflammatory tissue can be a life threatening complication, if not treated with 
glucocorticoids or endoscopic thermal ablation.63–65 Some designs have tried to mimic de tracheal 
geometry such as Natural Stent (TNO Company, Seoul – Korea),66 but despite all possibilities several 
complications, such as migration, formation of granulation tissue around the stent and retained 
secretions, are threaten the stent implantation.67 However, these problems can be avoided with 
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increasing the adaptability and designing a suitable stent for the desired implantation zone with an 
anatomical redesign of the stent.68 
 
Figure I-2. Trachea reconstruction from a Computed Tomography (CT) Scan. A) Inspiration reconstruction and B) Expiration 
reconstruction.69 
Taking all of these into account, the problems related with the tracheal stent implantation are caused 
by a low biocompatibility and low biofunctionality of the stent. Since biocompatibility and biofunctionality 
are determined by the interaction between the surface of the material and the surrounding tissues, in 
order to overcome the drawbacks of the tracheal stent, it is imperative to control the influencing factors 
that determine the behavior of the cells (or even bacterial colonization), such as the chemical structure 
and composition of the surface, hydrophilicity, hydrophobicity, morphology, the structure of a multi-
component system (crystalline and amorphous domains), stiffness and the topography.5 Therefore, the 
modification and control of the free-surface of the medical devices is critical to provide surface-cell 
interaction resulting in a higher biocompatibility.13  
For instance, surface modifications can encourage the immobilization of biomolecules, such as 
proteins or other chemical motifs to enhance cell recognition.70 Surface modification techniques allow 
to modify the surface of the materials, changing their surface properties without changing the bulk 
properties of the material.70 The most interesting advantage of surface modification is that it can modify 
almost all types of materials.71 Additionally, not only the chemical structure of the surface is important 
for the cellular recognition and biocompatibility, but also the structuration of the surface provides 
important information for cell adhesion and spreading.72,73 
The immobilization of a bioactive compound onto a polymeric surface can be done by adsorption via 
electrostatic interactions, ligand-receptor pairing or covalent attachment. However, one of the most 
interesting methods is the covalent bond because it provides a more stable bond between the 
compound and the functionalized surface. This stability increases the half-life of the biomolecule onto 
A) B)
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the medical device, preventing its metabolism, its migration to other tissues and allowing a continuous 
bioactivity.74 
 
Figure I-3. Different immobilization methods. A) Electrostatic interactions, B) Ligand-receptor pairing and C) Covalent 
attachment. 
Considering all surface modification techniques, plasma treatment seems to be one of the most 
promising techniques, because it has the ability to modify surfaces of inert materials leading to covalent 
bounds between the surface and the functional moiety. In addition, plasma treatments modify the 
surface of a material without using solvents and generating chemical waste. Moreover, in contrast with 
the conventional methods (oxidizing, aminolysis and alkaline or acidic hydrolysis)75, plasma techniques 
can modify the surface of the materials with less degradation and roughening of the material than many 
wet chemical treatments and has the advantage of controlling the modification and the final micro- and 
nano-structure of the surface.74,76,77 
Among all different plasma-based techniques, glow discharge plasma permits the functionalization 
of the surface or the deposition of a thin film of polymer covalently attached to the surface of the material 
without changing the bulk properties of the material.13 However, the functionalization or the chemical 
structures of the resulting polymer are controlled by experimental conditions, and the chemical 
structures can range from highly functional polymers networks with low cross-link densities to polymer 
networks with low functional groups, but high cross-link densities.78,79 
In the last few years, plasma polymerization and plasma grafting have appeared as interesting 
techniques to modify different types of substrates. These approaches have been optimized to covalently 
attach highly functional groups on the surface using a monomer with a terminal reactive group.80 
Pentafluorophenyl methacrylate (PFM) is one of such monomers that offers a highly reactive ester 
group, which is selective for amino groups, and a vinyl structure that can be easily polymerized. 
+ + + + + +
-
-
- -
-
-- - -
-
-
- -
-
-- - -
a) b) c)
Avidin / Streptavidin Biotin Reactive groups
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Figure I-4. Chemical structure of pentafluorophenyl methacrylate. 
PFM coated surfaces present high reactivity against primary amines in aqueous solutions, that can 
be used to covalently bind proteins, such as bovine serum albumin (BSA) and fibrinogen, chemical 
moieties and nanoparticles to the surface.79 
Therefore, plasma techniques can be used to develop reactive surfaces in order to provide different 
functionalities or bioactivities to the medical device. In addition, the advantage of the plasma process 
to occurs in vapor/gas phase, allows complex geometries to be easily modified. Thus, the surfaces of 
anatomical structures, such as prosthesis or stents, can be modified to increase the biocompatibility 
and the implanted device interaction, with the surrounding tissue. 
Finally, in addition to the development of a bioactive coatings to provide antibacterial properties and 
a drug release system, there is a need to increase the adaptability of the device to the anatomical area 
where it is implanted. However, anatomical geometries cannot be fabricated by conventional 
manufacturing processes because of the limitations of the technology. In this context, over the past few 
decades, printing technology has advanced from two-dimensional (2D) printing to an additive process 
in which successive layers of material are distributed to form three-dimensional (3D) shapes, leading 
to complex geometries for a wide range of applications, eliminating parts, materials, waste and reducing 
the need for tooling.81–83. This technology allows to create complex structures and can be applied to 
enable rapid prototyping and manufacturing in industry to produce customized products, such as bicycle 
parts, jewelry and electrical components. In addition, 3D printing is transforming other fields like science, 
education and specially medicine with an undeniable impact of 3D printing technology for our society.84 
Nowadays, there is a close relationship between the 3D printing field and regenerative medicine to 
the point that 3D printing technology has completely changed the paradigm of personalized medicine. 
3D printing creates a new approach that can be applied in nearly all issues that personalized medicine 
tries to overcome. For instance, reconstructive surgery85,86, scaffolds for aortic valve replacement87 and 
trachea prostheses for stenosis treatment88 are only few cases where 3D printing technologies is 
showing a critical impact by redesigning the devices and the treatments to provide a more personalized 
treatment (geometry of the scaffold or prosthesis) to treat the individual pathology which a specific 
patient is suffering. 
O O
F
F
F
F
F
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Actually, 3D printing technology aims to go much further seeking to reproduce any part of the human 
body89, such as the research in the development of materials to simulate complex tissues such as 
cartilage90–93, the fabrication of bioactive scaffolds94 or directly the printing of living tissue95. In addition, 
3D printing technologies show a great potential to develop personalized geometries, even personalized 
organs, due to its ability to recreate complex parts of the human body with high precision, its versatility 
that can be useful to fabricate new prostheses and, to produce custom products at relatively low prices 
using new materials. 
Despite all the progress made with different tracheal stent designs, the post-implantations problems 
remain still unsolved, threatening the life of the patients and shortening the life quality of the patients. 
In the first place, the new developments regarding to antibacterial agents such as silver nanoparticles 
or antibacterial drugs, anchored on the surface of the medical devices could be a very promising 
solution to avoid the bacterial colonization of the device and to enhance the performance implant.96 
Secondly, the research and clinical trials performed with antiproliferative drugs (topically 
administered) show a great potential to reduce the recurrence rate of the stenotic or tumor tissue and 
reduce the formation of the granulation tissue. Therefore, the tracheal stent or other medical device 
could be used as a controlled drug deliver platform to locally release different types of drugs (such as 
PCTXL or mitomycin) to treat abnormal proliferation or other types of pathologies. In this case, the 
surface plasma techniques show a great potential for the immobilization of chemical molecules, such 
as small drugs, or even high structures, such as proteins, antibodies97 and nanoparticles. 
Finally, in order to overcome the drawbacks and problems caused by the low adaptability of the 
current stent geometries, 3D printing technologies and computer-aided design (CAD) can facilitate the 
design and manufacture of new complex geometries of scaffolds, which fit more naturally and adapt to 
the patient geometries. As a result, the new scaffolds should present less migration rate, avoid the 
formation of the granulation tissue at the edges of the patient and increase the performance of the 
prosthesis, reducing the chronic pain. 
Taking into account the above-mentioned limitations of the current treatments for tracheal diseases, 
the main objective of this thesis is the development of new personalized prostheses (tracheal stent or 
similar) with different bioactivity, such as antibacterial and antiproliferative (regarding to its surfaces, 
internal and external) and with a customized geometry based on the patient anatomy. 
Therefore, in order to accomplish the main objective of this work, this thesis have been separated 
into the following goals: 
• Development, optimization and characterization of a covalent surface modification of different 
substrates in order to create reactive surfaces to be personalized with different bioactive agents 
(Chapter II). 
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• Design and characterization of flexible antibacterial surfaces functionalized with silver coating 
to be used in the internal or external tracheal stents surfaces (Chapter II). 
• Development and characterization of flexible antiproliferative surfaces functionalized with 
degradable drug loaded nanoparticles to be used in the external tracheal stent surfaces 
(Chapter III). 
• Design a protocol to extract, optimize and model different images from a CT scan (using 
different CAD software) to design injection molds to be printed with 3D printing technologies. 
This injection molds will be used to inject silicone and obtain a personalized and fully adaptable 
tracheal stent to the patient anatomy (Chapter IV). 
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2.1 Introduction 
As mentioned in the previous chapter, bacterial colonization and biofilm formation on implanted 
medical devices, i.e. tracheal stents, are a serious problem accounting for over 80% of microbial 
infections in the body.1 Moreover, in recent years, the incidence of laryngotracheal stenosis in the adult 
population has been rising due to the increasing number of patients suffering from post-intubation injury, 
approximately 1 in 200,000 adults per year.2 Prolonged ischemia by inappropriate pressure of the cuffed 
endotracheal tube, together with concomitant infection, can cause necrosis of the tracheal wall. This 
damage results in the formation of granulation tissue first and abnormal scarring tissue afterward.3 
Depending on the decrease of the tracheal-free section lumen, or stenosis, this injury can induce 
dyspnea at exertion, if it is mild, or even the death by asphyxia, if it is severe. 
This pathology requires restoration of the free airway to the lungs that can be accomplished by 
complicated resective surgery techniques or through insertion of a silicon trachea prosthesis (stent).4 A 
variety of silicone or metallic stents are currently used to restore the stenosed airway. Metallic stents 
may seem a good solution, but they can cause damage of tissue by penetration, fracture of the stent, 
bronchial or tracheal wall perforations or release of metallic ions.5,6 
 
Figure II-1. Piece metal removal of a metal stent.7 
The use of silicone stents was first evaluated in 1965, when Montgomery reported the use of the 
silicone T-Tube tracheal stent. In 1990, Dumon designed the currently most widely used stent.3,8,9 Some 
of the reason why silicone stents are a safe solution is because they avoid all the problems with the 
breakage of the stent, the diffusion of metallic ions and perforations or tissue damage.10,11 Additionally, 
silicone has been found to be a relatively non-irritating substance, which makes it a suitable material 
for a structural prosthesis.12 However, they present the disadvantage of interfering with mucociliary 
function, avoiding the clearance of bronchial secretion and are potentially life-threatening due to the risk 
of displacement13.14 
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Figure II-2. Different tracheal tubes. A) Montgomery silicone tracheal T-tube stent15 and B) Dumon stent.16 
One of the major complications of stent implantation is bacterial colonization with potentially 
pathogenic microorganisms, such as Pseudomonas aeruginosa, Staphylococcus aureus, and many 
others,17 that may threaten the viability of the prosthesis or even cause the death of the patient, if 
appropriate care is not taken. Bacterial colonization is mainly associated with poor quality of life in terms 
of daily symptoms, such as coughing, sputum, or halitosis. In addition, in some patients it can threaten 
their lives by obstruction of the stent by thickened mucous plugs and even cause severe infection, 
sepsis, and deaths. 
The reason why there is bacterial colonization on the stent is not fully understood. It has been 
hypothesized that bacterial colonization may be related to microscopic irregularities on the 
macroscopically smooth internal surface of the stent.18 However, it has been demonstrated that the use 
of antibiotic-impregnated stents showed interesting results reducing the colonization during the initial 
implantation days.17 
Since the discovery of penicillin, antiseptics and other antibacterial agents such as gentamicin, 
titanium dioxide, or chitosan coatings are used to treat a broad range of bacterial infections increasing 
human survival.19 Despite the success of narrow and broad spectrum antibiotics, not all bacterial 
infections can be resolved; in addition, bacteria can generate resistance to those antibacterial agents.20 
Therefore, the use of hypochlorite21, copper salts22,23 or chlorhexidine24,25 should be an attractive 
strategy to avoid the development of resistant strains and reduce bacterial infection. Silver is an 
excellent agent to fight bacterial infections as it has been corroborated since ancient times. Hippocrates 
used silver as an antibacterial agent to treat the Greeks,26 and recently the use of silver as an 
antibacterial has risen again to treat bacterial infections due to its high toxicity against microorganisms, 
wide spectrum of action, reduced bacterial resistance, and low toxicity to animal cells.27 Due to its broad 
spectrum of antibacterial activity, silver has been used in multiple applications, such as topical 
bandages for burn wounds28,29, topical creams for burns30,31, additives in food32, chronic wounds33, 
urinary catheters34 or dialysis catheters35, with excellent results reducing and avoiding bacterial 
colonization and infection. 
B)A)
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The mechanism of action of silver ions is not clearly defined, but there is some evidence of silver ions 
interacting with thiol (sulfhydryl) groups of the proteins and enzymes, losing essential activities, such 
as replication and respiration. Silver ions are deposited in the cell wall as granules damaging the cell 
wall, and consequently, the cytoplasmic membrane, cytoplasmic contents, and outer cell layers exhibit 
structural abnormalities.36 Finally, silver-coated surfaces of medical implant can avoid bacterial 
infections and biofilm formation.37 At this point, it is fundamental to control the surface of the biomaterial 
because this is where the interactions between tissue body, bacteria, and medical devices are 
produced. Therefore, it is necessary to use surface modification technology to create covalently 
attached silver-coatings. 
As it has been previously introduced in the introduction chapter of this work, plasma treatment 
techniques are interesting methods to modify material surfaces. These techniques can be used to 
enable chemical surface modifications, fabricate thin films, and can be applied to flexible and complex 
shaped scaffolds without cracking. These modifications can be easily tailored concerning type and 
density of functional groups without changing the intrinsic bulk properties of the substrate.38–40 
Furthermore, surface functionalization can be achieved by avoiding the use of hazardous solvents 
because these kinds of techniques are solvent-free.41 Additionally, plasma allows the production of 
different topologies on surfaces, presents the ability to model the macroscopic and microscopic surface 
morphology, and carries out chemical pattering.41 
Plasma-based techniques are effective methods for the modification of medical implants because 
they can change chemical properties42, improve the adhesion strength43, surface and coating 
properties20,44,45 and biocompatibility38.46–48 In addition, plasma processes provide reproducible 
modifications and reactors or processes can be scaled up to industrial dimensions.42 Another advantage 
of plasma is its ability to allow protein47,49 or other biomolecules immobilization or polymer coatings 
deposition with final sterile surfaces.46 
Plasma Polymerization (PP) also called PECVD (Plasma Enhanced Chemical Vapour Deposition) or 
plasma deposition is referred to a deposition of polymeric thin films on the surface of the substrate 
without changing the bulk properties of the material.46 PECVD has been described previously as an 
excellent technique to obtain thin films that are biocompatible50,51, adherent52, and flexible enough to 
minimize static forces on the surrounding tissue53 and endure the flexibility of the material. However, 
the functionalization or the chemical structures of the resulting polymer is controlled by experimental 
conditions, and the chemical structures can range from highly functional polymers networks of low 
cross-link densities to polymer networks of low functional groups, but high cross-link densities.54,55 
Despite a wide variety of different functional monomers used in plasma polymerization such as 
allylamine56, acrylic acid57 or allyl alcohol/1,7-octadiene58, in the last few years our lab GEMAT has 
been working to obtain highly functional groups on the surface by using the polymerization of a 
monomer with a terminal reactive group. Pentafluorophenyl methacrylate (PFM) is one of such 
monomers that offers a highly reactive ester group (that efficiently reacts with amino groups) and a vinyl 
structure that can be easily polymerized by PECVD technique.54 The resulting reactive polymeric thin 
Chapter II. Antibacterial Surfaces 
26 
films were covalently attached to the surfaces. These plasma polymerized PFM (pp-PFM) surfaces are 
capable of being adapted to the flexibility of elastic materials such as PDMS, can be micro– and 
nanostructured, and can react preferably with amine bearing molecules to obtain biocompatible and 
bioactive surfaces with antibacterial properties.40,59,60 
The optimization of working parameters shows a great impact in the final properties of the polymer 
layer. Previous works on the plasma-polymerized PFM (pp-PFM) have proved that the deposition under 
pulsed plasma conditions controlled by the duty cycle (DC), Equation II-1, is crucial for the correct 
formation of the active polymer film.54 The DC is defined as the relation between the time in which 
plasma is on (ton) and the total duration of the pulse (ton + toff). 
 𝐷𝐶 = 𝑡%&𝑡%& + 𝑡%(( Equation II-1 
Pulsed plasma is characterized for being carried out at higher power Ppeak (working power), Equation 
II-2, maintaining the same equivalent power (Peq) as the continuous plasma. This can be possible 
because the Peq (that is actually reaching the sample) is dependent on the pulse due to the relation with 
the DC and the Ppeak.61 
 𝑃*+ = 𝑃,*-. · 𝐷𝐶 Equation II-2 
The tuning properties of the duty cycle and the different processes that takes place during a pulsed 
plasma polymerization can be observed in Figure II-3 and can be directly compared to the treatment 
that the surface is receiving, when continuous plasma is applied. 
 
Figure II-3. Pulsed plasma polymerization process. 
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Initially, during the activation (ton), the dissociation of the monomer and the gas present in the 
chamber yields different ions, radicals and electrons. Additionally, UV radiation is generated due to the 
relaxation process of the electronically excited species. The material surface is then exposed to an 
excited and high reactive atmosphere resulting in the surface modification, deposition, and ablation 
process. However, during the relaxation process (toff), ions and electrons disappears due to their limited 
lifetime and high reactivity. In contrast, the organic radicals formed during the activation process have 
a longer lifetime than these other species and they remain on the chamber sufficient time to continue 
the radical polymerization on the surface. As a result, the monomer is activated and reacts producing 
the polymer chain onto the surface of the material with soft conditions, avoiding secondary reactions, 
and retaining a higher reactive functionality.54,61 
During the plasma polymerization, there is a fragmentation and a deposition of organic monomers 
into a thin film on the surface of a substrate under vacuum. The building blocks of the coating are 
generated in the plasma by the fragmentation of the gas feed (the monomer).42 This activated monomer, 
monofunctional or difunctional free radicals, can react with themselves to form a polymer chain. Either 
this growing polymer chain or the activated monomer, can react with the activated surface. Finally, the 
reaction between radical species ends the growing of the polymer chain as in a free radical 
polymerization.62,63 
Plasma treatment, uses O2, N2, H2, NH3, CO2, CF4 or inert gases such as Ar or He. The plasma of 
these gases generates charged particles that interact with the surface, usually via free radicals’ 
chemistry, generating a functionalization. This process leads to covalent bonds suitable for the 
attachment of other coatings, to cross-link the topmost surface layer and finally a surface ablation, which 
can be used for surface cleaning, activation and plasma grafting.42,64–66 
Additionally, the treatment can be used as an ablation process (plasma etching). The ablation can be 
produced by reactions with active species, generated in the plasma, with the surface, in order to form 
volatile products.65,67 In this kind of process, the atoms of the gas (Ar, O2) are excited ions that collide 
with atoms on the surface and these surface’s atoms dislodges from the crystalline structure transferring 
its energy to a neighboring atom. This energy transfer continues until one of the atoms is knocked out 
into the vapor phase.46,67 As a result of this knocking out, the surface contains active sites that can be 
used for the immobilization of molecules. Normally, this technique is used to obtain clean surfaces by 
removing dust or remaining coatings or as a pre-treatment, to activate the surface, before a plasma 
deposition or direct immobilization of chemical molecules. 
During a plasma treatment, it is possible to obtain a mixture of processes, such as functionalization 
with a monomer or with hydrophilic groups if oxygen is used, Figure II-4. Similar to pulsed plasma 
polymerization, the grafting process avoids the monomer exposure to harsh conditions in order to 
preserve its chemical integrity when polymerized. Thus, the surfaces are coated with a low density of 
organic molecules by depositing a monomer, such as pentafluorophenyl methacrylate molecule. In 
addition, hydroxyl groups can be obtained when the activated surfaces, that has not been reacted with 
the organic monomer, come in contact with the atmosphere (oxygen and nitrogen). This type of surface 
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functionalization can be interesting to enhance the interaction between the soluble bioactive molecules 
with the reactive surface coated with PFM in order to provide a covalent bond. 
 
Figure II-4. Scheme of different plasma treatment techniques. 
In a previous work carried out at GEMAT group, a comparison between the two plasma techniques 
for immobilization, plasma grafting and plasma polymerization (PECVD) was evaluated. Results 
showed that plasma polymerization with PFM resulted in a thick coating film with high density of reactive 
PFM groups and a high roughness, while in plasma grafting the conditions were smoother and a low 
density of reactive groups and homogeneous surface with less roughness of PFM was obtained. This 
homogeneity and low roughness of PFM on the surface were suitable for enzyme and protein 
immobilization, because biomolecules could be spaced out, avoiding the agglomeration, which could 
difficult the accessibility of the substrate for the active site. Furthermore, this work proved that plasma-
grafting modification allowed the retention of the native structure of biomolecules upon immobilization, 
whereas immobilization via PECVD resulted in a mixture of conformations.68 
Therefore, as mentioned before, there is an increasing need to create antibacterial surfaces for 
medical devices capable to avoid bacterial colonization and biofilm formation in combination with high 
biocompatibility. Considering the previous developed work to create bioreactive surfaces onto different 
materials using plasma treatments, this chapter goes beyond surface modification to describes a 
methodology for immobilizing bioactive molecules on different materials, such as silicone, to obtain 
functionalized surfaces capable of interacting with human tissues. 
Finally, this chapter describes a micro– and nanostructured silver coatings onto flexible PDMS 
surfaces for sustained release of silver ions, resulting in antibacterial and hydrophobic surfaces that 
avoid biofilm formation surfaces, which have potential applicability on implanted medical devices. 
PDMS substrate (used as control for medical grade silicone) are coated with PFM using PECVD 
technique in order to obtain a flexible thin coating that is incubated with amine sugar (glucosamine). 
Because of the sugar aldehyde thin film, silver ions are reduced on the surface to obtain a 
nanostructured silver coating on a highly flexible PDMS surface. In addition, this work develops a new 
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customizing modification method capable of selectively functionalizing different sides of a (polymeric) 
substrate. The resulting material presents different bioactivity for each side, with the potential of micro- 
and nano-structuration of the surface. This approach opens the possibility to design medical devices 
with high personalizing potential, able to include in the same material different functionalities, such as 
antibacterial properties on one side, and a drug delivery system on the other.
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2.2 Materials and Methods. 
2.2.1 Materials. 
Argon 5.0 and oxygen 5.0 were purchased from Abelló Linde S.A. (Barcelona, Spain). PFM was 
purchased from Apollo ScientificLTD (Stockport, UK). D-(+)-Glucosamine hydrochloride, sodium 
dodecyl sulphate (SDS), Hellmanex, nitric acid, fluorescein-5-thiosemicarbazide and silver nitrate were 
purchased from Sigma-Aldrich (Madrid, Spain). Ethanol were purchased from Scharlab (Barcelona, 
Spain), a Sylgard 184 kit was purchased from Ellsworth Adhesives (Madrid, Spain) and Si-wafers were 
purchased from Wafer World (West Palm Beach, FL, USA). Alexa Fluor® 350 and Alexa Fluor® 488 
(AF350 and AF488 respectively) were purchased from Invitrogen (Carlsbad, CA, USA). Ultrapure water 
(Milli-Q) was obtained using a Synergy UV® system from Merck Millipore (Billerica, MA, USA). 
2.2.2 Preparation of substrates. 
The substrates used were Si-wafers and PDMS samples. In order to fabricate the PDMS plates, the 
Sylgard kit (10:1) was spread by a paint applicator to obtain films of 500 µm thickness. Additionally, 
cylindrical PDMS tubes (10 mm of internal diameter, 45 mm of length) were obtained by spreading the 
kit (10:1) into PTFE (polytetrafluoroethylene) cylinders with PTFE concentric tubes. Both films and tubes 
were incubated overnight at 70°C. The PDMS films were cut in circular shapes of 21 and 10 mm. It is 
important to denote that due to the high hydrophobicity and electrostatic charge of PDMS, samples 
need an accurate washing treatment. PDMS samples were washed with 5% SDS solution, rinsed with 
Milli–Q water, washed with 2% Hellmanex solution, rinsed again with Milli–Q water and finally with 
ethanol. Si-wafers were washed with the same protocol as PDMS samples. Finally, samples were dried 
in a stream of nitrogen and stored. 
2.2.3 Plasma Reactor. 
2.2.3.1.1 Reactor 1: Horizontal Plasma Reactor (HPR). 
The surface modifications carried out in this work were performed using a horizontal plasma reactor 
designed and developed at GEMAT as it can be observed in Figure II-5. This reactor is a home-built 
70 cm long and 4 cm cylindrical Pyrex reactor. The cylindrical tube contains the glass sample holder to 
introduce the samples for modification. Plasma were performed using an excitation frequency of 
13.56 MHz. Gases and monomers were feed to the system using a needle valve. At the opposite 
extreme of the reactor there is a CO2 / acetone cooled trap to collect the excess of the non-reacted 
monomer before reaching the pump (RV12 903 Edwards, UK). At the centre of the reactor there is an 
active Pirani gauge type vacuum meter (PN D02182000 Edwards, UK) to monitor the reaction pressure. 
In a home built system, the pulse generator controlled the pulsing of the radio frequency signal, which 
is amplified by a 150 W amplifier and passed via an analogue wattmeter and a matching box to a 10 cm 
long spiral located around the exterior of the reactor. The typical base pressure to all experiments was 
0.02-0.03 mbar and gases and the PFM monomer vapour were introduced at a constant pressure of 
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0.7 and 0.15 mbar, respectively. The reactor’s inner volume is approximately 3 L, while the effective 
plasma volume is about 1.7 L. 
 
Figure II-5. Horizontal Plasma Reactor (HPR). Schematic diagram of horizontal plasma reactor and its electrical components: 
(1) Monomer, (2) Gases, (3) Glass tube, (4) Sample holder, (5) coil, (6) Pirani gauge, (7) Cold trap, and (8) Wattmeter and 
matching box. 
2.2.3.1.2 Reactor 2: Stainless Steel Vertical Plasma Reactor (SSVPR). 
The surface modifications carried out in this work were performed using a stainless steel vertical 
plasma reactor. This reactor consists of a stainless steel chamber (diameter, 25.5 cm; length, 41.6 cm) 
vertical plate reactor, Figure II-6. The ground electrode is the reactor chamber, and the radio frequency 
(RF) electrode is an aluminium plate, which is used to hold the samples for polymerization. Additionally, 
the RF electrode is connected to a RF pulse generator (13.56 MHz) via a matching box. Gases and 
monomers were supplied via a standard manifold with gas fluxes adjusted with a tree of needle valves. 
The system pressure is monitored using a vacuum gauge controller (MKS PDR900, Andover, MA, USA) 
connected with a cold cathode/micropirani vacuum transducer (MKS 972 DualMag) positioned at the 
centre of the reactor. The system has a nitrogen cold trap and a chemical trap filled with active carbon 
connected to avoid nonreacted monomer from reaching the pump (Trivac D 16BCS/PFPE Leybold, 
Cologne, Germany). 
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Figure1.6presents a schematicdiagramof the second system. Itwas ahomebuilt70 cm long cylindrical
Pyrexreactor.Polymerizationswereperformedusinganexcitationfrequencyof13.56MHz.Gasesthatwere
fedthroughthesystempassthroughaglass,CO2/acetonecooledtrapforcollectionofexcessreactantbefore
reachingthepump(EdwardsRV12903).AnanalogicalPiranitypevacuummeter(MKS,USA)wasconnected
nearthemiddleofthereactorchamber,tomonitorthereactionpressure.Inahomebuiltsystem,thepulse
generatorcontroledthepulsingoftheradiofrequencysignal,whichwasamplifiedbya150W mplifierand
passedviaananaloguewattmeterandamatchingnetworktoa10cmlongcoillocatedaroundtheexteriorof
the reactor.The typicalbasepressureprior toallexperimentswas1x102mbar.PFMmonomer vaporwas
introducedataconstantpressureof0.2mbarviaaneedlevalve.ThereactorYsinnervolumeisapproximately
3l,whiletheeffectiveplasmavolumeisabout1.7l.



Figure1.6Schematicdiagramoftheplasm re ctoranditselectric lcomponentsi System2
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Figure II-6. Stainless Steel Vertical Plasma Reactor (SSVPR). Schematic diagram of stainless steel vertical plasma reactor and 
its electrical components: (1) monomer feed, (2) gases feed, (3) cylindrical chamber, (4) holder sample, (5) pirani gauge, (6) 
matching box and electrical system, (7) cold trap, and (8) chemical trap. 
2.2.4 Plasma Polymerization. 
Plasma polymerizations were carried as described in previous work.40,55 Before introduction of the 
substrate, the chamber was cleaned in continuous wave O2/Ar (1:1) plasma for approximately 1 h at a 
power of 150 W. Samples were placed on the centre of the coil in the HPR or at the centre of an 
aluminium plate in the SSVPR reactor. Vacuum was started until the base pressure of 0.02 mbar for 
HPR or 0.001-0.003 mbar for SSVPR was reached, respectively. Then, PFM was regulated through the 
needle valve and introduced to the reactor chamber in a vapour phase (heated at 75 ºC) until 0.15 mbar 
for HPR and 0.02-0.03 mbar for SSVPR, respectively. The continuous radio frequency power was fixed 
at 15 W (working power) and pulsed plasma polymerization duty cycle (DC) of 10/20 [DC = ton/(ton+toff)]61 
was carried out for 3-10 min. Plasma discharge was then turned off, and the PFM vapour flow rinsed 
was kept constant for additional 15 min. After the polymerization process, plasma-polymerized PFM 
(pp-PFM) samples were carefully removed from the reaction chamber and stored until further use under 
argon atmosphere. 
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2.2.5 Plasma Grafting and Activation 
The grafting started with an activation of the surface with O2 or a mixture of gases, Ar and O2. After 
the plasma treatment, samples were brought into contact with the PFM from the gas phase or immersed 
into liquid PFM. Samples were introduced into the reactor chamber and vacuum was started until the 
base pressure. Secondly, needle valves that regulate gases were opened to introduce Ar, O2 or a 
mixture of gases 50% (Ar:O2) until they reached a work pressure of 0.7-0.75 mbar for HPR and 
0.14 mbar for SSVPR, respectively. Thirdly, the frequency generator was switched on and set up 
individually for each experiment to the working power (10-120 W) and the treatment time (1-60 min). 
After the plasma activation treatment, the needle valves of the gases were closed. 
In order to perform a plasma grafting of PFM, the monomer was regulated trough the needle valve 
and introduced to the reactor chamber in a vapour phase (heated at 75 ºC) until 0.15 mbar for the 
desired experimental time (1-40 min). 
In order to perform a hydrophilic activation, instead of PFM, oxygen gas was feed until reach a 
working pressure of 0.7 mbar for HPR and 0.14 mbar for SSVPR, respectively, for the desired 
experimental time (1-40 min). 
After the treatment, the monomer or gases valves were closed, vacuum was cut off, and samples 
were removed from the reactor and stored with argon atmosphere until further use. 
2.2.6 Surface Selectivity, Pattering and Structuration. 
2.2.6.1.1 Surface Selectivity 
In order to selectively modify both sides of a sample, each side of the sample was modified with a 
micro-patterned pp-PFM layer (protecting the opposite side with aluminium foil) and subsequently 
reacted with the desired amine-bearing molecule such as either AF350 or AF488 fluorescent dye in 
Milli–Q water (blue and green respectively). After functionalization with the first molecule, samples were 
rinsed with Milli–Q water and dried under argon stream. Then, in order to obtain the second side 
modified, PFM were plasma-polymerized onto the non-modified surface (protecting the previous 
functionalized side) and reacted with a different molecule. 
2.2.6.1.2 Surface Pattering, Micro-Pattering and µContact Printing (µCP). 
The pattering and micro-pattering process were carried out by the modification of the substrate with 
a mask or with a cooper grid (G50P, Gilder Grids, Grantham, U.K.). The mask was stacked on the top 
of the substrates, by applying pressure, before the plasma treatments. The cooper grid was carefully 
placed on the desired part of the substrate guaranteeing full contact between the surface and the grid. 
Samples were then treated with plasma treatments. When the modification process was over, the mask 
or grid was carefully retired taking care not to scratch the modification. 
Chapter II. Antibacterial Surfaces 
34 
As it can be seen in Figure II-7, the experiments detailed on this work used a custom-made 
polymethacrylate squared mask (with a centered squared hole) and a cooper TEM grid. 
 
Figure II-7. Schematic representation of the used masks. A) Polymethacrylate squared mask with a centred squared hole. B) 
TEM grid used as a cooper mask G50P (with 50 mesh lines / inch, 85 µm bar width and 416 µm hole width) and G50HEX (with 
50 mesh lines / inch, 500 µm pitch, 70 µm bar width and 430 µm hole width). 
The µCP technique consists on a stamp that was used to print on the surface of a modified substrate. 
The fabrication of the stamp consisted on a silicon rubber (PDMS) prepared by using an 8:1 ratio (v/v) 
of elastomer and curing agent (Sylgard 184 kit). After mixing, the mixture was degassed under vacuum 
and it was spread over a master stamp, Figure II-8, which was previously designed by GEMAT group 
and fabricated by the Centro Nacional de Microelectrónica (CNM, Spain).63,69 Then, the extended 
PDMS mixture was cured over-night at 70°C to crosslink the dimethylsiloxane chains. To reduce 
contamination of the printed surface due to unreacted crosslinker or PDMS monomer/oligomers, the 
stamp was cleaned with ethanol for 5 min and 5 min in ethanol with the help of an ultrasonic bath, and 
finally, it was dried under a stream of nitrogen. Finally, the stamp was made hydrophilic by treatment 
with 50% Ar/O2 mixture plasma at 15 W for 10 min. Consequently, the surface could absorb hydrophilic 
substances such as fluorophores. After the immersion of the stamp in an alcoholic fluorescein-5-
thiosemicarbazide (FTSC) solution (for 50 min), the FTSC were absorbed on the stamp and dried in a 
stream of nitrogen. 
 
Figure II-8. Master stamp.63 
Printing was achieved by placing the stamp onto the PFM modified surface and applying a little 
pressure for 15 min to enhance the contact between the stamp and the sample. The fluorescent 
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substrates were analysed by a fluorescent microscope AxioVs40 (Carl Zeiss Inc., Deutschland) with 
the 546, 470 and 365 nm filters. 
2.2.7 Modified Surface Characterization. 
The modified surfaces were characterized through water contact angle (WCA; DSA100, Krüss), time-
of-flight secondary ion mass spectrometry (TOF-SIMS), ultrahigh-resolution field emission scanning 
electron microscopy (UHRFESEM; NovaNanoSEM 230, FEI) with high voltage, optical microscope and 
3D microscopy with dual confocal technology, Dual Core 3D Measuring Microscope, (DM2500 and 
DCM 3D, respectively, Leica, Wetzlar, Germany). To analyse the surface modification by WCA, 
samples were directly analysed after polymerization. 
The TOF-SIMS analyses were performed using a TOF-SIMS IV (ION-TOF, Munster, Germany) 
operated at a pressure of 5x10-9 mbar. Samples were bombarded with a pulsed bismuth liquid metal 
ion source (Bi3+2), at energy of 25 keV. The gun was operated with a 20 ns pulse width and 0.3 pA 
pulsed ion current for a dosage lower than 5x1011 ions / cm2, well below the threshold level of 
1x1013 ions/cm2 generally accepted for static SIMS conditions. Secondary ions were detected with a 
reflector time-of-flight analyser, a multichannel plate (MCPs), and a time-to-digital converter (TDC). 
Measurements were performed with a typical acquisition time of 10 s, at a TDC time resolution of 200 ps 
and 100 us cycle time. Charge neutralization was achieved with a low-energy (20 eV) electron flood 
gun. Secondary ion spectra were acquired from a randomly rastered surface areas of 100 μm x 100 μm 
within the sample's surface. Secondary ions were extracted with 2 kV voltages and postaccelerated to 
10 keV kinetic energy just before hitting the detector. Mass spectral acquisition was performed within 
the ION-TOF Ion Spec software (version 4.1). 
2.2.8 Silver Deposition. 
In order to achieve the antimicrobial coating, the silver was reduced by a reductive sugar using the 
silver mirror reaction (Tollens’ reagent),70 Scheme II-1. This method consists of the complexation of the 
silver ions with ammonia and its subsequent reduction using a reductive sugar on a heated bath. By 
using an immobilized sugar, the diamminesilver (I) ions will be reduced to metallic silver resulting in a 
surface coating. The glucosamine solution was prepared by dissolving glucosamine hydrochloride in 
Milli–Q water at 1 M. Then, pH was adjusted to 7.4 with concentrated sodium hydroxide. The reaction 
between glucosamine and the modified surface was performed by incubating the modified samples in 
a glucosamine solution for 6 h. Tollens’ reagent was prepared by adding 25 µL of 15% ammonia to 
1 mL of 0.1 M silver nitrate, observing the precipitation of the silver oxide. Then, another 25 µL of 15% 
ammonia was added, and the complete dissolution of the precipitate was observed due to the 
complexation of the silver by ammonia. The modified samples with the attached glucosamine were 
introduced on a vial with 4 mL of Milli–Q water. Then, 1 mL of the Tollens’ reagent was added and 
heated on a water bath at 90 °C for the desired time of reaction, 60 min. Silver was quantified using an 
inductive coupled plasma optical emission spectroscopy (ICP–OES; Optima 2100 DV, Perkin Elmer). 
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Scheme II-1. Silver Mirror Process. 
2[Ag(NH 3)2 ](aq)+ + RCHO + 3OH − → 2Ag + RCOO− + 4NH 3 + 2H2O  
2.2.9 Silver Release and Total Silver Amount. 
The Ag ion release of the coated samples was measured with ICP–OES.71 Different coated samples 
were immersed in 5 mL of tryptic soy broth (TSB) and in 5 mL of Milli–Q water at 37 ºC. After the desired 
time, 4 mL of each solution was collected for analysis and replaced with 4 mL of fresh solution. The 
solutions were replenished and analysed each day for 20 days. For the anoxic silver release, 
experiments were carried out in an argon atmosphere and used degassed Milli–Q water and TSB 
media. 
The total amount of silver onto the silver-coated samples was dissolved using nitric acid. After 
dissolving the silver layer, the solution was diluted with Milli–Q water and quantified with the ICP-OES 
(Optima 2100 DV, Perkin Elmer, Waltham, MA, USA). 
2.2.10 Bacterial in vitro Assay. 
Bacterial cultures were performed at the Hospital Universitari de Bellvitge in Barcelona using 
commercial P. aeruginosa (PAO1) and S. aureus subsp. aureus (ATCCÒ 29213) strains. An overnight 
bacterial culture was diluted with fresh TSB medium to obtain a bacterial density of 106 cfu / mL. PDMS 
samples (modified with silver and nonmodified) were placed at the bottom of the wells of a sterile 24-
well plate, and 1 mL of the previously prepared bacterial suspension was added. The well plate with the 
samples was incubated at 37 °C without agitation for 24 h. After the incubation time, the supernatant of 
each well was aspirated and the samples were washed 7 times with Milli–Q water. Subsequently, 
samples were placed in a sterile 24-well plate and stained with the fluorescent Live/Dead BacLight 
Bacterial Viability Kit (Invitrogen), following the manufacturer’s instructions. The 24-well plate was 
covered from light and incubated for 15 min. After incubation time, samples were washed with Milli–Q 
water and their fluorescence was observed on a confocal microscope; images of the double-labeled 
sections were acquired using a True Confocal Scanner Leica (TCS-SL) filter-free spectral confocal laser 
scanning microscope (Leica Microsystems, Mannheim, Germany) equipped with a 488 nm argon laser, 
543 and 633 nm He/Ne lasers (Serveis Científics i Tecnològics, Universitat de Barcelona, Barcelona, 
Spain) using a 63x oil immersion objective (1.4 numerical aperture), image resolution of 1024 x 1024 
pixels. 
2.2.11 Animal Cell in vitro Assay. 
In order to evaluate the cytotoxicity of the silver–coated samples, animal cell line experiments were 
performed using the Cercopithecus aethiops kidney fibroblast SV40 transformed (COS-7, ATCCTM 
CRL-1651) type. Cells were grown in cell media (DMEM supplemented with 10% FBS, 1% glutamine, 
and 1% penicillin/streptomycin) and plated in 96-well plates at a cellular density of 1.2x105 cells/ml. 
After cells were plated, the medium was aspirated and substituted with a previously incubated medium 
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with silver samples for 1, 2, 3, and 6 days (0.5, 0.3, 0.2, and 0.1 ppm, respectively). In addition, 1.2 ppm 
of pure silver nitrate was added as positive control because it corresponds to the high concentration 
that can be achieved during the silver release. After 24 h, cell viability was assessed via MTS (CellTiter 
96 AQueous One Solution Cell Proliferation Assay, Promega Corp., Madison, WI, USA) following the 
manufacturer’s instructions. Briefly, cells were washed with PBS and incubated with a solution of the 
MTS reagent and complete media at 37 ºC for 1 h. The absorbance was measured via a microplate 
reader (Spectramax M2, Molecular Devices, Sunnyvale, CA, USA) at the wavelength of 490 nm. 
Unless otherwise stated, all experimental data were done in triplicate and the average mean was 
represented with standard deviation represented as error bars.  
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2.3 Results and Discussion 
2.3.1 Grafting modification on nylon and PTFE plates 
Initially, a few exploratory experiments were carried out with flat disposable membranes to analyse 
the behaviour of the plasma treatments in the previously studied grafting conditions by our group, 
GEMAT72 and to evaluate the ability of perform bi-side modification. 
In the first experiments, nylon membranes were used to evaluate the degree of grafting modification 
using pentafluorophenyl methacrylate (PFM) in the horizontal plasma reactor (HPR). Modified samples 
were further reacted with a hydrophobic molecule, such as decylamine. The degree of modification was 
assessed by changes in the hydrophilicity / hydrophobicity of the final samples using WCA 
measurements. 
As shown in Figure II-9, plasma treatment resulted in membrane folding, which was probably caused 
by either the high temperature reached during the activation process. 
 
Figure II-9. Folded nylon membrane after the grafting treatment. The plasma power peak was set at 50 W for 10 min and the 
PFM monomer was fed for 10 min. 
As it can be observed in Figure II-10, the blank sample, non-modified nylon, had a contact angle of 
63°. The samples grafted with PFM and subsequently reacted with decylamine, showed a water contact 
angle of 118°; instead of 45º from the grafted nylon with PFM. The variation between the bare nylon 
and grafted PFM was not the expected, because PFM is a hydrophobic substance and an increase on 
the angle contact was expected, similar to the pp-PFM54. However, grafting treatments created active 
sites on the surface that react with the monomer in the vapour phase. If, after the reaction process, the 
PFM has reacted in a low density, several active sites may still be present and may further react when 
the sample was put in contact with the air or water, resulting in the formation of hydroxyl groups and 
other species on the surface that may increase the hydrophilicity of the surface. The grafting 
modification of the sample with decylamine showed an increased hydrophobicity on the surface, as it 
was expected due to the high hydrophobicity of the decylamine. 
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Figure II-10. Water contact angles (WCA) of modified samples. (Blank) non-modified surfaces, (PFM) modified surfaces with 
PFM, and (Decylamine) PFM + decylamine by plasma grafting technique. The plasma power peak was set at 50 W for 10 min 
and the PFM monomer was fed for 10 min. After that, samples were incubated in decylamine for 10 min. 
Additionally, when the modification was carried out using PTFE membranes, samples showed a 
similar behaviour than in nylon. Initially, non-modified PTFE showed a WCA of 123º, while after grafting 
modification with PFM, a decrease in WCA to 94º was observed because of the non-reacted active 
sites, similarly as before when nylon was used. However, after the reaction with the decylamine, there 
was an increase in the WCA until 129º, indicating that decylamine chains reacted with the grafted PFM 
groups and therefore the hydrophobicity increased due to the decylamine chains nature and 
entanglement. 
These results showed that plasma grafting is an interesting technique to modify the surface of 
different materials, such as nylon or even chemically stable materials, such as PTFE. The modification 
allowed the functionalization of the surface with grafted PFM and thus, the possibility to anchorage 
different amine-bearing molecules showing different surface behaviour versus the raw material. 
Due to the difficulty to modify chemical stable materials, the modification of PTFE was very promising 
and therefore, further experimentation was performed to evaluate the structuration and reactivity of the 
deposited coatings. 
2.3.2 Microstructuration of grafted PTFE plates 
In order to evaluate the ability of the plasma techniques to selectively modify the surfaces, it was 
interesting to explore the use of micro-contact printing techniques to selectively modify the surface and 
provide a fluorescent pattering. 
The samples were modified using the grafting technique and followed by PFM incubation. After the 
PFM treatment, the samples were washed with ethanol. While the samples were treated, the stamp 
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was activated with oxygen and soaked with a FTSC solution. In Figure II-11, the fluorescent pattern 
“IQS CNM” can be observed, which persisted after some washing treatments with ethanol, although the 
fluorescence pattern was slightly blurred. This phenomenon might be caused by the reaction of the non-
reacted FTSC with the remaining PFM active sites during the washing with ethanol. 
 
Figure II-11. µStructured samples using µcontact printing technique. PTFE sample patterned with the µcontact printing technique 
after treated by grafting method and reacted with PFM. A) Non-washed sample where the modified zone (right) and non-modified 
(left) can be observed. B) Non-washed sample. C) Washed sample. The plasma power peak was set at 50 W for 25 min followed 
by a 15 min of PFM treatment. After the PFM treatment, samples were washed with ethanol for 120 min. 
The WCA and micro-structure results showed that the grafting method was an interesting treatment 
to modify different kinds of substrates, although it provided lower functionalization leading a 
structuration with lower definition of the pattern. In addition, the obtained reactive surfaces allowed 
micro-structuration using µ-contact printing techniques, which increased the possibility to create 
structured patterns to, for example, avoid or increase cell adhesion. 
As mentioned before, controlled surface modification on medical devices opened the possibility of 
designing new systems with improved features, such as improved biocompatibility, tailored tissue 
regeneration or antimicrobial activity. Thus, to provide antibacterial activity to the medical devices, silver 
was immobilized onto the modified surfaces. 
2.3.3 Silver Deposition on grafted PTFE plates 
Once the PFM was clearly deposited onto the surfaces of different materials using plasma grafting 
modification, and the grafted-PFM was reactive with amine-bearing molecules (µcontact printing using 
FTSC solution), the next step consisted in the modification of the grafted-PFM to create antibacterial 
surfaces. Therefore, as mentioned before, a salt of metallic elements, such as silver, was used to 
provide antimicrobial activities to the materials. 
Silver coating was obtained using a three-step procedure design, (Figure II-12): (1) surface 
modification with PFM to create a reactive area, (2) immobilization of a reductive molecule, such as 
glucose, and (3) silver salt reduction using the previous reductive surface. 
Initially, material surface was modified with PFM to obtain a reactive coating capable to react with 
amine bearing molecules. After the plasma modification, a reductive amine-bearing molecule, such as 
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glucosamine, was reacted with the PFM. In this case, the amine group of glucosamine did not interfere 
in the reduction reaction, therefore it could be used to react with the PFM active group. Finally, a thin 
film of metallic silver was obtained using a complexed silver solution (Tollens’ reagent). 
 
Figure II-12. Schematic representation of antibacterial coating. The developed antibacterial surface used a three-step synthesis 
strategy in combination with silver mirror reaction. 
PTFE membranes were activated and then placed into a vial with PFM to react. Subsequently, 
samples were washed and reacted with glucosamine. After the immobilization with glucosamine, silver 
was reduced only on top of the surfaces. 
 
Figure II-13. PTFE sample coated with silver in a three-step process. Sample was, firstly, grafted with PFM using a square mask; 
secondly, sample was reacted with glucosamine; and finally, samples were incubated with Tollens’ reagent: A) Silver coated 
(brown); B) Structured sample, silver coated (brown, red arrow) and non-modified area (white, black arrow); and C) Reverse non-
modified surface (white). The plasma power peak was set at 50 W for 25 min with 15 min of PFM incubation. Samples were 
incubated with 3 mL of glucosamine 1 M for 5 h, and then washed with Milli-Q water. Finally, samples were incubated with Tollens’ 
reagent (1 mL AgNO3 1 M + 2 x 25 µL NH3, 15%) for 60 min at 90°C. 
As it can be observed in Figure II-13, the immobilization of silver was accomplished showing a brown 
surface onto the surface of the PTFE membrane. In addition, the result of the macro-structuration using 
a mask can be observed in the samples, showing silver modified areas (brown) and non-modified areas. 
However, the soft colour intensity of the silver reduced on the surface indicated that the modification 
process produced low density of the reactive groups leading to a low silver quantity around 0.3 µg/mm2. 
These results showed that the modification on different materials was achieved, even in a chemically 
stable and rough material, such as PTFE, and it was possible to control the desired side and the macro-
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structure of the surface. However, a low quantity of immobilized silver was achieved due to a low density 
of functional groups. 
Previous results clearly indicated that although plasma grafting showed a great potentiality and great 
versatility, the low amount of reactive groups minimized the yield of the process and difficult the 
possibility to obtain a homogeneous film coating.73 
Taking these results into account, it was interesting to move forward to use the plasma polymerization 
technique (PECVD) to create a homogeneous plasma polymerized (pp-) coating onto the surfaces. This 
technique allowed to obtain a thin film covalently attached to the material surface and it was possible 
to control the structure and reactivity of the resulted coating. 
2.3.4 PECVD modification on PTFE plates 
Plasma Enhance Chemical Vapour Deposition, technique produces a covalently attached polymeric 
coating on the surface, which is formed by the polymerization of the monomer. In comparison to grafting 
techniques, surfaces modified by PECVD present a higher density of PFM groups available to react 
with the desired target. Additionally, this technique does not require an intense process to activate the 
surface through an etching process. 
PTFE foil samples were modified with plasma polymerized PFM (pp-PFM) to create a continuous and 
homogeneous reactive surface. The resulting surface was further reacted with a hydrophilic amine-
bearing alcohol, such as ethanolamine. The ethanolamine reduced the hydrophobicity of the PTFE due 
to the reaction between the amine and the reactive group of the p-PFM resulting in a lower hydrophobic 
surface onto PTFE. In order to assess the control of PECVD on PTFE samples, half of the PTFE foil 
was protected in order to avoid plasma modification and the other half was left exposed to the 
modification treatment. Samples were then reacted with ethanolamine in an ultrasonic bath. After the 
treatment, the samples were removed and their water contact angle were measured. As it can be 
observed in Figure II-14, pp-PFM samples showed a WCA of 75º instead of the 89º of the bare PTFE. 
The reduction on the WCA indicated the change on the chemical nature of the surface, there was a new 
chemically structure on top of the surface, in this case, the value was around the expected (~80º) for 
the pp-PFM.54,74  
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Figure II-14. WCA measurements of different studied samples. Non-modified PTFE samples, modified pp-PFM samples, 
modified pp-PFM samples and non-modified pp-PFM area, both reacted with ethanolamine 10% for 30 min. The plasma power 
peak was set at 15 W with a DC of 0.5 for 5 min with PFM. After the plasma, there was a 3 min of PFM flow. 
After the reaction with ethanolamine, the coated surface presented a decrease in its water contact 
angle to 54º due to the loss of the hydrophobic fluorinated group and the attachment of the hydrophilic 
ethanolamine. As it was expected, after the treatment with ethanolamine, the non-modified area 
remained constant as the same as bare PTFE. 
In addition, the wettability behaviour of the non-modified and modified PTFE sample can be observed 
in Figure II-15, where half of the sample was modified with pp-PFM and subsequently with 
ethanolamine, and the other half was kept unmodified. When placed in water, the part of the sample 
modified with ethanolamine (reduced hydrophobicity) sank into the water, whereas the unmodified part 
remained on the surface due to its higher hydrophobicity. These results showed the novelty of the 
modification process to control the modification area and to change the chemical composition of the 
material surface (even chemical stable material, such as PTFE) allowing different properties and 
behaviour. In this case, PTFE showed a reduction in the hydrophobic properties allowing the material 
to be wetted by water.  
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Figure II-15. Wettability behaviour of modified PTFE sample. PTFE was partially modified with PFM by PECVD and treated with 
ethanolamine (yellow) in Milli-Q water. The plasma power peak was set at 15 W with a DC of 0.5 with PFM for 3 min and After 
the plasma, there was a 3 min of PFM flow. 
2.3.5 Silver Deposition on PTFE plates 
As mentioned before, the key factor was to obtain a metallic silver surface covalently attached onto 
the materials surface with a homogeneous, stable, and with enough quantity of silver to present 
antibacterial properties due to the release of the silver ions. 
After evaluating the viability to pp-PFM on the surfaces of the materials (even on PTFE), the next 
step consisted in the reduction of the silver onto the modified PTFE substrates. To evaluate the novelty 
selectivity of the treatment and the silver mirror process, half of the PTFE sample was covered and the 
sample was modified by PECVD with PFM. After the modification, the sample was reacted with 
glucosamine and washed with Milli-Q water. Subsequently, immobilized glucosamine was used to 
reduce silver on the surface of the sample using the silver mirror reagent. 
 
Figure II-16. PTFE sample coated with metallic silver. Two areas can be differentiated, a non-modified one (left) and the coated 
with silver (right). The plasma power peak was set at 15 W with a DC of 0.5 with PFM for 3 min. After the plasma, there was a 
3 min of PFM flow and then samples were incubated with 3 mL of glucosamine 1 M for 5 h, and then washed with Milli-Q water. 
Finally, samples were incubated with Tollens’ reagent (1 mL AgNO3 1 M + 2 x 25 µL NH3, 15%) for 60 min at 90°C. 
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In Figure II-16, two differentiated areas, the non-modified and the coated area with silver, can be 
observed. As it was expected, only the modified pp-PFM surface was coated with silver, while the non-
modified remained unaltered. This result showed the ability of the plasma techniques to modify the 
materials surfaces and even to create a reactive layer able to develop further chemistry. In addition, the 
results showed the ability to control the structure of the modification areas. PECVD samples showed a 
homogeneous and continuous metallic silver coating instead of the dispersed and aged (brown) silver 
coating obtained using the grafting technique. The amount of silver was similar (0.37 µg/mm2), but the 
homogeneity of the coating indicates the possibility to control the silver amount by controlling the time 
and conditions of the silver mirror reaction. 
The results suggest that, when a homogeneous and continuous coating is required, the former 
technique should be prioritized over grafting processes. 
2.3.6 PECVD Modification and Structuration of PDMS Plates 
In order to move forward the aim of the work, to obtain a controlled silver deposition on a material 
used in medical applications, such as silicone, it was necessary to further assess the feasibility of 
PECVD technique to immobilize PFM groups and obtain a homogeneous and stable silver coating onto 
PDMS substrates (material used to manufacture the tracheal stents and other medical devices). 
Initially, as a first step to evaluate the modification, silicon wafer was used to control the PFM 
deposition. Films deposited from PFM showed a water contact angle higher than 60º. However, an 
extremely hydrophobic surface became an inconvenient for enhancing the interaction between the 
surface and water-soluble molecules. The WCA results showed the hydrophobicity of the PFM coating 
onto silicon wafer samples, which was 83 ± 1º 54,74 instead of 39 ± 4º from silicon wafer, indicating the 
correct deposition of the pp-PFM film onto the surface of the PDMS. These results showed chemical 
changes onto the PDMS surface and therefore, the next step consisted on the modification and 
characterization of modified samples to further asses the reactivity of the pp-PFM coating. 
The interaction between the pp-PFM and the PDMS surface plays an important role regarding the 
nano-structuration of the surface. As it can be observed in Figure II-17, the PFM polymerized onto the 
PDMS surface created a homogeneous nanostructured PFM film with wrinkle- and fold-like structures 
(rippling surface) of about 100-200 nm caused by the interaction between the pp-PFM layer and the 
PDMS surface. Additionally, after incubation in aqueous solution (Milli-Q water), pp-PFM showed a non-
swelling behaviour as a result of PFM chains reorientation causing nanometer protrusions75 (about 
50 nm) that lead to a nanostructured surface inside the previous nanostructured surface. The amine 
bearing biomolecules shall adopt this structuration after reacting with the pp-PFM-modified surface. 
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Figure II-17. SEM images of the PDMS samples. A) Non modified PDMS, B) Modified PDMS with PFM and C) Modified PDMS 
with PFM incubated with aqueous solution (Milli-Q water). 
In order to assess the potential of micro-structuration of the PDMS surfaces, samples were modified 
with a grid onto their surface, resulting in modified and non-modified areas corresponding to the grid 
shape, as it can be observed in Figure II-18. Additionally, samples were incubated with AF488 resulting 
in fluorescent samples, where the fluorescent areas matched with the PFM modified areas. These 
results highlight the ability of the PECVD to easily modify PDMS samples or other materials and the 
capability to microstructure the surface as desired. 
 
Figure II-18. Fluorescent micro-structured PFM coated PDMS. 
In addition to the structuration ability using masks, this technology has a tremendous potential to be 
used to create selective modifications regarding to each side of samples. It should not be ignored that 
in the current days, where the medical implants are revolutionizing the medicine, there are a lot of 
medical implants that require direct contact with different tissues at the same time. Moreover, the 
capability of differential modification between the surfaces could be an interesting tool for increasing 
the personalization of the devices. 
Considering previous results, that one side-modification of PDMS can be achieved with amine-
bearing molecules using the reactive pp-PFM, for the next step it was interesting to evaluate the 
B)A) C)
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possibility to modify different sides of the material. These results could provide a prove of concept 
methodology to create bi-side modifications onto the same material to allow different functionalities and 
behaviors. 
As it can be observed in Figure II-19, the bi-side functionalization of the PFM structured surfaces 
achieved a high degree of selectively and specificity. It is possible to observe the first modification with 
the AF350 fluorophore and the second modification (on the opposite side) with the AF488 fluorophore. 
Additionally, it is important to remark that if the protective step was performed correctly, due to the 
transparency properties of the PDMS, it was possible to focus one side at a time and no contaminations 
of surfaces were observed. 
 
Figure II-19. Bi-side modification of PDMS samples. A) First side modification with AF350. B) Second side modification with 
AF488. C) Merge of both modifications. 
As it can be observed, these modifications can be easily controlled and only the desired surface was 
modified. Regarding the micro-structuration, the technology allowed the possibility to create different 
shapes on the surface using masks. In this sense, the technology presented in this paper, showed the 
potential to create functionalized surfaces capable to be micro-structured with different functionalization 
regarding to each surface. 
At this point, it is important to remark the ability of these new selectively modified surfaces to be 
functionalized in order to present biological activity. Due to the preferential reactivity of the PFM with 
amine-bearing molecules, surfaces coated with PFM could be functionalized with different 
biomolecules55, antibacterial agents like silver76 or even nanoparticles. 
2.3.7 Silver modification onto PDMS plates by PECVD 
Once single and bi-side modification onto PDMS samples were achieved with promising results, the 
next step was to move forward to create antibacterial surface using silver. Therefore, after the 
deposition of pp-PFM onto PDMS plates, samples were incubated with glucosamine and the silver 
mirror reaction was performed to reduce metallic silver on top of the surfaces. 
In Figure II-20, the corresponding WCA results, using silicon-wafers as controls, can be observed, 
showing changes on the WCA. After the reaction between the pentafluorophenyl groups with 
A) B) C)
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glucosamine, WCA changed from 83 ± 1º to 51 ± 1º. Reduced silver by the coated glucosamine 
originated an interesting hydrophobic surface with a water contact angle of 104 ± 1º. This hydrophobic 
surface of metallic silver could be attributed to the nanostructured silver coating (similar to the lotus 
leaves).77,78 Some authors have previously discussed the hydrophobic and superhydrophobic behaviour 
of surfaces, and it seems to be clearly related to multivalued topography where air was trapped79 
beneath the liquid in the valleys.70,80–83 In fact, this hydrophobic effect could maximize the antibacterial 
effect of silver by acting as an antifouling surface to reduce bacterial adhesion. 
 
Figure II-20. WCA, σ (deg), of silicon wafer samples. Samples were modified with different coatings on the surface, pp-PFM 
(PFM), pp-PFM + glucosamine (Glucosamine) and pp-PFM + glucosamine + silver (Silver). 
2.3.7.1.1 ToF-SIMS Analysis of Modified Surfaces 
In order to demonstrate that surface modification onto PDMS was possible, the corresponding TOF-
SIMS spectra, positive and negative ion, of PDMS samples with PFM, glucosamine, and silver coatings 
were studied (see the Supporting Information). The nonmodified PDMS samples showed the silicon 
mass fragment, m/z = 28, and additional PDMS typical peaks -𝑆𝑖𝐶𝐻34, 𝐶𝐻3𝑆𝑖𝑂6, 𝑆𝑖𝑂76, 𝑆𝑖𝐶3𝐻84, 𝐶𝐻3𝑆𝑖𝑂76 
and 𝑆𝑖7𝑂𝐶9𝐻:94  (m/z = 43, 59, 60, 73, 75 and 147).84 The PFM modified samples exhibit the typical 
methacrylate low mass fragments -𝐶7𝐻34 and 𝐶7𝐻94(m/z = 27 and 29);85,86 however, there was an 
interference between PDMS and PFM signals on the positive spectra. In these types of samples (PDMS 
based), the negative mass fragment ions could be more interesting in order to elucidate the fragments 
of the coating. In this case, the typical negative ion fragments related with the fluorinated ring consisted 
of -𝐹6 and 𝐹7𝐻6 (m/z = 19 and 49). 
These fluorinated fragments confirmed the fluorinated ring in the polymeric structure, which was key 
for the further reactivity. Moreover, reassembling a series of different mass fragments (Table II-1) 
related with the fragmentation of the monomer confirmed the retention of the monomeric structure. In 
all spectra, there was a higher concentration of low-mass fragments. However, the presence of the 
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molecular ion (M) could be detected at M+1 (m/z = 253). This effect of high concentration of low-mass 
fragments could be caused by a little etching or ablation process of the polymer, consequently with a 
coating reactivity decrease caused by plasma powers.87 
Table II-1. Structure of Characteristic Peaks of pp-PFM. Possible Structure of the Secondary Ions for the Characteristic Peaks 
of the pp-PFM under Pulsed Plasma Conditions. 
 
Additionally, an overlapping of the characteristic glucosamine peak can be observed (m/z = 72 and 
180)88,89 with the PDMS mass fragments when glucosamine sample (PDMS coated with PFM and 
incubated with glucosamine) was analysed. Finally, silver samples presented more simple spectra with 
the characteristic silver peaks -Ag+ (m/z = 107 and 109). 
At this point, what was really interesting was the possibility to observe the reactivity of the coatings 
by the variation on the fragments intensity.90,91 There was an intensity variation between PFM 
characteristic peaks on the PFM-coated samples and glucosamine-coated samples. Initially, PFM 
samples presented a high intensity of m/z = 167 and 253 (about 0.04 for both cases), but after 
incubation with glucosamine both intensities were reduced (about 75% and 50% for m/z = 167 and 253, 
respectively) as a consequence of the reaction between the ester and glucosamine. 
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2.3.7.1.2 Surface Structuration of Silver Coated PDMS Samples 
Besides examining the physical and chemical properties of the plasma treated films, the surface 
morphology was also investigated using an optical microscope and a scanning electron microscope 
(SEM). In Figure II-21, a PDMS sample containing a thin film of metallic silver onto its surface is 
presented. As it can be observed, metallic silver was microstructured using a TEM grid to produce 
structured metallic silver surfaces onto flexible materials, such as PDMS. Additionally, the metallic silver 
was only located on the modified areas where the functionalization agent was immobilized. The 
controlled process and the structuration ability of the PECVD technique allowed the possibility to 
fabricate complex structures onto the surface without limitations. 
 
Figure II-21. Surface microscopy of structured silver surfaces. Optical microscopy of micro- and nanostructured silver coating of 
plasma polymerized PFM onto PDMS substrates for antibacterial applications. 
In addition, significant differences in surface morphology were found between modified areas and 
nonmodified areas of PDMS samples. In Figure II-22 – A and B, the novel ability to structure the surface 
by PECVD can be clearly observed. This type of plasma modification technique allowed the possibility 
to fabricate homogeneous geometries with different chemical composition on the surface. In contrast 
to the surface homogeneity of the unmodified area, there was an increase of roughness on the areas 
that have been microstructurated (Figure II-22 –A, B) attributed to the polymerization of the PFM onto 
PDMS surface. Furthermore, in Figure II-22 –C, D the nanostructuration of the silver coating resulted 
A) B)
C) D)
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in nanostructured branches and silver nanoparticles (about 70 - 150 nm) can be observed onto the high 
flexible PDMS surface. 
 
Figure II-22. Surface characterization of samples: SEM images of silver modified samples. A) modified sample with a G50P 
mask (Gilder Grids), B) magnified section of the grid structuration, C) nanostructuration of the modified area showing the 
multivalued roughness, and D) magnified of the nanostructuration of the modified area showing the fractal-like structures 
(modified area, black arrow; non-modified area, white arrow). 
After the characterization of the surface morphology, modified samples were incubated for 2 h with 
different solvents (water, ethanol and hexane) in order to assess the behaviour of the nanostructure 
after immersion in solvents of different polarities. In Figure II-23, it can be observed that after the 
immersion of the samples with ethanol or hexane, the micro– and nano-structures did not change their 
size and shape (see Figure II-22 – 3, 4). This can be explained because ethanol and hexane did not 
interact with the silver nanoparticles and the silver coating. However, when samples were incubated 
with water there was an interesting change in the nanostructure, while the microstructure remains 
unaltered. As it can be observed in the water-incubated sample, the nanoparticles around 70-150 nm 
have disappeared and the remaining nanoparticles were around 20-40 nm. This can be explained by 
the digestive ripening92,93 where (contrary to the Ostwald ripening94–96 where small particles dissolve 
and diffuse to large nanoparticles) large nanoparticles broken apart and small nanoparticles increased 
A) B)
D)C)
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until a stable and uniform size was reached. As a result, water incubation resulted in a homogeneous 
distribution of small silver nanoparticles. 
 
Figure II-23. Surface morphology of silver-coated PDMS samples after immersion with different liquids (water, ethanol, and 
hexane). 
Considering that future devices will be in contact with different body liquids, such as mucus in the 
case of the trachea, the previously observed hydrophobic behaviour of the silver coated samples, was 
evaluate with mucus (mucine to simulate the mucus). In Figure II-24, when samples were treated with 
water, silver coated silicone samples showed an increase in the WCA higher to 100º in contrast with 
the 75º of the nonmodified silicone, similar to the previous results with silicon wafers, Figure II-20. In 
addition, silver coated samples showed a similar behaviour when treated with mucine, with an increase 
to 100º of the WCA. This increase in the hydrophobicity of the surfaces was very interesting to maximize 
W
at
er
Et
ha
no
l
He
xa
ne
Chapter II. Antibacterial Surfaces 
53 
the antibacterial effect of silver coated samples by acting as an antifouling surface, reducing bacterial 
adhesion. 
 
Figure II-24. WCA of silicone and silver modified silicone with water and mucine(10% p/v). 
2.3.7.1.3 Behavior of Silver Coated 3D Structures 
Additionally, silver coating was deposited onto a PDMS tube in order to demonstrate the method’s 
novelty with complex shapes, such as 3D structures. As it can be observed in Figure II-25, the coating 
was perfectly adapted to 2D or 3D surface. In order to assess the flexibility of the coating, samples were 
twisted several times to observe the stability of the coating. These results showed that the coated tube 
could be easily twisted and non-delaminated after the implantation process because the thickness and 
flexibility of the coating allowed it to be adapted to the shape. 
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Figure II-25. Surface behaviour of 3D modified samples. Different PDMS-coated geometries before being twisted, during the 
twisting process, and finally, after being twisted. 
2.3.7.1.4 Silver Release of Coated PDMS Samples 
The silver release of PDMS samples coated with silver (total amount of silver-coated samples, about 
0.45 ± 0.15 µg / mm2) is illustrated in Figure II-26. Initially, there was a maximum release of Ag+ about 
0.6 and 1.1 ppm (from TSB media and Milli–Q water, respectively) between the first 24 h of incubation. 
During the following 10 days of incubation, a concentration decay and a subsequent stabilization of 
silver ion release of about 0.1 ppm can be observed. As it is well-known, the antibacterial activity of 
silver is not attributed to a metallic element but to the silver ion (Ag+). Its activity mechanism is currently 
controversial, however it seems to be related to the complexation ability between silver ion and 
cysteine,21,97 interaction with DNA,98,99 cell disruption, 36 or inhibition of electron transport.100,101 
Non-twisted Twisted After-twisted
2D
3D
Chapter II. Antibacterial Surfaces 
55 
 
Figure II-26. Silver release of samples in different media, TSB and Milli-Q water in oxic conditions. 
In addition, in Figure II-26, different release profiles can be observed between water and TSB media 
related to the pH variation, 5.5 and 7.3 for water and TSB media, respectively. According to the 
thermodynamics of the silver oxidation, the amount of dissolved silver was directly proportional to the 
amount of dissolved oxygen and indirectly proportional to the pH.102 Consequently, acidic pH increased 
silver release while basic pH decreased the silver release of silver ion. However, in the previous 24 h, 
even samples incubated with water and TSB media showed a burst of silver release that did not follow 
the kinetics of the oxidative reaction and was attributed to the release of the chemisorbed silver from 
the metallic silver surface.103 
In order to further assess the release of the chemisorbed silver, in Figure II-27, samples incubated 
with oxic and anoxic conditions can be observed. In comparison with the oxidative conditions, 1.1 and 
0.6 ppm for water and TSB, respectively, in anoxic conditions there was a mildly release of silver, around 
0.5 and 0.3 ppm for water and TSB, respectively. This silver release under anoxic conditions could not 
be attributed to the oxidative process as samples were incubated in an argon atmosphere and with 
absence of oxygen in the media, that was previously degassed with argon. These results proved that, 
at the beginning, both phenomena happened at the same time, the release of the chemisorbed silver 
ions from the metallic silver surface to the media that produced the initial burst release and the oxidative 
process. 
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Figure II-27. Concentration of silver in solutions incubated with oxic and anoxic conditionsfor 5 h and 1day. 
At the beginning, Figure II-28, there was an initial burst of silver due to the release of the chemisorbed 
silver ions (fast and short process) and, at the same time, a homogeneous and stable release (slow 
and long process) due to the oxidative dissolution of the silver metal deposited on the surface. 
The initial burst of silver was very promising due to its high concentration. This was because the 
reversible bacteria adhesion onto the medical implants occurred in the first hours after 
postimplantation.71 High initial concentrations of silver ions in a short period of time could be a 
tremendous advantage to enhance the antibacterial activity once the device is implanted on the body. 
In addition, a continued release after this initial burst is desired in order to avoid the formation of the 
biofilm structures that takes place over a large time period.104 
 
Figure II-28. Scheme of silver ion release. Initially, there is a desorption of the chemisorbed silver and an oxidative process, and 
at the end only the oxidative process takes place.103 
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At this point, it was important to compare the experimental silver ion concentrations released with the 
necessary silver concentrations for antibacterial activity. The initial concentrations, about 1.1 ppm for 
the water incubation and about 0.6 ppm for TSB, were clearly higher than the minimum concentration 
required for antimicrobial efficacy, 0.1 ppb71. In addition, even the basal release extended a long time, 
0.1 ppm for Milli-Q water and TSB media, was higher than the minimum concentration. Moreover, these 
silver ion release levels were lower than the maximum toxic concentration for human cells, 10 ppm.105 
2.3.7.1.5 Bacteria Cultures onto Silver Coated Surfaces 
In order to test the antibacterial activity of the modified samples, PDMS were incubated using S. 
aureus and P. aeruginosa as Gram-positive and Gram-negative representatives, respectively. In 
Figure II-29A, the bacterial growth and biofilm structures can be clearly observed, especially on the 
nonmodified P. aeruginosa samples. However, the antibacterial effect of the silver ions onto the 
modified surfaces can be observed, causing a considerably decrease on bacteria viability, showing a 
0% of bacterial survival. In Figure II-29B, an increase in the bacterial death caused by the silver coating 
can be observed. In addition, both strains had the same behaviour showing about 100% bacterial cell 
death in contrast to the 25% bacterial cell death in the control samples (PDMS). 
Additionally, no extra bacterial adhesion on the modified surfaces could be observed as a 
consequence of the high antibacterial action of the silver ions and due to the hydrophobic surfaces 
caused by the nanostructures of the silver coating. In addition, after incubation of the nonmodified and 
modified samples with 105 cfu / mL (Figure II-29C) there was a complete reduction of bacteria viability, 
causing the death of all bacteria in the media. 
Taking into account that post-implantation problem of bacterial colonization is localized on the device 
(not systemic) and requires the extraction of the stent and implantation of a new one, the goal of this 
work consisted on design an antibacterial device that is able to protect itself against bacteria 
colonization and increase the life-time of the device. In addition, the silver release in the surroundings, 
close to the surface of the modified samples, showed clear antibacterial properties avoiding the 
attachment of the bacteria and causing bacteria death. 
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Figure II-29. Bacterial viability on coated and noncoated samples: A) bacterial cultures of different modified samples with silver 
stained with Live&Dead kit [Non-modified PDMS samples (PDMS) showing biofilm formation and silver-coated PDMS samples 
(silver); scale bar, 20 μm]; B) bacterial death comparison between different bacterial strains [results obtained analyzing previous 
images using imageJ software]; C) bacterial viability in the supernatant after being incubated with nonmodified and silver-coated 
samples with 105 cfu / ml. Row 1 is S. aureus, and row 2 is P. aeruginosa. 
2.3.7.1.6 In Vitro Cytotoxicity of Silver Coated Samples 
The in vitro cytotoxicity of the silver-coated surfaces was evaluated on COS-7 cells using MTS assay 
and silver nitrate as comparison. Cells were incubated with different silver releases with concentrations 
of silver ions around 0.5, 0.3, 0.2 and 0.1 ppm (obtained from cumulative release of samples incubated 
for 1, 2, 3 and 6 days, respectively). As shown in Figure II-30, no differences were observed for the 
released silver ions in the media in comparison with silver nitrate. Silver ions, in the range of the tested 
levels, showed no significant decrease in cellular viability. These results showed that the concentration 
of the silver ions released from the silver-coated samples were highly biocompatible for COS-7 cells. 
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Figure II-30. Cell viability of silver modified samples on COS-7. Cells were incubated with media that was previously incubated 
with the nonmodified and modified samples for 1, 2, 3 and 6 days (0.5, 0.3, 0.2 and 0.1 ppm of silver ions, respectively). Cell 
viability (%) is expressed relatively to the untreated control cells. 
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2.4 Concluding Remarks 
As it has been commented previously, in the current development of medical devices it is imperative 
to design and control the surfaces of the materials used. In this work, plasma treatments let to control 
the modification process and created selectively single or bi-side modified surfaces capable to 
covalently react with amine-bearing molecules. Additionally, different topologies on surfaces can be 
easily achieved with the ability to model the macroscopic and microscopic surface morphology and 
carries out chemical pattering. In addition, the process allowed to control the modification area and even 
the selectivity modification of each side of the material. Thus, medical devices could be selectively 
functionalized regarding to each side with different biological activities to interact with different tissues 
at the same time. 
This work presents a novel methodology to create new structured surfaces capable to covalently 
immobilize nanostructured antibacterial agents, such as silver, showing hydrophobic surfaces to reduce 
biofilm formation and bacterial colonization. Additionally, this methodology has the advantage that it 
can be applied on different substrates and shapes allowing the possibility to microstructure the surface. 
Furthermore, the silver coating showed a highly antibacterial activity against Gram-positive and Gram-
negative bacteria due to the silver ion release. Additionally, the hydrophobic behaviour related to the 
nanostructuration of the silver coating reduced bacteria adhesion and biofilm formation that contributed 
to a lower probability of postimplantation infections. 
Finally, the initial rapid release of silver ion presented a remarkable antimicrobial activity within the 
first 24 h, followed by a lower sustained release for 20 days, which prolonged the biological activity of 
the device. The silver amounts achieved during the release showed no cytotoxic effect for COS-7 cells, 
but silver concentration was high enough to avoid P. aeruginosa and S. aureus adhesion. As a result, 
these functional surfaces could be promising candidates to develop implantable materials with 
antibacterial properties. 
Once the development of a methodology to produce antibacterial surfaces onto the silicon-base 
materials, such as PDMS, has been achieved, the next step of this work will consist on the development 
of a surface platform for therapeutic drug delivery system. As previously described, the next unmet 
clinical need consists on the development of drug delivery surfaces to treat surrounding tissues of 
implanted devices, such as stenotic tissues. Therefore, considering the ability to selectively modify each 
side of the material, the next chapter will be focused on the development of silicon-based surfaces with 
a drug delivery system using nanoparticles capable of releasing antiproliferative drugs. 
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3.1 Introduction 
The previous chapter (Chapter II) showed a study of plasma surface modification (grafting and 
PECVD) capable of modifying the surface of different materials, such as silicone for medical 
applications, to fabricate reactive bioactive surfaces. These modified surfaces were designed to react 
specifically with amine-bearing molecules via the activated ester contained in the polymeric layer. In 
addition, the novelty and versatility of this technique allowed to selectively modify different surfaces of 
the same material with different reagents. This allows bi-side modification, which opens a wide range 
of modifications and coatings to provide different bioactivity to materials in order to interact with different 
tissues at the same time. 
The combination of the modified surface with a modified silver mirror reagent resulted in a metallic 
silver coating on the surface of the materials. In addition, the silver coating was completely flexible, 
avoiding cracking, due to the nanometric thickness. Additionally, it was observed that the resulting 
metallic surface was formed by fusion of silver nanoparticles yielding a nano-structuration with 
interesting hydrophobic properties (similar to the lotus leave). Finally, the developed silver surface 
showed antibacterial and antifouling properties against gram-positive and gram-negative strains. 
In this context, and considering the second main problem after stent implantation, which is the 
recurrence of the tracheobronchial stenosis and granulation tissue formation, this chapter aims to 
design a solution to treat biological tissues with abnormal growth, such as stenotic or granulation tissue 
using drugs. 
As mentioned before, tracheal stenosis is defined by a gradual reduction of airway lumen caused by 
different conditions.1 Stenosis carries different degrees of morbidity and even causes death by 
asphyxiation if it is not treated correctly.2 Often, its diagnosis occurs in advanced stages in the form of 
severe acute respiratory insufficiency, which requires urgent treatment.3 
Different benign and malignant conditions can cause tracheobronchial stenosis resulting in a 
respiratory distress with dyspnea, and if not treated early, can lead to asphyxia and death. The most 
common benign etiology is usually prolonged post-intubation and prolonged post-tracheotomy4,5, 
although there are other causes, such as idiopathic, infections, chemical aggressions 
(gastroesophageal reflux or toxic inhalation), radiotherapy or associated systemic diseases (i.e., 
Wegener). Despite the different causes, the most common mechanism seems to be an abnormal re-
epithelialization with chronic inflammation and fibrosis of the epithelium-tracheal mucosa after an 
aggression, which conditions an increase of the thickness of the mucosa.6 
Post-inflammatory tracheal stenosis is the most common non-malignant tracheal lesion and is usually 
caused by prolonged ischemia and concomitant infection causing tracheal wall necrosis. Repair of the 
damaged wall may result in abnormal formation of granulation tissue and stenotic scarring.7 Regarding 
the malignant tracheal stenosis, it originates from primary tumors of the thorax (lungs, pleura and 
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esophagus) or from metastases. Different resective endoscopic procedures can be performed to 
recover the opening of the lumen, and once open, to implant a stent to prevent re-stenosis. Current 
stents only present mechanical expansion, obviating adaptability, biocompatibility, biofunctionality and 
stability. However, re-stenosis of post-inflammatory scars (50% of patients)8, as well as the growth of 
inflammatory granulation tissue, can be a life-threatening complication, if it is not treated properly. Both 
complications could be resolved by activating pharmacologically the stents with antiproliferative drugs, 
such as the drug-eluting stents used in cardiology9–11. 
Mitomycin and paclitaxel (PCTXL) are antimitotic drugs that have been used in the treatment of a 
wide variety of tumours and stenotic tissue with effective results reducing the abnormal proliferation. 
The published results, mainly in dogs and in children, indicate that the topical use of mitomycin or 
paclitaxel reduce the tracheal stenotic tissue, avoids the occlusion of the stent, and the restenosis.12,13 
Thus, it is reasonable to propose a combination of local use of antiproliferative agents with stents to 
significantly reduce the stenotic tissue and the tissue growth (granulation tissue) around the stent, 14,15 
resulting in tissue healing and reduced stent implantation time.16,17 In addition, another action of 
antiproliferative drugs, beyond inflammation, would be focused at locally treating some type of tumours. 
For example, after various animal model assays,18 various treatments based on coating stents with 
antiproliferative drugs, such as cisplatin, have been proposed to treat patients with tumors causing 
airway occlusion. 
Some reports indicated a reduction in the tracheal stenosis when mitomycin was applied either 
topically or using a bioabsorbable stent.19–21 However, there is a controversy in the literature regarding 
the beneficial activity of mitomycin. In this regard, the activity of mitomycin depends on the dose, and 
high doses of drug leads to toxic effects.22 Previous results (in animal model) indicated that while with 
low doses of mitomycin (lower than 0.4 mg / mL) showed a reduction of stenotic tissue, higher doses 
of mitomycin (0.4 mg / mL and higher) did not prevent stenosis tissue. These results are especially 
relevant when mitomycin is used to treat laser wound, since a significant risk of acute airway obstruction 
was observed.23 Some studies found necrotic ulcer, skin necrosis, and even tracheal stenosis when 
high doses of mitomycin were used (0.5 mg / mL) topically.12,24 According to the literature, it seems that 
the activity of topical mitomycin is highly dose-dependent showing interesting results when low dose 
was used and tissue damage, if the correct dose was exceeded. 
Similar results have been observed when topically paclitaxel was used in the trachea wall and even 
in the bile duct.25 Local drug accumulation of paclitaxel could damage the tissue in contact, leading to 
epithelial denudation, moderate mucosal inflammation and fibrosis. However, these damages were 
expected and acceptable respectively to safety, considering the beneficious clinical therapeutic 
results.26,27 Recent studies have demonstrated a reduction of tissue growth around the stent and a 
reduction of stenotic tissue, increasing patient’s patency, when paclitaxel was used topically, with drug-
eluting balloon or with exhale drug eluting stents.15,16,21,28,29 Therefore, considering all the data around 
the use of paclitaxel to treat stenotic tissues, in the airway track and even in cardiology, paclitaxel 
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showed promising results to create drug eluting stents with a controlled time-release and doses to treat 
stenotic tissues and increase stent patency. 
As mentioned before, the main problem and limitation of using antiproliferative drugs is the local 
concentration in the treatment area. Topically administered drugs showed high concentration, and due 
to the different histological differences of trachea wall compared to blood vessels, the accumulated 
drugs caused important damages in the tissues. In contrast, when this type of drugs where used in 
blood vessels, where blood flow produces a continuous lavage of drug, there was no overdose in the 
treatment area and no toxic or damaging effects on tissues were observed.28 
In addition to dose-dependent toxic effects and poor therapeutic outcomes caused by the systemic 
distribution of PCTXL, the application of PCTXL is compromised due to its poor solubility in aqueous 
media. To overcome these disadvantages, various drug delivery systems, such as liposomes30, 
nanoparticles (NPs),31,32 polymer drug conjugates33 and micelles34, have been developed from different 
viewpoints. Among them, biodegradable polymeric NPs in the range of 70-300 nm, have been 
successfully utilized to encapsulate PCTXL, reducing PCTXL-associated side effects as well as better 
therapeutic benefits over commercial Taxol.35 
Taking into account the previous described problems when using dose-dependent drugs with non-
controlled delivery system, and considering the demonstrated feasibility of nanoparticles system to 
control the drug delivery, and the clinical benefits of low doses of paclitaxel to treat tracheal stenosis; a 
nanoparticle system capable to release paclitaxel in low doses in a controlled manner over time could 
show promising results to treat tracheal stenosis. However, most nanoparticles systems have been 
designed to be administered through oral36,37 or intravenous38,39 system and this application (tracheal 
stent) requires a surface-immobilized drug delivery system in order to treat only the affected surrounding 
tissues where stent is implanted. Then, the nanoparticles technology must be designed to be able to 
be immobilized onto the surface of the silicone-based materials. 
In this case, the previous chapter (Chapter II) showed the modification of a surface to provide bi-side 
modifications and antibacterial properties. Considering that the system was designed to react with 
aminated-molecules, this creates a wide range of possibilities and applications. Therefore, this 
previously developed technology could be adapted to go beyond the previous results and design more 
complex surfaces with a drug delivery system to release PCTXL in a controlled manner on the desired 
tissues. To obtain a suitable drug delivery system, the polymer must be biodegradable, non-toxic and 
capable of entrapping PCTXL. Additionally, the polymer must be able to form nanoparticles and the 
system must be stable, present amine groups on the surface of the formed NPs and degrade in aqueous 
media. 
To achieve this goal, this chapter seeks to combine the previously described surface modification 
technology, with an adaptation of previously developed intravenous polyester-PEG NPs technology (by 
our research group40) into an effective amine-bearing immobilized drug delivery nanoparticles system 
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for efficient delivery of active drug molecules. The resulting technology could be implemented in the 
surfaces of medical devices, such as tracheal stent, to avoid granulation and stenotic tissue.
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3.2 Materials and Methods. 
3.2.1 Materials. 
Argon 5.0 and oxygen 5.0 were purchased from Abelló Linde S.A. (Barcelona, Spain). PFM was 
purchased from Apollo ScientificLTD (Stockport, UK). Acetone, acetic acid, methanol, tween-80, 
fluorescein diacetate (FDA), 1,8-octanediol (98%), D-(+)-Glucosamine hydrochloride (99%), ethidium 
bromide (EB), Phalloidin-TRITC, 4',6-diamidino-2-phenylindole (DAPI), Triton x-100, Phosphate-
buffered saline (PBS), paraformaldehyde (PFA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), insulin human transferrin and sodium selenite (ITS), docetaxel and amphotericin B were 
purchased from Sigma-Aldrich (Madrid, Spain). PEG bis(amine) (Mw 2.000) were purchased from 
Sigma-Aldrich and Iris Biotech GMBH (Marktredwitz, Germany). Glutaric acid (99%) was obtained from 
Alfa Aesar (Haverhill, USA). Paclitaxel (PCTXL) was purchased from Yunnan Hande Bio-Tech CO, 
LTD, (Kunming, P.R. China). Ultrapure water (Milli-Q) was obtained using a Synergy UV® system from 
Merck Millipore (Billerica, MA, USA). 
DMEM high Glucose with L-Glutamine, F12K, EMEM, fetal bovine serum (FBS), penicillin and 
streptomycin were purchased from Gibco Life Technologies (Grand Island, NY, USA). 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) was purchased from MBL, International 
Corporation (Woburn, MA, USA). Sylgard 184 kit was purchased from Ellsworth Adhesives (Madrid, 
Spain) and Si-wafers were purchased from Wafer World (West Palm Beach, FL, USA). 
3.2.2 Preparation of substrates. 
The Si-wafers and PDMS substrates were prepared as described in the previous chapter. Briefly, 
Sylgard kit (10:1) was spread using a paint applicator to obtain films of 500 µm thickness and incubated 
overnight at 70°C. Then, films were cut in circular shapes of 21 and 10 mm. PDMS samples were 
washed with 5% SDS solution, rinsed with Milli–Q water, washed with 2% Hellmanex solution, rinsed 
again with Milli–Q water and finally with ethanol. Si-wafers were washed with the same protocol as 
PDMS samples. Finally, samples were dried in a stream of nitrogen and stored. 
3.2.3 Surface modification by plasma techniques 
The surface modifications carried out in this work were performed using a stainless steel vertical 
plasma reactor as it was described in the previous chapter using the SSVPR. Briefly, for plasma 
polymerization, vacuum was started until the base pressure of 0.001-0.003 mbar for was reached. Then, 
PFM was regulated trough the needle valve and introduced to the reactor chamber in a vapour phase 
(heated at 75 ºC) until 0.02-0.03 mbar. The continuous radio frequency power was fixed at 15 W 
(working power) and pulsed plasma polymerization duty cycle (DC) of 10/20 [DC = ton/(ton+toff)]41 was 
carried out for 3-10 min. Plasma discharge was then turned off, and the PFM vapour flow was kept 
constant for additional 15 min. After the polymerization process, plasma-polymerized PFM (pp-PFM) 
samples were carefully removed from the reaction chamber and stored until further use under argon 
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atmosphere. For plasma activation, a working power between 10-100 W was used and instead of PFM, 
oxygen gas was feed until a working pressure of 0.14 mbar for the desired experimental time (1-40 min) 
was reached. 
After the treatment, the monomer or gas valves were closed, vacuum was cut off, and samples were 
removed from the reactor and stored under an argon atmosphere until further use. 
3.2.4 Polymer Synthesis 
A block co-polymer, constituted by a rigid and a flexible alternating blocks, was synthesized by the 
esterification of 1,8-octanediol with glutaric acid and subsequently with PEG bis amine. 
3.2.4.1.1 Microwave Polycondensation Polymer (PAm) 
Briefly, 1,8-octanediol (5.48 g, 37.5 mmol) and glutaric acid (5.95 g, 45 mmol), molar ratio of 1:1.2, 
were reacted in a microwave reactor (Discovery CEM) at a power of 100 W for 60 min.40 The reaction 
was performed under vacuum (100 mbar) with continuous stirring and cooling the system with 
compressed air to maintain the temperature constant at 120 ºC. Once the pre-polymer or rigid block 
was generated (PreAm), it was subsequently reacted with PEG 2000 at a molar ratio of 1:1. The 
polycondensation was performed in the microwave reactor under the previously described conditions. 
The resulting polymer (PAm) was stored in a desiccator until used. 
3.2.4.1.2 Polymerization via acid chloride (PAmN) 
Briefly, 1,8-octanediol (200 mg, 1.4 mmol) and glutaryl dichloride (0.21 mL, 1.6 mmol), molar ratio of 
1:1.2, were reacted with continuous agitation at 70 ºC for 30 min. Then, PEG 2000 in a molar ratio of 
1:0.2 with 1,8-octanediol, was added and the polycondensation was performed at room temperature for 
45 min. After the reaction, the polymer was washed three times with MilliQ-water to rinse the non-
reacted PEG 2000. The resulting polymer (PAmN) was stored in a desiccator until used. 
3.2.5 Nanoparticles Synthesis 
Nanoparticles were obtained according to a modified nanoprecipitation method (or solvent 
displacement method)42 using a KD Scientific syringe pump (Holliston, USA). Briefly, 20 mg of (PAm or 
PAmN) polymer were suspended in 1 mL of acetone. The solution was vortexed and collected in a 1 mL 
syringe (4.70 mm inner diameter) connected to a peek tube (1/16" OD x .010" ID) using a Luer Adapter 
1/4-28 (IDEX Health & Science, Oak Harbor, USA) and placed in the syringe pump. The droplets were 
collected in a 20 mL of Milli–Q water with an agitation about 120 rpm at room temperature. The syringe 
pump was set with a continuous flow rate of 50 µl/min. 
In order to encapsulate drugs, such as paclitaxel (PCTXL), 20 mg of polymer and the specified 
quantity of PCTXL were dissolved in acetone, a suitable organic solvent pharmacologically accepted 
regarding to toxicity. This organic phase was then added to a dispersing phase, in which the polymer is 
insoluble, using the syringe pump as described previously. The resulting nanoparticles (NPs) 
suspension was stirred at room temperature until complete evaporation of the organic solvent. 
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After nanoprecipitation and solvent evaporation, NPs were purified by centrifugation or tangential flow 
filtration (TFF). Briefly, the centrifugation processes (EBA 21, Hettich Centrifuge, Tuttlingen, Germany) 
was performed at 6000 g for 45 min with an ultra-centrifugal device (Amicon Ultra-15, Ultracel 
membrane with 100.000 MWCO, Millipore, USA). The supernatant containing the dissolved free drug 
was discarded and the pellet was suspended with Milli–Q water and the suspension was ready to use. 
The TFF process was performed using a regenerated cellulose membrane (Pellicon® XL Cassette, 
Ultracel® 300 kDa, 0.005 m2, Millipore, USA) with a peristaltic pump. Briefly, a freshly precipitated NPs 
suspension was mixed the same volume of Milli–Q water. Then, after sonicating and washing the TFF 
cassette with Milli–Q water, the flow rate of the pump was adjusted to 30-50 mL/min to ensure optimal 
tangential flow filtration process (according to the manufacturer’s instructions). The diluted NPs 
suspension was connected to the “feed” and “retention” tube, and the “permeated” tube (waste) was 
connected to a waste beaker. During the filtration process, Milli–Q water was added to the NPs 
suspension until the osmolality of the suspension was lower than 10 mOsm/kg (analysed with a Fiske® 
Micro-Osmometer, 210, Tecil S.A., Spain). When the filtration process was completed, the suspension 
was ready to use. 
Finally, in order to determine the nanoparticles recovery, the filtrated NPs suspension was freeze-
dried (Telstar, LyoAlfa 6, Terrassa, Spain) for 48 hours without lyoprotectant. The nanoparticles 
recovery was calculated using Equation III-1. 
Equation III-1. Nanoparticles Recovery. 
𝑁𝑃𝑠	𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦	 %𝑤𝑤 	 = 	 𝑀𝑎𝑠𝑠	𝑜𝑓	𝑁𝑃𝑠	𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑	𝑀𝑎𝑠𝑠	𝑜𝑓	𝑝𝑜𝑙𝑦𝑚𝑒𝑟	𝑎𝑛𝑑	𝑑𝑟𝑢𝑔	𝑢𝑠𝑒𝑑	𝑖𝑛	𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛	 	𝑥	100 
 
3.2.6 Nanoparticles Characterization 
3.2.6.1.1 Determination of Nanoparticles Size, Polydispersity and Surface Charge 
and Morphology 
The NPs size distributions and polydispersity were measured by Dynamic Light Scattering (DLS) 
(Zeta Sizer Nano Series, Malvern Instruments, UK) at 25 ºC with a scattering angle of 90º. Briefly, just 
after centrifugation and resuspension of NPs, sample or a dilution about 1:10 with Milli–Q water was 
measured with the DLS. For each sample, the intensity-weighted mean value was recorded as the 
average of three measurements. 
NPs were also characterized in terms of the zeta (ζ) potential. The analysis was performed in triplicate 
on DLS (Zeta Sizer Nano Series, Malvern Instruments, UK) with a Smoluchowsky constant F(Ka) of 1.5 
to achieve zeta potential values from electrophoretic mobility. For each sample the mean zeta potential 
was recorded as the average of three measurements. 
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3.2.6.1.2 Drug Incorporation Efficiency and Immobilized Drug Quantification 
Freeze-dried NPs loaded with PCTXL and dried PDMS samples with immobilized NPs loaded with 
PCTXL were dissolved in acetonitrile and the amount of entrapped drug was detected by Ultra 
Performance Liquid Chromatography (UPLC) (Waters ACQUITY UPLC H-Class). A reverse phase BEH 
C18 column (1.7 μm 2.1 x 50 mm) was used. The mobile phase consisted in a mixture (65:35 v/v) of 
mobile phase A (Milli-Q water, containing 0.1% of acetic acid) and mobile phase B (methanol, containing 
a 0.1% of acetic acid) and was delivered at a flow rate of 0.6 mL/min. A 1.0 µl aliquot was injected into 
de UPLC system, and total analytical run time was 3 min. Paclitaxel and docetaxel as internal standard 
(I.S.) were quantified by UV detection (λ=227 nm, Waters TUV detector). Drug incorporation efficiency 
expressed as drug content (D.C. %), encapsulation efficiency (E.E. %), and drug immobilization content 
were calculated by Equation III-2, Equation III-3 and Equation III-4, respectively. 
Equation III-2. Drug Content (D.C. %). 
𝐷𝑟𝑢𝑔	𝐶𝑜𝑛𝑡𝑒𝑛𝑡	 %𝑤𝑤 	 = 	 𝑀𝑎𝑠𝑠	𝑜𝑓	𝑑𝑟𝑢𝑔	𝑖𝑛	𝑁𝑃𝑠	𝑀𝑎𝑠𝑠	𝑜𝑓	𝑁𝑃𝑠	𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑	 	𝑥	100 
 
Equation III-3. Encapsulation Efficiency (E.E. %). 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛	𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦	 % 	 = 	 𝑀𝑎𝑠𝑠	𝑜𝑓	𝑑𝑟𝑢𝑔	𝑖𝑛	𝑁𝑃𝑠	𝑀𝑎𝑠𝑠	𝑜𝑓	𝑑𝑟𝑢𝑔	𝑢𝑠𝑒𝑑	𝑖𝑛	𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛	 	𝑥	100 
 
Equation III-4. Drug immobilization content (D.I.C. ng/mm2). 
𝐷𝑟𝑢𝑔	𝐼𝑚𝑚𝑜𝑏𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛	 𝑛𝑔𝑚𝑚7 	 = 	𝑀𝑎𝑠𝑠	𝑜𝑓	𝑑𝑟𝑢𝑔	𝑖𝑛	𝑠𝑎𝑚𝑝𝑙𝑒	 𝑛𝑔𝐴𝑟𝑒𝑎	𝑜𝑓	𝑠𝑎𝑚𝑝𝑙𝑒	 𝑚𝑚7  
 
3.2.6.1.3 In vitro Drug Release Analysis 
In vitro drug release of PCTXL loaded NPs was performed using a modified dialysis-bag diffusion 
technique.43,44 Briefly, a known amount of freeze-dried PCTXL-NPs (about 0.3 mg of PCTXL) was 
suspended in a dialysis bag (regenerated cellulose tubular membrane, Cellu SEP® T2, nominal MWCO 
6000 – 8000, membrane filtration products, Inc, TX) containing 10 mL of PBS solution (0.1 M at pH 7.4 
and 0.3% v/v of Tween-80). The bag with NPs suspension was placed in a 50 mL centrifuge tube (Fisher 
Scientific Company, Houston, TX) containing 30 mL of release medium (PBS solution and 0.3% v/v of 
Tween-80). The system was then shacked with an orbital shaking incubator (LM-450D, Yihder Co., Ltd) 
at 37°C, 200 rpm. Defined aliquots, such as 1 or 2 mL, of released medium was withdrawn and replaced 
with an equal volume of fresh medium to maintain the sink conditions. Then, the withdrawn aliquots 
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were lyophilized, suspended with acetonitrile and filtered through a 0.2 μm syringe filter directly into 
UPLC vials and immediately capped. The total amount of PCTXL released in each time point was 
quantified using UPLC with a reverse phase BEH C18 column (1.7 μm 2.1×50 mm) coupled with a UV 
detector (λ=227 nm, Waters TUV detector). The mobile phase consisted of a mixture of Milli-Q 
water/acetonitrile delivered at a flow rate of 0.5 mL/min. The percent drug release was calculated as 
percentage of the total encapsulated drug. 
3.2.7 Nanoparticles Immobilization 
Nanoparticle immobilization was carried out using a suspension of nanoparticles between 20-
100 mg/mL. The pH of the suspension was adjusted to 7.4 with concentrate sodium hydroxide. The 
immobilization reaction of nanoparticles was performed incubating pp-PFM PDMS samples in a NPs 
suspension for 6 h with an agitation of 140 rpm. After the incubation process, samples were washed 
exhaustively with Milli–Q water and dried with compressed air until further use. 
In order to study the cell viability of different cell types, some samples were incubated with blocking 
agents, such as FBS or collagen, to react with the non-reacted PFM groups. 
3.2.7.1.1 FBS coating of silicones 
After NPs immobilization, NPs immobilized on PDMS samples were incubated with a FBS solution of 
0.1 mg/mL to react with the remaining active points of the PFM coating. 
3.2.7.1.2 Collagen coating of silicones 
After NPs immobilization, NPs immobilized on PDMS samples were incubated with a collagen 
solution of 0.1 mg/mL to react with the remaining active points of the pp-PFM coating. 
3.2.8 Determination of in vitro cytotoxicity of drug-loaded nanoparticles 
In order to evaluate the cytotoxicity of the drug loaded nanoparticles, animal cell line experiments 
were performed using Human Lung Normal Fibroblast (IMR-90, ATCC, CCL-186), Adenocarcinomic 
Human Lung Alveolar Basal Epithelial cells (A549, ATCC, CCL-185), Normal Human Dermal 
Fibroblasts (NHDFs, Promocell, C-12302) and non-stenotic and stenotic Primary Respiratory Human 
Fibroblast, cells extracted from a patient by surgical biopsy, (T-01MVV). 
Human lung normal fibroblasts (IMR-90, ATCC® CCL-186TM) were purchase from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and cultured in EMEM medium supplemented with 
10% FBS and penicillin (100 U/ml) / streptomycin (100 μg/ml) solution according to the manufacturer´s 
recommendations. Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. 
Bronchial-alveolar epithelial human cells (A549, ATCC® CCL-185TM) were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in F12K medium 
supplemented with 10% FBS and penicillin (100 U/ml) / streptomycin (100 μg/ml) solution according to 
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the manufacturer´s recommendations. Cells were maintained at 37°C in a humidified 5% CO2 
atmosphere. 
Normal Human Dermal Fibroblast (NHDFs), were purchased form Promocell (C-12302, Heidelberg, 
Germany) and cultured in DMEM medium supplemented with 10% FBS and penicillin (100 U/ml) / 
streptomycin (100 μg/ml) solution and 1% Glutamine, according to the manufacturer´s 
recommendations. Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. 
All human tissues were procured and managed in accordance with the Declaration of Helsinki, and 
the study was approved by the ethics committee of Hospital Universitari de Bellvitge (Hospitalet de 
Llobregat, Barcelona, Spain). Written informed consent was obtained from all subjects before 
recruitment. 
Adult human tracheal fibroblasts (T-01MVV) were obtained from tracheal tissue from patients who 
underwent surgical procedure for the treatment of tracheal stenosis. The harvested tracheal tissue 
samples were maintained in DMEM high Glucose with L-Glutamine medium with HEPES and insulin 
human transferrin and sodium selenite (ITS) until processing. Then, samples were cut into small pieces, 
and placed into 6 well-plates (Nunc Thermo Scientific, Waltham, MA, USA) with growth medium; DMEM 
supplemented with 10% FBS, penicillin (100 U/ml)/streptomycin (100 μg/ml) solution and 25 μg/ml 
amphotericin B. Cells were cultured at 37 °C in a humidified atmosphere of 5% CO2. Spindle-like primary 
fibroblasts started to grow out from tissue samples on day 2 to 3. Outgrowth of fibroblasts took 1 to 2 
weeks. Tissue samples were then removed by aspiration, and cells were allowed to reach confluence. 
Fibroblasts at confluence were expanded by trypsinization and passaged every 4 to 5 days at 1:4 ratio. 
Tracheal fibroblasts were identified by the typical spindle morphology and immunohistochemistry; 
vimentin and α-smooth muscle actin (α-SMA) positive, and factor VIII and surfactant C-negative 
staining. Cells between passages numbers 4 and 7 were used in this study. 
3.2.8.1.1 Cytotoxicity of Drug Loaded Nanoparticles 
IMR-90, A549, and extracted non-stenotic and stenotic T-01MVV cells were plated in 96-well plates 
at a cellular density of 1000 cells/well. After 24h, medium was aspirated and substituted with medium 
with various paclitaxel concentrations (10 nM, 14 nM and 20 nM) of free drug, 1% and 3% theoretical 
drug loaded nanoparticles. The experiment was designed as the following: one column of cells with 
non-encapsulated paclitaxel at the same range of concentrations (10-20 nM) was used as positive 
control; one column of cells without nanoparticles and without paclitaxel was used as negative control, 
and another column without cells was used as blank. Between 1 and 14 days, cell viability was assessed 
via MTT (Quick Cell Proliferation Assay Kit II, JM-K302-500) following the manufacturer’s instructions 
and pictures were taken to follow the changes in the cell morphology. Briefly, cells were washed with 
PBS and incubated with a solution of the MTT reagent and complete media at 37 ºC. The absorbance, 
which represented cell viability, was measured via microplate reader (Multiskan Ex, Thermo Scientific) 
at 450 nm with 650 nm of reference wavelength. Cells stained positively with MTT were considered 
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viable cells. Cell viability was calculated using Equation III-5 and expressed as percentage of viable 
cells compared to control cells. 
Equation III-5. Cell Viability. 
𝐶𝑒𝑙𝑙	𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦	 % 	 = 	 𝐴𝑏𝑠.[-\,]*− 𝐴𝑏𝑠._]-&.𝐴𝑏𝑠.`%&ab%]− 𝐴𝑏𝑠._]-&. 	𝑥	100 
 
3.2.8.1.2 Viability of Drug Loaded Nanoparticles Immobilized onto PDMS plates 
Cell culture dishes were washed with 4 mL PBS 1X and treated with 2 mL of trypsin for 3 min at 
37 ºC. Next, the activity of trypsin was inhibited by the addition of 8 mL of supplemented DMEM. Then, 
the cell suspension was centrifuged at 1000 rpm during 5 min and suspended with the appropriate 
volume of cell culture media to achieve the desired cell concentration. 
Cells were seeded onto the silicones previously subjected to different treatments at a cell 
concentration of 1.2x105 cells/mL for the silicones (45900 cells/silicone). As control, cells were seeded 
in well of the plate without silicone at a cell concentration of 1.2x105 cells/mL for the 24-well plate wells 
(52312 cells/24-well plate). Cell densities were calculated taking into account the surface area 
difference between the silicones and the 24-well plate wells. 
3.2.8.1.3 Live & Dead Staining 
In order to evaluate the toxicity of cells cultured onto silicones, cells were treated simultaneously with 
fluorescein diacetate (FDA) and ethidium bromide (EB). FDA is used as viability probe that measures 
both enzymatic activity and membrane integrity. The first, leads to the hydrolysis of FDA by intracellular 
esterases yielding fluorescein, while the latter allows the intracellular retention of the fluorescent 
product. In contrast, EB is not permeable for living cells and it only stains dead cells or cells with a 
damaged cell membrane. 
First, culture medium was removed from the well using a micropipette and cells were washed three 
times with PBS 1X. Next, cell cultures were covered with 100 µl of staining solution, which contains 
FDA and EB in a concentration of 10 µg/ml and 40 µg/ml in PBS 1X respectively45–47. Cells were 
incubated with the staining solution during 5 min in the dark at room temperature. Then, the staining 
solution was removed and cell cultures were washed three times with PBS 1X. Finally, cell cultures 
were observed under fluorescence microscope (Axiovert 200M inverted microscope with coupled 
ApoTome system, Carl Zeiss AG, Germany). 
3.2.8.1.4 Dapi/Phalloidin Staining 
This staining method allows the simultaneous observation of the cell nuclei and cytoskeleton, as DAPI 
(4',6-diamidino-2-phenylindole) binds to the minor groove of double stranded DNA and phalloidin binds 
to the F-actin filaments of the cytoskeleton of cells. First, cell cultures were fixed with sterile 1% (w/v) 
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PFA for 30 min at 4 ºC, then three washes of 10 min each with PBS 1X on an orbital shaker were 
performed. Next, in order to permeabilize the cell membrane, fixed cell cultures were incubated with a 
0.1% (v/v) Triton x-100 in PBS 1X during 30 min at room temperature. Then, cells were incubated with 
Phalloidin-TRITC at a final concentration of 1 µg/ml in PBS 1X for 25 min in the dark. Next, a DAPI 
solution of 1µg/ml was added onto the previous solution and incubated for 5 min in the dark. Finally, 
three washes of 10 min each with PBS 1X on an orbital shaker were performed. Samples were observed 
under fluorescence microscope (Axiovert 200M inverted microscope with coupled ApoTome system, 
Carl Zeiss AG, Germany). 
Unless otherwise stated, all experimental data were done in triplicate and the average mean was 
represented with standard deviation represented as error bars. 
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3.3 Results and Discussion 
As mentioned before, in order to obtain an immobilized drug delivery system based on the previous 
developed surface technology, it was necessary to develop and characterize a degradable polymer. 
The structure of this polymer must present terminal amines in order to react with pp-PFM. Additionally, 
this polymer must be capable form nanoparticles and entrap hydrophobic drugs such as paclitaxel. 
Finally, the resulting drug delivery system should present a controlled antiproliferative activity against 
different types of cells such as fibroblast over time in order to avoid stenotic tissue, recurrence and 
reduce the toxic behaviour of high doses of paclitaxel. 
3.3.1 Synthesis and Characterization of Block Co-polymers PAmX 
Polyester-PEG polymers, have been described as suitable polymers to be used for encapsulation of 
hydrophobic drugs, such as paclitaxel.42–44 Previously in our group, a degradable polymer capable to 
create nanoparticles were synthesized.40 The design of the polymer allowed to entrap hydrophobic 
drugs, such as paclitaxel in order to create a controlled drug-release platform. Therefore, an amphiphilic 
polymer was necessary to design to encapsulate hydrophobic drugs and disperse the nanoparticles or 
polymer-drug conjugates in aqueous media. The proposed co-polymer, presented a rigid block 
(polyester) suitable to encapsulate hydrophobic drugs and secondly, a flexible block (PEG), which 
consists of a hydrophilic molecule to stabilise the core in aqueous media. However, the resulting 
nanoparticles were not able to react with the previously developed pp-PFM surfaces because no amines 
were present in the structure of the initial polymer. Therefore, an PEG with an amino terminal group 
was selected in order to create nanoparticles with an amine corona capable to react with the reactive 
pp-PFM surfaces. 
 
Scheme III-1. Synthesis of block co-polymer PAmX by polycondensation. 
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Block co-polymers PAmX formed by flexible (PEG bis amine 2000) and rigid blocks (1,8-octanediol 
and glutaric acid) were synthesized by polycondensation. The characterization of the obtained polymers 
was determined by using FTIR, 1H-NMR and GPC. In Figure III-1 can be observed the FTIR of PAm 
and PAmN polymer, which are consistent with the expected structure. A strong band at 1732-1735 cm-
1 can be observed corresponding to the C=O stretch of the ester. In addition, the absorption band at 
3200-3500 cm-1 can be attributed to the N-H stretch (for both polymers) and even some residual O-H 
stretch of non-reacted 1,8-octanediol (in the case of PAm). At 2919-2850 cm-1, the C-H stretch band of 
the polyester CH2 can be observed. In addition, some differences between both polymers (PAm and 
PAmN) can be observed such as the band between 1180-1148 cm-1 corresponding to C-N stretch of 
aliphatic amines. These differences could be explained by the presence of residual non-reacted PEG 
bis amine. After the synthesis of each polymer, PAmN was washed gently with Milli-Q water, while the 
PAm was used without any workup or washing step which may result in the presence of unreacted 
PEG. 
 
Figure III-1. FTIR spectra of the synthesized polymers. 
Taking the IR spectrum results into account, the composition of the different polymers was confirmed 
by 1H-NMR. In Figure III-2 and Figure III-3, the 1H-NMR spectrum of the PAm and PAmN polymers can 
be observed, respectively. The large signals at 3.63 and 3.64 ppm (PAm and PAmN, respectively) were 
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assigned to the methylene groups of the PEG bis amine 2000 (signal 11). The multiplets at 4.05 and 
4.06 ppm (PAm and PAmN, respectively), 1.60 and 1.61 ppm (PAm and PAmN, respectively) and 
1.31 ppm corresponded to the −𝐶𝐻7 − protons of 1,8-octanediol (signal 5, 6 and 7, respectively). The 
multiplets at 2.35 and 2.36 ppm (PAm and PAmN, respectively) were assigned to the glutaric acid 
methylene protons in a of the carbonyl group (signals 4 and 8); while the multiplet at 1.94 ppm (signal 
3) was assigned to the glutaric acid methylene protons in b of the carbonyl group. Finally, as it can be 
observed in Figure III-4, the amine coupling was successfully accomplished. In the spectra, a shift from 
2.87 ppm, corresponding to −𝐶𝐻7 − bonded to the amine of the PEG (signal b), to 3.45 ppm (signal 10) 
can be observed because of the pegylation. 
 
Figure III-2. 1H-NMR of the PAm polymer. 
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Figure III-3. 1H-NMR of the PAmN polymer. 
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Figure III-4. 1H-NMR stack of PEG bis amine (green) and PAmN polymer (red). 
In addition to the structure identification, the polymer was also characterized by GPC to evaluate the 
polymer chain distribution. In Figure III-5 and in Table III-1, the molecular weight distribution of the 
different polymers synthesized in this work, polyester-PEG bis amino (PAm and PAmN) can be 
observed. PAm polymer was obtained by a two-step synthesis in which, initially, there was a 
polycondensation of the alcohol and the acid (synthesis of the PreAm) and then, the addition of the 
PEG bis amino, to the residual acids of the polyester chains, was performed without any workup or 
washing step. PreAm showed a wide distribution with polydispersivity (Q) around 1.9. However, when, 
PEG bis amine was added, PAm polymer showed an increase in its molecular weight with similar wide 
distribution (Q = 2.0). Regarding to PAmN polymer, after the polycondensation between the acid 
chloride and the di-alcohol (PreAmN), PEG bis amine was added with no workup or washing step. As 
it can be observed, in Figure III-5 and in Table III-1, PreAmN showed higher MW distribution than PreAm 
because of the polycondensation reaction which showed a higher rate of reaction than in the µwave 
synthesis. 
As expected, after the addition of the PEG bis amine, the resulting polymer, PAmN showed higher 
distribution than PreAmN (due to the polymer chain growth and the PEG addition) with a wide MW 
distribution (Q = 3.1).  
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Table III-1. Characterization of different synthesized nanoparticles by GPC. 
 PreAm PAm PreAmN PAmN PEG Bis amine 
Q 1.90 2.00 1.70 3.10 1.50 
Mn 2451 2992 5993 6517 548 
Mw 4766 5846 10018 20306 847 
Mz 13401 13715 12837 38499 1331 
Mp 2122 3603 9609 18767 935 
 
The comparison between PAm and PAmN polymers showed wide MW distributions with a difference 
in the size of the MW distribution. This difference can be explained due to the kinetics of the reactions 
and consequently due to the length of the rigid block. Analysing the rigid blocks of each polymer, the 
so-called pre-polymers, it can be observed that the reaction on the microwave (PreAm) resulted in 
polymer chains with a wider distribution and lower MW than PreAmN. 
Addtionally, it is important to highlight that PAmN polymer had a washing step with Milli-Q water after 
the synthesis to purify the polymer and remove the non-reacted chains. Considering the MW of PreAmN 
and the PAmN, it can be observed that the difference in the MW between them were almost two units 
of PreAmN. However, it was difficult to conclude the type of the chains that formed the resulting 
polymers (PAm and PAmN) because the calibration was performed using polystyrene standards. 
Therefore, it is possible to assume that the MW increase between PreAm and PAm could be caused 
by the addition of PEG one or two PEG chains, while PAmN could present two units of PreAmN and 
one or two units of PEG bis amine in its structure. 
 
 
Figure III-5. GPC elution profiles of synthesized polymers.PEG Bis amine is used as reference.  
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3.3.2 Preparation and Characterization of Nanoparticles 
As mentioned before, the drug loaded nanoparticles are nanocarriers of great interest to locally 
deliver antiproliferative drugs, such as paclitaxel (PCTXL) to treat the stenotic tissue of the trachea wall. 
In this work, PCTXL loaded nanoparticles were successfully synthesized and characterized through 
chain distribution, size, zeta potential, release profile and in vitro activity. 
The GPC characterization of the synthesized nanoparticles, Figure III-6 and Table III-2, showed no 
obvious differences between the synthesized nanoparticles of each polymers. However, PAm polymer 
and its nanoparticles, NP_PAm, showed a different distribution being the nanoparticles distribution 
more concentrated in polymer chains of high molecular weight. 
On the one hand, as it was observed previously, PAm showed a lower MW than PAmN with a wide 
distribution. Because PAm was used as synthesized, without any washing steps to remove non-reacted 
PEG, polyester chains, diol or acid, the precipitation process acted as a purification process causing a 
high molecular polyester-PEG chains enrichment and eliminating the non-reacted PEG. At this point, 
these results are in line with the 1H-NMR (Figure III-2) where the signal ratio between signal 5 and 11, 
indicates an excess of non-reacted PEG for the PAm polymer. Considering these results, it is possible 
to expect that the yield of the process could be diminished due to the washing process. 
 
Figure III-6. GPC elution profiles of PAmX and its nanoparticles. Continuous lines indicate polymers and dashed lines indicate 
nanoparticles. 
Table III-2. Characterization of different synthesized nanoparticles by GPC. 
 NP_PAm NP_PAmN 
Q 3.00 2.50 
Mn 6301 8601 
Mw 19057 21185 
Mz 46144 40176 
Mp 13123 18767 
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On the other hand, PAmN and its nanoparticles showed the same MW distribution, indicating that 
during the washing step with water (same solvent used to synthesize the NPs), the non-pegylated 
chains and low MW chains were discarded, and only the polymer chains with a suitable 
hydrophilic/hydrophobic relation to form NPs were purified. These results are in concordance with the 
distribution changes of PAm and its NPs once the polymer was washed during the precipitation process. 
Additionally, it is possible to observe that both type of nanoparticles had similar MW distribution. 
Considering the width of each distribution, this slightly difference can be attributed to the differences 
between the length of the rigid block of each polymer and can probably be avoided. 
These GPC results showed that the precipitation process worked as a washing step (when non-
washed PAm polymer came in contact with the aqueous solution, the non-reacted PEG, alcohol and 
acid, were washed) and the nanoprecipitation process acted as a filter to only select high molecular 
weight of polyester-PEG chains with some specific hydrophobic/hydrophilic block relation to form the 
nanoparticles. 
3.3.2.1.1 Size Distribution and Zeta Potential 
The PCTXL loaded NPs were characterized using the dynamic light scattering technique to ensure 
the stability at different pHs. The pH of concentrated NPs was analysed after synthesized, showing a 
pH about 4.5-5. Then, to evaluate the stability of the NPs, a pH titration was performed between pH 4 
to pH 7.4. Considering the previous mentioned application, the immobilization of NPs onto a pp-PFM 
surface of a medical device, the final pH of the titration curve was decided with a balance between non-
protonated amines (negative zeta potential of the NPs) and a slightly basic pH to avoid hydrolysis of 
the reactive pp-PFM groups. 
In Figure III-7, the Zeta Potential and Size Characterization of the different NPs formulations can be 
observed. Both families of polymer NPs (PAm NPs and PAmN NPs) showed the same behaviour 
regarding to the zeta potential. Initially, due to the free amines on the termini of the polymers, NPs 
showed a positive charge (about 30 mV) indicating the protonation of the amines and corroborating the 
previous results of the IR, 1H-NMR and GPC. During the basification process, protonated amines were 
neutralized and the global net charge was reduced until the isoelectric point (IEP) was reached, around 
pH 5.5. At higher pH, nanoparticles started to show negative charge, which can be explained due to the 
deprotonation of terminal carboxylic acids of some polyester chains (non-pegylated) that, in 
combination with the pegylated-polyester chains, form the nanoparticles. 
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Figure III-7. Zeta potential and size characterization of the synthesized nanoparticles. A) Zeta Potential of nanoparticles with 0% 
(non-loaded PCTXL) and 3% of loaded PCTXL, and B) Size characterization of nanoparticles with 0% (non-loaded PCTXL), and 
3% of loaded PCTXL. PAm and PAmN correspond to NPs synthesized with PAm and PAmN polymer, respectively. 
Besides the zeta potential, the size characterization showed stable NPs in the range of analysed pHs. 
In this case, PAm NPs showed smaller size than PAmN, approximately 117 nm (130 nm for 0% PCTXL 
and 104 nm for 3% PCTXL) and 244 nm (238 nm for 0% PCTXL and 250 nm for 3% PCTXL) 
respectively. As mentioned before, the differences between samples can be attributed to the differences 
in the length of the chains of each polymer, because to the differences between the rigid block of each 
polymer. Nevertheless, both type of NPs, are in correlation with previous works, with expected values 
for this type of polyester-PEG NPs nanoprecipitated in water, about between 100-275 nM.40 
Besides examining the surface characterization, the nanoprecipitation yield was studied. As it can be 
observed in Figure III-8, the NPs recovery (Equation III-1) showed similar values between polymers, 
70% for the PAmN polymer vs 53% for PAm polymer. The higher yield of PAmN can be explained with 
the structure of the NPs and the purity of the polymers. As expected, the differences in the purity of 
each polymer and the washing step of the nanoprecipitation process are directly related with the NPs 
recovery, being the PAm polymer the one with lower NP recovery. 
3.3.2.1.2 Drug incorporation Efficiency 
Taking into account all this characterization, it is important to evaluate the yield of the encapsulation 
process to assess the capability of this system to entrap drugs in its core. Besides the NPs recovery, 
the Encapsulation Efficiency (EE) for both polymers showed similar behaviour with EE values of 57% 
and 63% for PAm and PAmN polymers, respectively. This result indicates that the composition of the 
NPs, more specifically the composition of the core of the NPs, were similar in both types of NPs families, 
with the polyester part of the chains entrapping the paclitaxel in the core of the NPs, protecting itself 
and the drug from the water. These results are consistent with previous results in the literature, where 
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pegylated NPs and polyester base NPs showed a 70% of PCTXL EE.31,40,48 In addition, Figure III-8 
shows the measured Drug Content (DC) of different polymer samples, which was 3.4% and 2.6% (for 
PAm and PAmN, respectively) with no statistical differences between polymers. Also, the CV% around 
10% (13%) seems appropriated for this type of systems. These results encourage to choose this system 
as method to encapsulate hydrophobic drugs, such as PCTXL. 
 
Figure III-8. NPs Characterization showing NPs Recovery (%) and Encapsulation Efficiency (%) of different polymers. The 
comparison has been performed with theoretical 3% loaded NPs. 
Based on the previous results and considering that both polymers had the same chemical 
composition, it can be assumed that their ability to form NPs was the same. In addition, formed NPs 
present the same capacity to encapsulate hydrophobic drugs, such as PCTXL, and the similar ratios of 
EE of both polymers. Therefore, both synthesized polymers were used indistinctively. However, for the 
scalability it should be considered that the acid chloride route was more controllable, resulting in the 
increased reproducibility and reaction yields. Additionally, this reaction allows fabrication of larger 
batches of polymer. These characteristics are highly sought for pharmaceutical development of this 
type of technologies. 
3.3.2.1.3 In vitro Drug Release from Loaded Nanoparticles 
To evaluate the potential of the synthesized polyester-PEG NPs with amide bond, the in vitro release 
profile was performed and it was compared with the release profile of a previous studied polyester-PEG 
NPs using the P polymer, a polyester-PEG (polyethylene glycol MW 1.500 Da) with only ester bonds in 
its structure.40 
In Figure III-9, the release profile of different PCTXL loaded NPs can be observed, showing an 
interesting first-order release with an initial release about 20% of PCTXL at day 1 and with a 90% of 
drug release at 10 and 14 days for P polymer and PAmX polymer, respectively. Both polymers have 
similar behaviour with the new synthesized polymer PAmX showing slower release kinetics. Since NPs 
are prepared by the same synthesis process and with similar reagents, diol, di-acid and PEG, the 
difference in PCTXL percentage release can be explained as follows. Both NPs were synthesized using 
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polymers with the same hydrophobic block (rigid block) formed by the polycondensation of the 1,8-
octanediol and glutaric acid. However, the pegylation of the polyester chains had a slight difference. 
For the P polymer, the coupling between the polyester and the PEG were performed yielding an ester 
bond while PAmX uses an amide bond. This difference in pegylation could cause a more controlled 
release for the PAmX NPs. While the ester bonds are easily hydrolysed, the amide bond are less 
susceptible because the carbonyl carbon of the amide bond is less electrophilic and the aminated 
moiety is a poor leaving group. Therefore, during the hydrolysis process, the amide group showed a 
lower degradation process than the P polymer with ester bonds in all its structure. Considering that the 
resulting polymer has two types of bonds, amide and ester, the amide bond hydrolysis delayed the 
initial degradation while the ester bond showed similar behaviour than pure polyester-PEG polymer with 
only ester bonds in its structure. This confirms the importance of the amide bond because, can delay 
the release profile and therefore, changing the nature of the chain bonds it is possible to control de 
release profile. 
 
Figure III-9. In vitro release kinetics of PCTXL loaded nanoparticles at 3% w/w theoretical drug content. P indicates previous 
studied polymer with only ester bonds in its structure (hydroxyl terminal polyester-PEG chains); PAmX consists on ester and 
amide bonds in its structure (amine terminal polyester-PEG bis amine chains). 
Moreover, the initial burst absence and the almost nearly linear behaviour indicates the absence of 
adsorbed PCTXL on NPs surface. Considering the previous results, the developed polymer, PAmX, 
showed an interesting PCTXL release behaviour, similar to previous developed PEG-polyester 
nanoparticles40. Just by changing the bond types, the addition of amide bonds in the structure of the 
polymers, allows the system to control the release profile creating a controlled release over time, about 
14 days. 
The developed NPs showed a more controlled PCTXL and better results against other pegylated 
systems, such as poly lactide-co-glycolide, poly(trimethylene carbonate) and poly e-caprolactone, with 
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a PCTXL release over 50% in the first hours and the total cargo released in 2-4 days.31–33,35,49 The 
amide-pegylated NPs (PAmX) allows a controlled sustainable release of PCTXL over 14 days, which 
could increase the efficacy of clinical therapy. 
3.3.3 Nanoparticles Immobilization 
Despite the characterization of the NPs release profile, it was necessary to study the immobilization 
capacity of the synthesized amine bearing nanoparticles. As seen before, the formulated polyester-
PEG bis amine nanoparticles showed free amines on the surfaces which can interact with the reactive 
surface of pp-PFM. However, direct formulation of the NPs showed a pH around 4 with positive zeta 
potential indicating the protonation of the amines. To obtain the coupling between the nanoparticles 
with the surface, the pH of the NPs solution should be adjusted to ensure the non-protonation to the 
amines. As seen before, when the pH was adjusted from 4 to 7.4, the zeta potential of the surface 
nanoparticles was shifted from positive (protonated free amines) to negative (non-protonated free 
amines) (Figure III-10), indicating that the free amines of the nanoparticles were available to react with 
the pentafluorophenyl groups of the pp-PFM on the surface of the samples or devices. 
 
Figure III-10. Scheme of the amine bearing nanoparticles behaviour under different pH conditions. 
After adjusting the pH of the nanoparticles suspension to 7.4 (negative zeta potential of the 
suspension), no changes in the NPs size were observed. Different pp-PFM samples (silicon wafer and 
PDMS plates) were incubated with the adjusted suspension of NPs during 6 h. This time of incubation 
was chosen taking into account the kinetics of a reaction involving an immobilized reagent (on the 
surface) and the release profile of the NPs, considering that at 1 day there was about 20% of released 
PCTXL. 
In order to further asses the nanoparticles immobilization, covalently attached drug-loaded NPs were 
quantified. Despite the difficulty to quantify the NPs attached on the surface, an indirect quantification 
using PCTXL was performed. Samples were incubated with acetonitrile to dissolve the nanoparticles 
and extract the PCTXL. As it can be observed in Figure III-11, the quantification of the PCTXL indicates 
that about 0.5 and 0.4 ng/mm2 of PCTXL were immobilized for silicon and PDMS samples, respectively 
with no statistical difference. These results indicate the novelty of the system to obtain a bioactive 
coating on the surface of the materials (or device) capable of releasing hydrophobic drugs, such as 
paclitaxel, in a controlled manner. In this case, and taking into account the release profile of the 
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synthesized nanoparticles, this system should create a coating onto the surfaces of the materials and 
devices capable to release the treatment (paclitaxel or other hydrophobic drugs) to the surrounding 
tissues during 20 days, having its maximum release point between day 3 and 5, about 50% of released 
PCTXL.  
 
Figure III-11. Immobilization of PCTXL loaded nanoparticles at 3% w/w theoretical drug content. A) Quantification of the 
immobilized PCTXL on different substrates, silicon wafers and PDMS plates. Data normalized by area of each sample, ng/mm2. 
B) Representation of the immobilized amine-bearing PCTXL drug loaded nanoparticles onto pp-PFM substrate. 
3.3.4 In vitro Assessment of Developed Nanoparticles 
3.3.4.1.1 In vitro Antiproliferative Efficiency of Suspended NPs 
In order to further assess the behaviour of the designed system, synthesized nanoparticles were 
evaluated in in vitro cell cultures to determine the biocompatibility and activity of the drug release 
system. 
First, it was necessary to evaluate the behaviour of the suspended NPs with different cells lines 
located in the implantation area of a tracheal device. In this case, the cell viability of epithelial cells 
(A549), Human Lung Fibroblast cells (IMR-90) and ex vivo samples (Primary Respiratory Human 
Fibroblast cells (T-01 MVV) with synthesized NPs were analysed. Cells were incubated with drug-free 
NPs and with 3% PCTXL loaded NPs at 10, 14 and 20 nM PCTXL concentrations. This range of 
concentrations was selected because it corresponds to plasma levels of the drug achievable in humans 
with clinically relevant intracellular concentrations.26,27,50,51 
In Figure III-12, the in vitro assay of anti-proliferative effect of paclitaxel-loaded nanoparticles with 
different human cell lines can be observed. It can be observed that in A549 cell line, free drug loaded 
nanoparticles showed no obvious cytotoxicity indicating the biocompatibility of the synthesized 
polymers. However, when cells were treated with loaded nanoparticles (with a total concentration of 
PCTXL about 14 nM at 100% drug release) there was a rapid decrease in cell viability, indicating that 
A549 cells were very sensitive to PCTXL treatment. In addition, after some time point (between day 4 
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and 6) it can be observed a gradual recovery in cell viability attributed to the immortality behaviour of 
the cell line. 
 
Figure III-12. Cell viability of different in vitro cell lines with synthesized NPs (total concentration of PCTXL about 14 nM at 100% 
drug release). A) viability of A549 cells and B) viability of IMR-90 cells. Samples incubated with PCTXL NPs at 10 nM and 20 nM, 
exhibited similar results. All plots are normalized to untreated cell. 
Regarding the Human Normal Lung Fibroblast (IMR–90) cell line, free drug loaded nanoparticles 
show a slight decrease in cell viability but the effect is more dramatic with paclitaxel loaded 
nanoparticles with similar behaviour to pure paclitaxel. The same profile was observed when ex vivo 
fibroblasts (non-stenotic and stenotic) were treated with nanoparticles, (Figure III-13). In all cases, drug 
free nanoparticles showed no obvious cytotoxicity confirming the biocompatibility of the synthesized 
nanoparticles polymer. 
In addition, when cells are treated with both, PCTXL NPs and pure PCTXL, a clear inhibitory effect 
can be observed, Figure III-12 and Figure III-13. However, both drug loaded nanoparticles (1% and 3%) 
with a total amount of drug above 14 nM (100% drug release), showed a decrease in cell viability (about 
80% for both, 1% and 3% respectively, in case of IMR-90; and 70% and 80% for 1% and 3% 
respectively, in case of ex vivo stenotic fibroblast) being a slightly more drastic with the ex vivo non-
A)
B)
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stenotic fibroblasts. Moreover, during the treatment, a progressive reduction in cell viability was 
observed. This controlled reduction can be explained by taking into account the results of released 
PCTXL from NPs, about 93-97% at 14 days, with an accumulation of paclitaxel on the media until a 
total drug concentration about 14 nM. Additionally, comparing drug loaded nanoparticles treatment with 
pure paclitaxel a similar behaviour can be observed, but it can be appreciated that drug-loaded 
nanoparticles improves cytotoxicity effect increasing in some cases the cell decreasing viability caused 
by the effect of the paclitaxel in the media. 
 
Figure III-13. Cell viability of different ex vivo cell lines with synthesized NPs (total concentration of PCTXL about 14 nM at 100% 
drug release). A) viability of T-01 MVV cells (healthy area, away from stenotic tissue) and B) viability of T-01 MVV stenotic cells. 
Samples incubated with PCTXL NPs at 10 nM and 20 nM, exhibited similar results. All plots are normalized to untreated cell. 
Finally, it may be concluded that in all cases, despite the specific effect of paclitaxel in each type of 
cell, PCTXL loaded NPs showed a controlled release of paclitaxel causing a significant decrease in cell 
viability, in a similar behavior of pure paclitaxel. Additionally, the behavior and cell viability of non-loaded 
nanoparticles confirmed the biocompatibility of the polymeric material. PCTXL-loaded NPs (3%) at 10 
and 20 nM showed similar effects on all types of tested cells (IMR-90, A549 and non-stenotic and 
stenotic T-01 MVV) than 3% PCTXL-NPs at 14 nM, indicating that the developed drug-loaded 
nanoparticles did not decrease the PCTXL activity and that the cytotoxicity against the evaluated cells 
was time dependent.  
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3.3.4.1.2 In vitro Antiproliferative Efficiency of Immobilized NPs 
Taking into account the idea of a manufactured medical grade silicone device, first of all, it was 
necessary to evaluate the cell viability onto PDMS samples. In Figure III-14, the cell viability of human 
fibroblasts onto PDMS samples during 15 days can be observed. Initially, PDMS (non-treated) showed 
a cell viability around 30% and a slight increase until 70% at 15 days, indicating a low biocompatibility. 
This low cell viability was probably caused by the hydrophobicity and the surface chemistry (methylene 
groups) of the PDMS samples causing a low protein and cell adhesion. In order to overcome this 
problem, PDMS samples were treated with oxygen plasma in order to increase the surface free energy 
and increase the adhesion.52 In this case, treated PDMS samples showed a high cell viability during all 
time points of the treatment (until 15 days), caused by the surface modification with oxygen, increasing 
the wettability and the adhesion of molecules. In addition, it can be observed that this increase in 
biocompatibility was constant during the time of experimentation indicating the robustness of the 
treatment. 
 
Figure III-14. Cell viability of human fibroblast with non-treated and treated PDMS with O2 plasma. Normalized to untreated cell. 
After the activation treatment of the PDMS to create a biocompatible PDMS surface, synthesized 
NPs were immobilized onto a pp-PFM surfaces. During this process, amine groups of the aminated 
NPs covalently reacted with the pentafluorophenyl groups of the pp-PFM PDMS surfaces. Samples 
with immobilized NPs were incubated with normal human dermal fibroblasts (NHDFs) in order to 
evaluate the biocompatibility of the non-drug loaded NPs and the cell viability of the drug loaded NPs. 
Initially, after NPs immobilization, samples were incubated with FBS in order to block the remaining 
reactive sites of pp-PFM. After the blocking treatment, different modified samples (oxygen activated 
PDMS, pp-PFM PDMS, non-drug loaded NPs onto pp-PFM PDMS and 3% drug loaded NPs onto pp-
PFM PDMS) were incubated with NHDFs during 10 days. In Figure III-15-A, the Live&Dead® staining 
of the NHDFs over different samples can be observed. As expected with previous results, oxygen 
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activated samples acted as the control treatment, and showed a biocompatibility surface for normal 
human dermal fibroblasts. However, when cells were previously incubated with FBS to block the pp-
PFM, there was a decrease in cell viability indicating some cytotoxicity of the surface. In this case, due 
to the toxic nature of the pentafluorophenol group, the possible remaining non-reacted 
pentafluorophenyl groups in the polymer surface could lead to the release of this toxic group in the 
media during the cell incubation.53 In addition, the cells incubated with theses samples where not 
homogeneously distributed, showing a cluster behaviour caused by the hydrophobicity of the surface 
and the toxicity effect of the non-reacted polymer. Nevertheless, non-drug loaded NPs samples showed 
better biocompatibility, but cells showed the same cluster behaviour. In this case, the non-drug loaded 
nanoparticles showed no obvious toxicity and the viability was only affected by the polymer surface 
such as with the pp-PFM samples. Finally, when cells where incubated with immobilized drug-loaded 
NPs on the surface, no viability was observed, all cells were dead as a result of the antiproliferative 
activity of the released paclitaxel. 
 
Figure III-15. Cell viability of Normal Human Dermal Fibroblasts (NHDFs) on coated and noncoated samples: A) cell cultures of 
different modified samples with drug loaded and non-drug loaded NPs, blocked with medium, and stained with Live&Dead kit 
(scale bar, 100 μm); B1) cell cultures of different modified samples with drug loaded and non-drug loaded NPs, blocked with 
collagen, and stained with Live&Dead kit (scale bar, 100 μm); B2) dapi/phalloidin staining on B1 collagen blocked samples (scale 
bar, 50 μm). 
In order to further assess the influence of the blocking treatment to avoid the release of the 
pentafluorophenol groups from the pp-PFM, a collagen coating was used after NPs immobilization. 
Collagen was selected because it is the major component of the extracellular matrix and has been 
widely used in tissue engineering and biomedical applications. Collagen fibrils were incubated with NPs 
immobilized surfaces to react with the active sites of pp-PFM and increase the biocompatibility of the 
O2-PDMS pp-PFM-PDMS ØNPs-PFM-PDMS (3% PCTXL)NPs-PFM-PDMS
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designed surfaces. As it can be observed in Figure III-15-B1 and B2, the use of collagen instead of the 
FBS coating increase tremendously the biocompatibility of the surfaces (pp-PFM and non-drug loaded 
NPs surfaces) causing the NHDFs cells to show their characteristic morphology (elongate cells), such 
as in the FBS coating but in this case, there was no cluster observed and the samples were 
homogeneously coated with cells. On the contrary, when cells were incubated with drug-loaded NPs, 
all cells were dead, as expected due to the paclitaxel activity. 
These results indicate the capacity of the PDMS samples with immobilized drug-loaded NPs to 
release paclitaxel on the media avoiding the proliferation of the cells. These surfaces can be used on 
different medical devices to treat abnormal proliferative tissue, such as stenotic or cancerous tissues. 
In addition, it has been observed that the blocking step of the remaining active sites of the pp-PFM are 
a key point to evaluate in order to avoid the toxicity of the pentafluorophenol group and increase the 
biocompatibility of the samples.
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3.4 Concluding Remarks 
This chapter presents a proof of concept of bioactive surfaces to be used in medical applications with 
biodegradable polymeric nanoparticles capable to entrap hydrophobic to deliver drugs in a controlled 
manner. 
First of all, the synthesis of a biodegradable block co-polymer has been performed through different 
synthetic methods. This pegylated polyester showed two clear differentiated zones, a rigid block 
(hydrophobic) and flexible block (hydrophilic). The hydrophobic block (polyester) was designed to 
interact with hydrophobic drugs and to constitute the core of a nanoparticles. Due to the hydrophilic 
behaviour of the PEG (flexible block), the nanoparticles were stable in water and could interact or 
administrated on aqueous media and body fluids. The synthesized polymer was designed to show a 
terminal amine in order to express this amine moiety on the surface once the nanoparticles were 
formed. Due to this moiety, the nanoparticles could be used with click chemistry to functionalize different 
elements such as surfaces, drugs or carriers. 
Synthesized polymer was used to form biodegradable nanoparticles with a size about 117 nm for 
PAm and 244 nm for PAmN, respectively, similarly to other polymeric pegylated nanoparticles described 
in the literature. Due to the terminal amine of the polymer chain of NPs, the nanoparticles were pH 
sensitive, and its surface potential (zeta potential) could be adjusted by changing the pH of the solution 
(protonation or non-protonation of the terminal amine). In addition, the nanoparticles were able to 
encapsulate hydrophobic drugs, such as paclitaxel, with a drug content until 3% and showing an 
interesting nanoparticles recovery (50-70%) and encapsulation efficiency (60-70%). Additionally, these 
nanoparticles showed a controlled drug release on the first days, about 60% at day 6, with a total drug 
release at day 15. Moreover, the chemistry bonds of the polyester-peg polymer could be used to modify 
the hydrolysis kinetics and the drug release profile. The drug loaded nanoparticles were reacted with 
the reactive sites of the pp-PFM and after the reaction, the NPs were covalently attached to the modified 
surface of PDMS. 
In addition, NPs and immobilized NPs were tested in vitro with different cell lines to evaluate the 
biocompatibility of the synthesized materials and the activity of the drug delivery system. In this case, 
the designed drug delivery system showed an effective antiproliferative activity, with a reduction of 80% 
of the stenotic tissue in 12 days and the nanoparticles polymer showed no obvious cytotoxicity with the 
treated cells. However, it has been observed that the pp-PFM coating could show some toxic activity, 
if it is not blocked. Collagen coating showed interesting results by blocking the surface of the remaining 
active sites of pp-PFM and creating a biocompatible surface to increase cell adhesion. 
The results in this chapter and the obtained surfaces showed different technologies that combined 
could improve the behaviour of current medical devices. The developed surfaces were able to entrap 
hydrophobic drugs, such as paclitaxel, and the controlled drug release profile could be used to treat a 
desired pathology, such as abnormal proliferation, locally and avoiding burst releases. 
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The combination of the previous results in Chapter II, the development of antibacterial surface 
covalently attached to the surface of silicone (most used stents and other medical devices are 
manufactured by medical silicone) with the results in this chapter, demonstrated the possibility to design 
selectively bi-side bioactive surfaces onto medical devices. Additionally, some experiments with micro-
structures and cylinders, have demonstrated the novelty of this technology to be transferred to more 
complex structures such as 3D designed anatomical devices. Despite this technology is still in prove of 
concept, it showed promising results with a wide range of possible medical applications. 
As described in the Introduction (Chapter I), considering the proposed requirements to avoid pots-
implantation problems such as bacterial colonization, stenotic tissue and migration, the next step should 
be the development of an anatomical adapted stent to increase the adaptability. Therefore, the following 
chapter will be focused on the design of personalized stents by use customizable and versatile 
manufacturing techniques such as 3D printing. 
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4.1 Introduction 
The previous chapters (Chapter II and III) show the development of a technology capable of modifying 
the surfaces of different materials and furnish them with different activities. Initially, different applications 
require of an antibacterial surface to avoid bacterial colonization and biofilm. In this context, considering 
the antibacterial requirements of different medical devices, such as a tracheal stent, a flexible 
antibacterial coating was developed using metallic silver. This coating presents the ability to be applied 
onto different substrates, controlling the surface geometry and structure and additionally, showing an 
antifouling behaviour thus increasing the antibacterial effect. Furthermore, the developed technology 
was adapted to create a coating capable of releasing antiproliferative agents and acting as a drug 
release platform. The developed technology consists of a drug delivery system, using biodegradable 
nanoparticles loaded with PCTXL, covalently immobilized onto the surface of the material. The system 
allows a local controlled release of PCTXL during 14 days with drug dosses lower than reported toxic 
concentrations for human cells. The developed platform releases effective dosses against tested cells 
(IMR-90, A549 and human trachea extracted cells) which indicate that the platform can be a potential 
system to avoid the granulation tissue formation and eliminate the stenotic tissue. 
As mentioned before, there are different therapeutic approaches to treat airway stenosis, such as 
electrocautery, tracheal resection and reconstruction and a transoral endoscopic positioning of an 
endoluminal tracheal stent (stenting).1 Stents were engineered to be minimally-invasive procedure 
aimed to restore airway patency and for acute relief of dyspnea. It is mostly indicated in patients 
suffering from trachea stenosis untreatable by open-neck tracheal resection and anastomosis or 
tracheoplastic procedures or when surgery has already failed and it is not repeatable.2–4 
Current stents are concentrically silicone cylinders (tube-like geometries) with several dimensions to 
find some fit to the patient made of metallic wire, silicone or a mixture of both materials, and each device 
has advantages and disadvantages depending on the material and design.5 However, these designs 
do not take into account the patient anatomical features, such as pitch in between tracheal ring, 
angulations, non-circular section (D-shape) and diameter changes causing low adaptability and 
disadvantages.6–8 This means that stents may migrate from their original position back and forward 
through the trachea causing pain and formation of granulation tissue due to the mechanical stress and 
rubbing.9,10 As a result, several unwanted effects have been described, including perforation, 
malposition, esophageal impingement, granulation tissue formation and hemorrhage.11–14 Additionally, 
stent migration, especially in proximal lesions near the vocal cords, can acutely threaten the cords and 
the ability to speak. 
Previous report performed market analysis to evaluate the adaptability requirements of tracheal 
stents. The main missing characteristics consist on simple placing and removal of the stent, and the 
customization of the product. In fact, the common opinion of physicians is that personalized devices 
may avoid stent migration because of the correct fitting, and consequently the reduction or elimination 
of associated problems.4 In this case, it is clear that if the stent is designed considering the patient’s 
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anatomy, one of the most difficult choice for physicians (to choose the proper diameter and length) will 
disappear because the device shall exactly reproduce the patients anatomy and thus, the performance 
of the stent would be improved avoiding migration. 
Although customization of stents or implants, is an expensive and time-consuming process15, the 
demand for customized designs for biomedical applications is very high16. However, the number of 
implanted tracheal stents is relatively low, about 160,000 cases per year in developed regions, when 
compared with other implants.17,18 This suggests that to be economically competitive, the new stents 
must be produced using small batches.4 Moreover, hospitals spend great amounts of resources and 
time acquiring standardized implants and/or prosthetics that are not suitable for all patients, and many 
of them become unusable products that must be discarded after their expiration date.19 Therefore, a 
solution can be to manufacture personalized prosthesis, tracheal stents, using a CT scan of the patient 
in combination with the additive manufacturing (AM) technologies.20,21 
Therefore, in order to design a workflow to manufacture personalized devices, the development 
process for anatomically personalized medical devices presents multiple steps, as shown in Figure IV-1. 
Initially, anatomical data from the patient must be obtained, usually through a Computerised Axial 
Tomography (CAT) or Magnetic Resonance Imaging (MRI). Both systems are medical imaging systems 
that provide a series of image, which corresponds to slices of the internal and external tissues.21 
Typically, the output format of the CAT consists on a digital imaging and communication in medicine 
(DICOM) file that contains the linear attenuation coefficient of the patient’s body material at each 
scanned point. Each point represents a volume in the space and are defined as voxels. In order to 
obtain a precise anatomical model, high quality medical data is imperative and this relies on the 
thickness of the slice (defined by the radiologists with a maximum about 0.8 mm on both directions on 
the plane normal to the CAT and 0.5 mm for the axial direction) and the size of the pixel. 
Secondly, after the data acquisition, DICOM files are transferred into a visualization software, where 
data is treated and analysed, region of interest (ROI) is set and anatomical structures are selected using 
the threshold of the linear attenuation coefficient of each voxel.6 After this process, an STL file (set of 
triangles with associated vector) is generated with a 3D reconstruction of the selected object/tissue. 
Then, the STL file requires an optimization to avoid holes, intersecting triangles, bad contours, noise 
shells and overlapping triangles. 
At this point, it is possible to characterize the object (analysing the dimensions) and perform different 
CAD operations to design and remodel the 3D reconstructed object and even design devices or 
prosthesis, to be inserted or adapted to this anatomical geometry. Once the object is designed and 
optimized, the generated STL file is segmented into a set of layers than can be interpreted by an AM 
printer and manufactured. 
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Figure IV-1. Workflow to manufacture anatomical personalized medical device. 
After the manufacturing process, samples require a post-processing step to finish the fabricated 
piece. In this case, surfaces treatments, such as polish, paint, varnish or other coatings, smooth 
contours and other pieces assembling are typical finishing processes. 
Additive manufacturing, known as 3D printing, is a process of joining materials to create objects from 
three-dimensional (3D) data, usually layer by layer. As mentioned, the principle of AM consists on taking 
the information from a computer-aided design (CAD) and then, the CAD model is virtually segmented 
in different cross-section (layers), which are jointly manufactured by an AM printer, creating the final 
object.22 
Since the first development of AM in the 80’s, various AM machines have been developed (Figure 
IV-2), stereolithography (SL), fused deposition modelling (FDM), selective laser sintering, (SLS) 
selective laser melting (SLM), laminated engineered net shaping (LENS), electron beam melting (EBM), 
3D printing or inkjet (3DP), direct metal deposition (DMD), laser metal deposition (LMD) and laminated 
object manufacturing (LOM). This versatility of printers and technology allows the use of a wide range 
of materials, covering from metals23,24, and plastics25–27 to ceramics28,29 and even biological30,31. The 
interesting advantages of AM is that these new technologies are revolutionizing the current 
manufacturing systems and the business models because they provide a cost-effective and time-
efficient way to produce low-volume, customized products with complicated geometries, advanced 
material properties and functionalities, reduce, or eliminate, the assembling parts and minimize the 
waste materials.32,33 
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Figure IV-2. AM classification technologies according to the raw material. 
However, despite the wide range of techniques and materials used in AM, there are some limitations 
due to the lack of biocompatible polymers approved for medical use and capable to be printed with AM 
technologies.34 More specifically, polydimethylsiloxane (PDMS) elastomer has been widely used as 
biomaterial to manufacture prosthesis and medical devices, micro-fluidic channels,35,36 stretchable cell 
substrates37, spiders nets38 and even bionic organs such as ears39. PDMS shows great 
biocompatibility40, optical transparency and high oxygen permeability41 properties and considering the 
ease of fabrication by spin-coating or moulding, makes it a suitable material for biomedical applications, 
such as medical device fabrication. However, the low viscosity of the liquid pre-polymer and its low 
reticulation kinetics, limits its use in more advanced fabrication approaches, such as 3D printing. 
Additionally, the relatively long gelation time allow the material to flow once deposited making to loss 
the print fidelity.26 Therefore, despite some promising advances in additive manufacturing have led to 
new methods to 3D-print hydrogels or PDMS, such as syringe-based extrusion or freeform reversible 
embedding of suspended hydrogels (FRESH)42, the scalability and regulatory framework requires time 
and more research and optimization. Therefore, it is possible to mix the conventional manufacturing 
system with the most advanced personalized fabrication, such as 3D printing. It is possible to use AM 
to manufacture personalized and customized moulds, using CT data and then, use the fabricated 
moulds in a classical injection moulding process. 
To sum up, considering that current stents (normalized geometries and dimensions) are causing 
problems of migration, pain and granulation tissue because of their low adaptability, this work aims to 
develop a fabrication protocol for producing personalized tracheal stents, using a CT scan with the 
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patient information, with 3D printing technologies (AM). Considering that the most widely used tracheal 
stents are the silicone-based, and the difficulty to 3D print PDMS elastomer, a combination of advanced 
and classical manufacturing systems will be used. Patient’s information will be used to generate the 3D 
model and design the most suitable stent to perfectly fits in the trachea lumen and then the AM 
technology will be used to manufacture a mould, which will be subsequently filled with silicone as 
traditional injection process. Despite the final device will be manufactured with medical grade silicone, 
this work uses PDMS as proof of concept in order to evaluate the behaviour and the techniques required 
to achieve anatomical silicone based medical devices. 
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4.2 Materials and Methods 
4.2.1 Materials 
Argon 5.0 and oxygen 5.0 were purchased from Abelló Linde S.A. (Barcelona, Spain). PFM was 
purchased from Apollo ScientificLTD (Stockport, UK). D-(+)-Glucosamine hydrochloride, sodium 
dodecyl sulphate (SDS), Hellmanex, and silver nitrate were purchased from Sigma-Aldrich (Madrid, 
Spain), ethanol was purchased from Scharlab (Barcelona, Spain) and a Sylgard 184 kit was purchased 
from Ellsworth Adhesives (Madrid, Spain). Ultrapure water (Milli-Q) was obtained using a Synergy UV® 
system from Merck Millipore (Billerica, MA, USA). 
4.2.2 3D model generation 
4.2.2.1.1 Data acquisition 
The scanner used to examine thorax and the trachea was a Toshiba Aquilion One characterized by 
a 320-row detector that enables ultra-fast scanning of organs in one rotation, resulting in multiplanar 
and 3D images demonstrating perfect continuity along the Z-axis, without motion and distortion image. 
Airway imaging was accomplished using a central airway protocol, which includes thin-cut helical 
images of the neck and chest in expiration and inspiration phase of respiration43 using no contrast 
material (slice thickness, 0.5 mm; interval, 0.5 mm; pitch, 1.388:1; pixel spacing, 0.69/0.69; kilovolt 
peak, 100 mA). The output was a DICOM file with a 616 (512 x 512) bitmap images. 
4.2.2.1.2 Software 
The generated DICOM file from the CT scan were imported to two visualization software, 3D Slicer 
(https://www.slicer.org) and the MIMICS Innovation Suite® (Materialise, Belgium, 
http://www.materialise.com/en/medical/mimics-innovation-suite). 
3D Slicer is a free, cross-operating system, open source software platform for medical image 
informatics, image processing, and three-dimensional visualization. Built over two decades on the basis 
of experiences at the Massachusetts Institute of Technology and Surgical Planning Laboratory and 
through support from the National Institutes of Health and a worldwide developer community, Slicer 
brings processing tools to physicians, researchers, and the general public.44–46 
Mimics Innovation Suite® is a commercial medical image processing and analysis software. Built over 
the experience for more than 25 years, Mimics® is the most advanced segmentation toolbox for patient 
specific-device design or medical image-based research and development. Mimics® provide both basic 
functionality and an additional Pulmonology module to process the airways in lung CT scans. 
Additionally, Mimics Innovation Suit® present the design and meshing software (3-matic®) capable to 
treat, modify and create surfaces with CAD capacities.47,48 
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4.2.3 3D Printer 
In this work, two type of printers have been used, an FDM Fortus 400mc® and the Insight® software 
(Stratasys®, MN, US) and a stereolitography printer, Stalactite Series 102 (Stalactite, Barcelona, Spain) 
with the Stalactite Workshop software, Figure IV-3. The FDM printer used a polycarbonate as a printing 
material and a “SR-100TM” as a printing-support material (acrylic copolymer) both acquired from the 
manufacturer. The support material was gently removed following the manufacturer’s instructions, using 
a high alkaline solution with a pH up to 12.6-13 at 70-85 ºC until material dissolution. 
For the Stalactite printer, an acrylate base resin “standard” was used with a visible photo-crosslinker 
provided by the manufacturer. The printing process was performed following the manufacturer’s 
instructions for the selected material. 
 
Figure IV-3. Scheme of different 3D printers used in this work.A) FDM printer and B) Stereolitography printer. 
4.2.4 Prosthesis unmoulding 
After the mould fabrication, it was washed gently with Milli-Q water and ethanol. After the washing 
treatment, the mould received a visible light bath between 15-60 min to ensure the curation process of 
the resin. After this process, the mould was washed again with water and ethanol and dried under 
compressed air. Then, a PDMS kit (10:1) was injected inside using the injections holes designed to 
allow the silicone to fill the mould. PDMS filled with silicone was introduced in the oven between 73 º-
110 º for 180-10 min respectively. 
Once the curing process of the PDMS was completed, the mould was cooled at room temperature 
and the silicone prosthesis was unmoulded by cracking the mould. The resulting silicone prosthesis 
was washed with Milli-Q water and ethanol and dried with compressed air. 
4.2.1 Surface modification and Silver Deposition. 
The surface modifications carried out in this work was carried as described in previous work.49,50 
Briefly, before introduction of the substrate, the chamber was cleaned in continuous wave O2/Ar (1:1) 
plasma for approximately 1 h at a power of 150 W. Samples were placed at the centre of an aluminium 
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plate and vacuum was started until the base pressure of 0.001-0.003 mbar was reached. Then, PFM 
was regulated through the needle valve and introduced to the reactor chamber in a vapour phase 
(heated at 75 ºC) until 0.02-0.03 mbar. The continuous radio frequency power was fixed at 15 W 
(working power) and pulsed plasma polymerization duty cycle (DC) of 10/20 [DC = ton/(ton+toff)]51 was 
carried out for 3-10 min. Plasma discharge was then turned off, and the PFM vapour flow rinsed was 
kept constant for additional 15 min. After the polymerization process, plasma-polymerized PFM (pp-
PFM) samples were carefully removed from the reaction chamber and stored until further use under 
argon atmosphere. 
For the silver deposition, silver was reduced by a reductive sugar using the silver mirror reaction 
(Tollens’ reagent)52. The glucosamine solution was prepared by dissolving glucosamine hydrochloride 
in Milli–Q water at 1 M. Then, pH was adjusted to 7.4 with concentrated sodium hydroxide. The reaction 
between glucosamine and the modified surface was performed by incubating the modified sample in a 
glucosamine solution for 6 h. Tollens’ reagent was prepared by adding 25 µL of 15% ammonia to 1 mL 
of 0.1 M silver nitrate, observing the precipitation of the silver oxide. Then, another 25 µL of 15% 
ammonia was added, and the complete dissolution of the precipitate was observed due to the 
complexation of the silver by ammonia. The modified sample with the attached glucosamine were 
introduced on a vial with 4 mL of Milli–Q water. Then, 1 mL of the Tollens’ reagent was added and 
heated on a Milli-Q water bath at 90 °C for the desired time of reaction, 60 min. 
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4.3 Results 
As mentioned before, in order to obtain a 3D model ready to manufacture, extracted data from the 
patients must be imported to visualization and sketch (CAD) software to analyse, modify and re-design 
the device. For this work, 3D Slicer and Mimics® software have been used. 
4.3.1 Data Extraction and Analysis 
4.3.1.1.1 Data import 
Thorax data of the patient scanned using the CT was imported in both 3D Slicer and Mimics® 
software. Once data was imported, software interpreted the CT images and produced a visualization of 
the scanned structures. For 3D Slicer, data was imported using the Welcome to Slicer module with the 
Load DICOM Data command, and for the Mimics®, the import command was the New project wizard, 
located under the File menu. 
Table IV-1. Commands for Data import into 3D Slicer and Mimics®. 
ROI Command 
3D Slicer Welcome to Slicer / Load DICOM 
Mimics® File / New project wizard 
 
As it can be observed in Figure IV-4, once files were loaded in both software, it was possible to find 
three or four different views, corresponding to axial, coronal and sagittal planes of the thorax. The fourth 
view corresponded to the 3D reconstruction of the selected area. Additionally, there were different 
scroll-bars for each view to move the plane along the different slices that form the scanned area. It is 
interesting to observe the difference threshold values of the soft tissues in grey (organs and tissues) 
versus the hard tissues in white (bones) because of higher radiation absorption in hard tissues. This 
was useful because tissues could be easily differentiated and the tissue selections through different 
masks could have better resolution. 
4.3.1.1.2 Region of Interest (ROI) 
After data loading, it was necessary to define a region of interest (ROI) to design the working area. 
Therefore, a cubical ROI with the length, width, and a height that covers the area of the airway to study. 
This cubic ROI represented the tracheal airway from the neck to the bronchial ramification, discarding 
the lungs to minimize calculations and visualization.  
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Table IV-2. Commands of selected ROI for 3D Slicer and Mimics®. 
ROI Command 
3D Slicer Volume Rendering / Crop Volume 
Mimics® File or Image / Crop Project or Segmentation Crop mask 
 
 
Figure IV-4. Different views of axial, coronal and sagittal planes of thorax after file imported. ROI was selected according with 
the dimensions of the airway. A) 3D Slicer view and B) Mimics®. 
4.3.1.1.3 Thresholding and Assessment of Tracheal Tissue 
After ROI definition, the area was cropped and it was necessary to start the segmentation to generate 
a 3D volumetric images of the patient’s trachea. To do so, different layers or masks for each tissue were 
created using a manual, semi-automatic or automatic method. For manual segmentation, it is necessary 
to perform the entire structure delineation slice by slice. Considering that the defined ROI can contain 
more than 300 slices and the complexity of the structure, manual segmentation can be very time-
consuming and impractical. Semi-automatic segmentation, Table IV-3, consists on a defined threshold 
B)
A)
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range, normally between -990 HU to -50 (or -120 HU), for the trachea47, that selects all pixels in that 
range. However, the results are not accurate and there was a lot of noise. However, some software, 
such as Mimics®, besides of the previously detailed options to create masks, have other algorithms that 
solves the reproducibility and the time-consuming problems. A “Dynamic region growing” is an algorithm 
that segments a region based on the connectivity of grey scale in a certain range, and the “Deep airways 
segmentation” module segmented the trachea based on two seed points in the axial view. The first point 
was the starting point of the trachea and the second point was defined several slices down, to define 
the trachea direction. During the pre-processing, it was possible to select different levels of leakage 
detection. Higher leakage detection levels showed a 3D reconstruction with lower leakages but the 3D 
structure has fewer branches. On the contrary, lower leakage detection level could lead more detected 
branches, even parts of the lungs but it is possible that the algorithm starts calculating inside the lungs, 
which is very time-consuming and the results could not provide additional information. 
Table IV-3. Commands to create new masks for segmentation under 3D Slicer and Mimics®. 
Masks Module Command 
3D Slicer Threshold Editor / ThresholdEffect 
Mimics® Threshold Segmentation / Thresholding 
 Dynamic Region Growth Segmentation / Dynamic Region Growing 
 Segmentation Airway Pulmonary / Segment Airway 
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Figure IV-5. Visualization of different mask selection with threshold and 3D reconstruction. A) 3D Slicer mask (blue) definition 
between -1,050 to -200 HU and B) Mimics® mask (green) definition between -1024 to -600 HU. Final mask after manually edited 
the selected pixels in C) 3D Slicer (blue) and D) Mimics® (green). 
As it can be observed in Figure IV-5, the manual threshold works in both cases by just adjusting the 
correct threshold range, by trial and error (despite the previously defined values), but not only the 
desired area (airway) was selected. Instead, as mentioned before, other tissues, such as lungs and air 
cavities were selected. Therefore, a manual process to edit each mask, slice by slice, was necessary 
to correct the erroneously selected pixels. There are some commands that can perform manual 
operations or semi-automatic operations. Manual commands, Table IV-4,work as a paintbrush or eraser 
to add or remove pixels, while the semi-automatic commands work by removing or adding pixels at the 
border of all islands of the currently selected layer mask. This hand-made pixels’ edition increased the 
quality of the masks, however it was very time-consuming and due to the definition of the bronchial 
ramification, and the pixels’ size, the decision to select or un-select some pixels was very subjective 
causing very low reproducibility.  
C) D)
A) B)
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Table IV-4. Selection of most used commands to edit mask pixels under 3D Slicer and Mimics®. 
Masks Command Effect Function 
3D Slicer Paint Add pixels’ layer 
 Erase Remove pixels’ layer 
 Erode Add pixels at border of islands 
 Dilate Remove pixels at border of islands 
Mimics® Cavity Fill Fills internal gaps of the selected mask 
 Edit mask Add or remove pixels’ layer 
 
Besides preparing the masks by the manual threshold method, semi-automatic modules, such as the 
Dynamic Region Growth (DRG) and the Segmentation airway module (Segmentation Airway, SA) of 
Mimics® was used to create masks. In both cases, it was necessary to indicate a seed point or a start 
point in the inside of the trachea. For the DRG, the seed point set a base point with a value of greyscale, 
and then with a deviation range (defined by the user), the algorithm started to compare the grey values 
of the neighbouring pixels that obeyed the defined parameters. It was possible to provide additional 
seed points to increase the threshold range of the selected pixels. The combination of the seed point 
and the additional points created a minimum and a maximum range of greyscale values that act as a 
threshold. As a result, this command created a new mask that completely selected the airway with the 
lungs and the air cavities un-selected. However, in Figure IV-6, the generated mask with some pixels 
unidentified can be observed, showing that the obtained mask was not perfectly defined. Therefore, 
despite the high quality of the generated masks, a manual edition with the previously commented 
limitations was necessary. In contrast, the Segment Airway module (SA) is a command that semi-
automatically segments the airway track using a comparison between the contrast of the airway regions 
and the airway wall. If a decrease in the contrast was detected, this indicated that there was a leakage. 
In such regions, the segmentation leaked into the pulmonary parenchyma and subsequently, lung tissue 
was erroneously selected as airway. However, low values of leakage found and selected higher 
numbers of airway branches. As it can be observed, SA gave a mask with higher definition of the airway 
track than DRG and in addition, a higher number of bronchial branches was observed, while in DRG it 
was very difficult to obtain due to the manual process required. 
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Figure IV-6. Overview of the generated mask by different methods. A) Dynamic Region Growth (DRG) and B) Segment Airway 
(SA). 
After the segmentation and mask generation, it was possible to generate a 3D model with the 
information of the selected points in the mask. During the 3D model generator, it was possible to define 
several parameters to create the 3D object, such as the label from which the information is extracted, 
the matrix and triangle reduction, and the smoothing. 
Table IV-5. Selection of the most used commands to edit mask pixelsunder 3D Slicer and Mimics®. 
Masks Command Effect 
3D Slicer Model Maker 
Mimics® Calculate 3D from mask 
 
A)
B)
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These parameters were used to create the 3D model by means of triangulation of the segmented 
area. It is important to highlight that the number of triangles determines the quality of the reconstruction, 
higher number of triangles resulted in a higher quality 3D model. However, a greater number of triangles 
required greater requirements of memory and calculations. In this context, the matrix reduction can be 
very useful because allows grouping of voxels to calculate triangles resulting in reduced calculation 
times, but also reducing the quality of the final reconstruction. Additionally, rough surfaces can be 
smoothed using the “smooth” function, which works as a noise filter. This filter function increases the 
finished quality of the 3D object, but greater number of iterations of smoothing factor could turn 3D 
object into a sphere-like object. Normally, small number of iterations are recommended, specially with 
a high smooth factor. 
In Figure IV-7, the results of the 3D object generation can be observed. The 3D model generated 
using the masks obtained by the threshold method showed no bronchial branches. Only the left and 
right bronchus, with only few millimetres of the intermediate trunk and the upper lobe of the right 
bronchus were observed. Despite the good quality and definition of the object, this low ramification was 
expected because the mask did not contain the ramification information due to the difficulty to manually 
select the airway track. However, the 3D object generated by the DRG mask showed a high number of 
ramifications because the semi-automatic algorithm was able to identify differences in the threshold 
values. But despite this high number of branches, the airway track was not well defined, with great 
number of holes and noise because it requires several additional seed points to obtain all the threshold 
ranges that presents the airway. Nevertheless, it was important to take into account that great number 
of seed points in order to obtain a wide range of thresholds could lead to additional tissues selection, 
such as the lungs. Finally, the SA module showed more reliable results. The resulting objects showed 
more defined airway track and additionally more ramification branches (depending on the leakage 
factor). This semi-automatic algorithm compares the contrast between the airway and the airway wall 
and was developed and optimized to segment the airway track. Therefore, the resulting masks showed 
higher definition and results than the other methods. However, as mentioned before, high number of 
leakage detection could difficult the mask selection (with large calculations time) and a 3D object with 
high amount of structures.  
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Figure IV-7. 3D reconstruction of masks obtained by different methods. A) 3D reconstruction of generated mask by threshold 
method in 3D-Slicer. B) 3D reconstruction of generated mask by threshold method in Mimics®. C) 3D reconstruction of generated 
mask by the Dynamic Region Growth with values of threshold about -1,024 HU to -960 HU. D) 3D reconstruction of the mask 
generated by the Segmentation airway module with 75% of strong leakage detection. E) 3D reconstruction of the mask generated 
by the Segmentation airway module with 0% of strong leakage detection. 
Additionally, the matrix reduction and the smoothing tool was evaluated to compare the different 
results. In Figure IV-8, different parameters used to generate the 3D models can be observed. When 
3D model generation was used with low quality, the obtained object showed no homogeneous surface 
with low definition. Low quality only showed a matrix reduction with a ratio 6:3, causing great number 
of grouped triangles, which was translated into to low definition of the surfaces. However, when the 
matrix reduction is reduced (from 6:3 to 1:1), the definition of the object surface increased (medium, 
high and optimal quality). In addition, when the smooth factor was used, the rough surfaces were 
smoothed reducing the noise (high quality). But, as expected, differences between low and high values 
of smooth factor, lead to noised or polished surfaces. Comparison between high and optimal quality, 
lower matrix reduction should result in an increase of the surface definition. However, the smooth factor 
was reduced too, causing lower polish effect. Thus, the resulting object showed good definition of the 
branches and the airway track, but very noised surface. 
 
Figure IV-8. Different 3D models generatedfrom the same segmentation using Segment Airway module. A) model generated 
with “Low” quality (6:2, matrix reduction); B) generated with “Medium” quality (3:2 matrix reduction); C) generated with “High” 
quality (2, iteration; 0.5, smooth factor; 2:1, matrix reduction and no triangle reduction); D) generated with “Optimal” quality (2, 
iteration; 0.3, smooth factor; 1:1, matrix reduction and triangle reduction); and E) model generated by “Custom” quality (3, 
iteration; 0.7, smooth factor; 1:1, matrix reduction and triangle reduction). 
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As observed in the previous results, the final 3D model generation requires some parameters that 
must be defined by the user. Therefore, in order to obtain an optimal 3D model, it is necessary to edit 
some of the parameters. In this case, Mimics® software recommends the use of the optimal conditions, 
however due to the pixelation and noise in the surface of the generated object, it was necessary to use 
customized conditions with the same parameters than optimal quality, but increasing the smooth factor 
to obtain a more smooth and polished surface. 
Despite both software allowed to segmented the patients’ information to extract a mask of the desired 
structure and generate a 3D model, Mimics® presents additional robust modules, such as advanced 
manual editing commands or DRG and SA, which results in better mask qualities. Additionally, the 3D 
module generation show additional parameters and calculations modules that result in better 3D 
objects. However, in this case, price and simplicity could tip the balance to the free-software (3D-Slicer). 
After the 3D model generation, the obtained structure was exported as a STL. This allowed to perform 
CAD/CAE operations with the structure to design a suitable tracheal stent to reduce migration and avoid 
granulation tissue. Once the STL file was imported into a CAD software, modifications such as deletion 
or addition of certain features and dimensions sizing was performed to redesign the stent. Additionally, 
considering the previous discussion about the difficulty to print silicone with AM, the redesigned STL 
file was used to create an injection mould to be filled with silicone and obtain a silicone airway. 
4.3.2 Treatment and modelling of the STL file 
After the data segmentation and 3D model creation, the resulting object was imported into a CAD 
software. In this work 3-matic® (Mimics Innovation Suite®) was used. This software has a specific 
module specially developed to treat meshes facilitating the treatment and modelling. 
To import an STL file to 3-matic®, can be easily drag to the software interface or through File / Import 
Part. Then, a fix module is used to analyse the quality of the imported triangles. The module analyses 
inverted triangles, bad edges, shells, overlapping and intersecting triangles. When the previous 
generated STL was imported (in Custom quality), errors about the last three parameters were found. 
The module fixed and eliminated the errors, but in some cases (shells and overlapping triangles), the 
module required a manual interaction because the automatic algorithm was not able to solve the 
problem due to the complexity of the triangles. However, in Figure IV-9-A, it can be observed that the 
problematic errors were triangles of regions with complex geometries, located where the mask lost its 
definition. 
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Figure IV-9. Overview of the branched airway. A) Selected errors (overlapped triangles, in red) by the fix module. B) Cut process 
of the noised branches. 
For the current work, with the trachea, right primary bronchus, left primary bronchus and few 
millimetres of right upper lobe and intermediate trunk was sufficient to design a silicone tracheal stent 
as a proof of concept. Therefore, the noised ramified branches of the airway track were deleted, Table 
IV-6, because no additional information was provided and consequently, the overlapped triangles errors 
were eliminated. Thus, the resulting mesh were cleaned and fixed and the model was simplified. 
Table IV-6. Most used commands to crop the STL file in 3-matic®. 
Masks Command 
3-matic® Finish / Trim or Design / Create Datum Plane and Design / Cut 
 
Once the model is analysed and cleaned, the structure required additional operations to redesign the 
stent. As commented before, stent consists on a concentric cylindrical tube to allow the air pass, but 
the current 3D object it was only a triangle mesh. Therefore, the next step consisted in generating an 
offset of the current mesh to create a hollow structure. The 3-matic® software has a command to 
generate an inside, outside or both directions offset to the mesh. Considering that stents were anchored 
on the trachea by applying mechanical pressure, they required to be overdimensioned normally, about 
a greater oversizing of 10% to 20% than the maximal tracheal diameter to avoid stent migration.53,54 
These values range is chosen to avoid radial stress on the tracheal tissue and therefore reduce in-stent 
restenosis.55,56 In Figure IV-10, a 1.5 mm outside offset can be observed, corresponding to an oversize 
of 19% to a tracheal diameter of 16 mm. 
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Figure IV-10. Oversized trachea with 1.5 mm offset. For a 16 mm tracheal diameter this offset increase in a 19% the final diameter 
of the stent. A) General overview of the resulting oversized trachea model with 2 surfaces. B) Zoom of the top region of the 
trachea model with the 2 surfaces. C) Cut of the top region of the trachea to observe the 2 meshes with an oversize of 1.5 mm. 
After the model was trimmed and the desired offset, between 10-20%, was applied, the model was 
ready to export as STL file in order to print. However, due to the different applied operations, the Fix 
Module was used to analyze the object. Then, the new 3D object was exported as STL file from the File 
menu. 
4.3.3 3D Printing of extracted model 
Once the model was analyzed, edited and exported to STL, it was imported into the Insight® software 
from Stratasys® to print using the FDM Fortus 400mc® and to Stalactite Workshop to print using the 
stereolitography printer Stalacticte. First, the model was imported into the FDM software with the back 
surface of the trachea lying down to the printing cuvette. Then, because the inside of the trachea model 
was empty and the low planarity of the trachea surface, it was necessary to fill the trachea with support 
material and create a support base in order to avoid errors during the printing process. After around 5h 
of printing process, the trachea object was printed in PC with SR-100TM acting as a support material. 
This type of support was selected because it can be eliminated using a hot sodium hydroxide solution. 
In Figure IV-11, the printed trachea model (in white) can be observed in the printing cuvette after the 
printing process was finished. Additionally, the support material (in brown) used to fill the cavity of the 
airway track can be observed. After the printing process, the resulting object was incubated in a heated 
sodium hydroxide solution to remove the support material and then, the trachea model was washed 
A) B)
C)
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with Milli-Q water and rinsed with ethanol. The resulting printed trachea model showed rigid properties 
because it was printed in polycarbonate and all the anatomical detail of the patient. However, due to 
the FDM technology, the use of support material to fill all the empty cavities could be a drawback 
because could difficult the printing of an injection mold with all the necessary cavities to inject the 
silicone. 
 
Figure IV-11. 3D-printed trachea model using FDM technology (Fortus 400mc®). A) 3D-printed model in the printing cuvette of 
the printer with the support material, and B) resulting 3D model without the support material. Green arrow (printing material, 
polycarbonate) and yellow arrow (support material, SR-100TM). 
Therefore, a stereolitography printer (Stalacticte 102) was used to print the trachea. This technology 
was selected because as its name reflects, the objects were built from top to bottom. In this case, the 
light source was a commercial video projector that irradiates, with a defined pattern, to a mirror which 
is under a photocurable liquid resin. The platform was moved upwards when each layer was 
photopolymerized. The printer resolution was at Z axis, layer thickness, from 100 to 25 µm, and at XY 
axis, construction area, from 100 to 50 µm. The printing speed was approximately 30 mm/h at 100 µm 
resolution, at Z axis. 
Once the STL file was loaded into the printer software, the object was located on the building area of 
the printer. Then, the object was rotated to ensure a correct centre of mass because the object was 
printed vertically. Considering that some parts of the trachea required supports, the trachea was located 
over a resin base to anchor the vertical supports and facilitate the cutting of the object from the printing 
platform. In Figure IV-12, the positioning of the trachea model with the supports on the printing platform 
can be observed. After the set-up, the slicing was performed to transform the printing object into a series 
of slices. Then, the printer started to project each layer onto the liquid resin in contact with the printing 
platform. After each layer, the platform moved upward and the next layer was printed. At the end, of the 
printing process, the object, with the corresponding supports, was obtained hanging from the printing 
platform. The printed object was cut from the platform and the supports were removed. In almost all 
cases, after the washing treatment with water and ethanol, the printed object showed sticky properties 
A) B)
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as a consequence of non-photocured resin. Therefore, the object was placed under a cabin with visible 
light to photocure the non-photopolymerized resin and eliminate the sticky properties. 
 
Figure IV-12. Printing process of the trachea model using the Stalactite printer. During the set-up, the model was placed in the 
printing platform and the base and supports were designed. After the set up and the slicing process, the trachea and the supports 
were printed layer by layer. Finally, after cutting the trachea model from the supports, the object was washed with Milli-Q water 
and ethanol and photocured under visible light if necessary. 
The previous results showed the great feasibility of 3D printing technology to print sophisticate 
geometries, such as anatomical geometries extracted from patients. Additionally, both technologies 
used in this work were able to use previously edited STLs’ created from a patient scanner. However, 
due to the printing process technology, stereolitography showed better results than FDM because of 
the printing orientation and the use of liquid material. 
4.3.4 Mould design of anatomical silicone tracheal stent 
As mentioned before, this work pretends to develop a process to obtain anatomical medical devices 
combining revolutionary new technologies (AM) with classical manufacturing techniques, such as 
molds. Therefore, in order to move forward to achieve the aim of this work, it was necessary to develop 
an anatomical mold capable to be injected with silicone. 
Therefore, the first step consisted in the importation of the previous STL file and the triangles mesh 
was analyzed and fixed with 3-matic®. Then, a 1.5 mm offset was generated to create the cavity of the 
mold where the silicone will be injected. In order to minimize the complexity of the mold, the bronchus 
and their ramifications were deleted from the trachea airway, just to select the trachea segment. Then, 
a rectangular hexahedron, Figure IV-13, was created using the command Create Mold Shape under 
the Tooling module. In this case, the hexahedron was adjusted to the trachea in order to minimize the 
use of material. Then, it was necessary to create the mould cavity from the trachea airway. To do so, a 
Set-up Print Result
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Boolean Subtraction operation was performed from the Design menu and selecting the tracheal airway 
as subtraction entity. 
 
Figure IV-13. Mould cavity creation from the trachea airway. A) Creation of a rectangular hexahedron over the edited trachea 
and B) Resulting mould cavity with subtracted trachea airway. 
Once the mold cavity with the anatomical geometry of the trachea airway was performed, it was 
necessary to create the injection channels to facilitate the silicone injection. Initially, due to the low 
viscosity of the PDMS, top channels should be sufficient to fill the mold with silicone by gravity. However, 
additional channels were designed to increase the filling process, avoid empty spaces and facilitate air 
release and oxygen diffusion. Channels were designed by drawing lines in the mold using different 
drawn plans. Firstly, using the Sketch menu, new planes were created (New Sketch) to anchor the 
channels. Secondly, the Create Line command allowed to draw channels on the desired location 
between the external surface of the mold box and the external surface of the trachea, using the previous 
created planes. Diameters (1 mm) were provided using the Create Runner command, and finally, a 
Boolean Subtraction operation between the mold box and the created channels was performed to open 
the channels. In Figure IV-14, the resulting mold can be observed with different channels to inject 
silicone and to allow air to be released during the injection process in order to avoid empty spaces. 
Chapter IV. Design of a 3D Printed Tracheal Device 
131 
 
Figure IV-14. Injection mould with different channels for injection and air release. A) Sketch of different channels created in the 
mould, B) Channels generation over the mould with 1 mm of diameter, and C) external mould overview to observe the entries of 
each channel. 
Finally, after the channels creation the mould was almost ready to be printed. However, as mentioned 
previously, the aim of this fabrication was to inject silicone and then unmould the silicone stent by 
breaking the mould. Therefore, to facilitate the stent cutting and to reduce material and weight, the 
mould was emptied using the previous commented Hollow command (Design menu) leaving a wall 
thickness of 1 mm. In Figure IV-15, the final design of the mould with the channels and the emptied box 
can be observed. The top of the trachea design was anchored to the top layer of the mould box, using 
injections channels, to avoid the use of supports. 
 
Figure IV-15. Final design of the tracheal stent mould to inject silicone. A) Internal mould overview of the trachea, channels and 
wall thickness, and B) external mould overview with the channels entries. C) Overview of the internal parts of the designed mould. 
A) B) C)
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4.3.5 3D Printing of Designed Mould and PDMS injection 
Once the mold was designed, the next step was to use the 3D printing technology to manufacture 
the personalized mold. Considering the design of the mold, the FDM technology will manufacture the 
box of the mold completely solid using high quantities of support material. Additionally, channels and 
the trachea reservoir for the silicone would be printed using support material, which would be difficult 
to wash and to empty the mold. Therefore, the mold was printed using the stereolitography to avoid the 
requirement of supports and to reduce the material because the non-reacted liquid resin will fall to the 
cuvette, leading the mold box empty of liquid. 
The trachea mold was printed similarly to the previous trachea model using stereolitography and with 
the top part of the mold box anchored to the printing platform to avoid the use of additional supports. In 
Figure IV-16, the printing process of the mould with a stereolitography can be observed. The mold was 
anchored to the printing platform because the channels were additionally used to anchor the internal 
part of the mold to avoid additional supports.  
 
Figure IV-16. Image of the mold’s printing process with a stereolitography printer. 
After the mould’s printing, it was washed with Milli-Q water and ethanol to remove non-cured resin. 
After the washing treatment, the mould was still sticky because the resin was not completely cured. 
Therefore, the mould was placed under visible light for 30-60 min to finish the curation process. Then, 
after the resin was completely cured, the PDMS kit was prepared and injected using 1-2 mL syringe 
through the injections channels. To facilitate the injection a new mould with additional channels on the 
top were designed and printed. The mould with the PDMS silicone was incubated at 75 ºC for 3 h and 
after PDMS curation, the tracheal stent was released by breaking the mould. In some designs, with no 
additional channels for air release, the curation process was not performed homogeneously and the 
silicone of the most distal part from the top, remained liquid. This can be explained because of the 
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aeration process inside the mould. The PDMS silicone requires oxygen to cure effectively. Therefore, 
if the mould has not a good aeration process, the curation process cannot be performed. However, it 
was important to take into account that a high number of air channels could difficult the injection and 
the curation process because silicone can be leaked through those channels. In Figure IV-17, the 
resulting 3D tracheal stents can be observed. The obtained tracheal stents were easily cutted from the 
mould, which was easily broken. The silicone trachea was completely flexible, homogeneous, 
transparent. However, some air bubbles due to the non-continuous injection process were observed. 
The air bubbles could be solved using a vacuum line during the injection and the use of an automated 
high pressure syringe could increase the injection speed, reduce the air bubbles and facilitate the 
silicone to completely fill the mould. In addition, when the wall thickness was small, about 0.5-1 mm 
offset, some printing and injection problems occurred. Printing problems could be solved by adjusting 
the printing parameters, such as printing speed and XY and Z resolution. Lower printing speed showed 
more defined results because the resin was completely cured and the layer was better defined. 
Regarding to the injection problems with lower wall thickness, normal syringe was not able to apply 
enough pressure to facilitate the silicone to flow over all the geometry in order to fill all the mould. In 
this case, the use of an automated injection syringe with an injection connection on the mould could 
increase the silicone injection and the result of the silicone object. 
 
Figure IV-17. Anatomical silicone stents manufactured using 3D printing technology in combination with mould fabrication. 
4.3.6 Silver deposition onto 3D anatomical stent 
Finally, after manufacturing of a patient’s anatomically stent, the next step consisted in the addition 
of the antibacterial properties. Considering that no changes in the chemical composition of the material 
was performed, the 3D stent was made of silicone (PDMS), the previous developed antibacterial 
coatings were easily applied. Anatomically stent was placed in the PECVD reactor and the same plasma 
conditions and post-process (reductive sugar immobilization and metallic silver reduction) was 
performed. In Figure IV-18, the resulting antibacterial anatomically stent with antibacterial properties 
can be observed. Despite the modification could be performed selectively on the desired surface side 
of the stent, the coating was deposited all over the surface of the material to avoid internal and external 
stent colonization. The most obvious colonization is formed on the internal side of the stent where the 
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mucus and the body fluids are flowing, however, the external side of the stent (in contact with the 
trachea wall) could present some holes between the trachea rings and the surface of the stent (even in 
an anatomically designed stent because it is oversized) which are interesting anchor sites for bacteria 
to colonize and grow. 
 
Figure IV-18. Patient’s anatomical stent with antibacterial properties 
The resulting stent, showed and homogeneous metallic silver coating on the surface with flexible 
properties and completely adapted to the complex geometries of the manufactured stent. These results 
showed the novelty of the previous developed surface modifications indicating that the developed 
coating can be applied on different geometries, not only on flat plates (2D) but in 3D structures such as 
cylindrical and anatomical tubes. 
This resulting 3D manufactured stent using patient’s information with antibacterial properties is a 
proof of concept of the next generation of medical devices. These devices combine bioactivities, 
functionalities and device-tissue interaction that increase the biocompatibility and the biofunctionality 
avoiding post-implantation problems, such as stenotic tissue, granuloma, migration, pain, colonization 
and tissue rejection.
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4.4 Concluding Remarks 
The described methodology showed the ability of the current available visualizers’ software to 
interpret DICOM images and extract different masks of the desired tissues. Additionally, different 
selection methods can be used, being the semi-automatic the most interesting because is faster, more 
reliable and provides a higher degree of detail than the manual methods. 
Moreover, once the tissue was selected, the pixels were easily transformed into triangles using the 
3D conversion commands, resulting in a 3D construction of the object. In addition, the use of specific 
software, such as 3-matic®, allowed to treat the triangles, fixing segmentation problems such as inverted 
triangles, bad edges, shells, overlapping and intersecting triangles. Furthermore, the software provides 
sketch’s modules that allowed to design parts of the 3D object, even with the possibility to re-design the 
3D object. Additionally, this work showed the ability of the CAD design to easily create injections moulds 
for the anatomical objects. Finally, the CAD object was exported to a 3D printers format, STL. 
Besides the CAD design, this work used two types of additive manufacturing technologies to fabricate 
the designed anatomical object. In this case, the trachea airway was manufactured using FDM and 
stereolitography technology, being the latter more interesting because of the reduction of the support 
material. This effect was more important for the mould printing in which the FDM was required to fill 
almost all the mould with support material. However, the stereolitography resulted in a mould free of 
support material. 
The obtained 3D printed object was manufactured using PDMS to demonstrate the feasibility of the 
technology and workflow. Despite PDMS cannot be implanted in humans, it acted as a control to 
evaluate the manufacturing proceedings. Additionally, PDMS kit showed low viscosity and could be 
injected easily into the manufactured mould, however, the viscosity of medical silicone is higher than 
PDMS and cannot be injected easily. Therefore, in future developments, the silicone injection process 
must be redefined to be adapted to medical silicone properties. 
Considering that a future final prosthesis should be implanted, the prosthesis must be sterilized. 
Therefore, this work obtained a silicone-based prosthesis, however, the future medical grade silicone 
prosthesis can be easily sterilized using typical sterilization processes, such as oxygen plasma, an 
autoclave or even ethylene oxide. 
As previously commented, the medical community requires new personalized solutions to avoid low 
adaptability causing migration problems, high acute pain and granulation tissue formation. The previous 
results showed the high potential of this technology to create new anatomical silicone stents. The 
previous workflow demonstrate the high potential of this methodology to extract, customize, design and 
manufacture personalized medical devices, such as anatomical models57, implants58 or even surgical 
instruments59. 
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Finally, resulting anatomically 3D manufactured stent with antibacterial properties were easily 
modified with the previously developed antibacterial coating showing and homogeneous metallic silver 
coating covalently attached to the surface of the stent. The coating was completely flexible and adapted 
to the stent geometries avoiding cracking and delamination. 
These results are completely in combination with the previous chapters in this work. As observed in 
the previous chapter, flat plates and even cylinders can be easily modified to provide antibacterial 
properties to avoid bacteria colonization and biofilm formation. In addition, an adapted version of the 
previously developed coating has been used in combination with degradable nanoparticles capable to 
entrap hydrophobic drugs, to release antiproliferative drugs, such as paclitaxel. Both chapters used the 
plasma deposition process, which showed high versatility to modify complex structures, and therefore, 
the 3D printed structures developed in this chapter could easily incorporate the previously developed 
properties, i.e. antibacterial and drug delivery features. 
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Conclusions 
A proof of concept of a bioactive material (silicone-based) with antibacterial properties capable to 
avoid bacterial colonization and biofilm formation was developed. In addition, the plasma treatments 
were adapted to create a controlled drug delivery platform onto the surface of the materials in order to 
avoid stenotic tissue and recurrence and reduce the formation of the granulation tissue. Finally, an 
anatomically personalized tracheal stent was developed using additive manufacturing technology to 
increase the implant adaptability and avoid migration and pain. 
• Surface modification has been performed on different materials, such as nylon, PTFE and 
PDMS, and it was possible to selectively attach different molecules to each surface (bi-side 
modification), adding different properties or activities depending on the materials sides. 
Additionally, surfaces have been micro-structured using µContact Printing techniques or 
micro-structured masks. 
• Glucosamine has been covalently attached to the surface through the reactive PFM group. 
Silver deposition was achieved through a three-step reaction using PFM, glucosamine and 
the silver’s mirror reaction by both methods, plasma grafting and PECVD. 
• PECVD method allowed the deposition a homogeneous thin film with higher amount of silver 
when compared to grafting methods. In addition, PECVD allowed different topologies on 
surfaces with the ability to model the macroscopic and microscopic surface morphology and 
carries out chemical pattering. The obtained silver coating, formed by the fusion of silver 
nanoparticles, resulted in a homogeneous micro- and nanostructured surface with 
hydrophobic properties. 
• Silver-coated surfaces were tested in vitro with bacterial cultures and presented antibacterial 
properties against Pseudomonas aeruginosa and Staphylococcus aureus avoiding biofilm 
formation. Furthermore, the hydrophobic silver coated surfaces showed lower bacterial 
adhesion on the surface of the developed materials (antifouling behaviour) when compared 
with the non-modified samples. 
• The in vitro release demonstrated the release of silver ions from the surface to the media, 
showing an initial rapid release within the first 24 h, followed by a lower sustained release 
over 20 days. The achieved silver amounts during the release showed no cytotoxic effect in 
vitro using COS-7 cells. 
• A block co-polymer (PAmX) with amines at both ends of the polymer chains was successfully 
synthesized via microwave or acid catalysis polycondensation to fabricate paclitaxel 
(PCTXL) loaded nanoparticles population with low polydispersity via nanoprecipitation. 
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• Paclitaxel loaded nanoparticles showed drug content of approximately 3% of paclitaxel with 
encapsulation efficiencies about 60%, resulting in similar values of other pegylated 
nanoparticles and polyester base NPs. 
• In vitro release experiments have demonstrated that NPs release PCTXL with an 
approximately first-order profile and without initial burst. The comparison between the 
synthesized nanoparticles (with amide bonds in its structure) and polyester-peg 
nanoparticles (previously developed in our group with just ester bonds), showed that amide 
bonds had slower release because of the stability of the amide bond. 
• For the in vitro cells experiments, biocompatibility and in vitro antiproliferative activity against 
epithelial cells (A549), Human Lung Fibroblast cells (IMR-90) and ex vivo samples (Primary 
Respiratory Human Fibroblast cells (T-01 MVV) and human fibroblasts cell lines, have been 
assessed. The drug-loaded nanoparticles caused a reduction of 80% in cell proliferation 
within 12-14 days of incubation similar to pure paclitaxel. Additionally, when pp-PFM was not 
blocked properly, cellular cytotoxicity was observed. 
• A mould with an anatomical design (extracted from patients’ scan) was designed with 
injection channels to allow oxygen diffusion and therefore, the curation of the PDMS. An 
anatomical silicone 3D printed trachea was obtained by injecting silicone (PDMS) onto the 
printed mould. The result was a transparent, homogeneous and flexible silicone trachea with 
100% anatomical geometries. 
• The obtained anatomical 3D tracheal stent was coated with the previous developed 
antibacterial coating technology allowing a homogeneous antibacterial silver coating onto the 
surface of the manufactured object. 
